---
document_datetime: 2024-04-04 09:53:25
document_pages: 86
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/opdivo-h-c-003985-x-0132-epar-assessment-report-variation_en.pdf
document_name: opdivo-h-c-003985-x-0132-epar-assessment-report-variation_en.pdf
version: success
processing_time: 226.5607731
conversion_datetime: 2025-12-27 14:00:57.281795
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

25 January 2024 EMA/93617/2024 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## OPDIVO

International non-proprietary name: Nivolumab

Procedure No. EMEA/H/C/003985/X/0132

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                | .............................................. 6                                                             |
|---------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier ......................................................................................     | 6                                                                                                            |
| 1.2. Legal basis, dossier content ...................................................................................     | 6                                                                                                            |
| 1.3. Information on Paediatric requirements                                                                               | ................................................................... 6                                        |
| 1.4. Information relating to orphan market exclusivity                                                                    | ..................................................... 6                                                      |
| 1.4.1. Similarity                                                                                                         | .......................................................................................................... 6 |
| 1.5. Scientific advice                                                                                                    | ................................................................................................... 6        |
| 1.6. Steps taken for the assessment of the product                                                                        | ......................................................... 6                                                  |
| 2. Scientific discussion ................................................................................                 | 8                                                                                                            |
| 2.1. Problem statement                                                                                                    | ............................................................................................... 8            |
| 2.2. About the product                                                                                                    | ................................................................................................ 8           |
| 2.3. Type of Application and aspects on development                                                                       | ...................................................... 8                                                     |
| 2.4. Quality aspects                                                                                                      | .................................................................................................... 9       |
| 2.4.1. Introduction                                                                                                       | ...................................................................................................... 9     |
| 2.4.2. Active Substance                                                                                                   | ............................................................................................... 9            |
| 2.4.3. Finished Medicinal Product                                                                                         | ................................................................................ 13                          |
| 2.4.4. Discussion and conclusions on chemical, pharmaceutical and biological aspects                                      | ....... 16                                                                                                   |
| 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                 | ...................... 16                                                                                    |
| 2.4.6. Recommendation(s) for future quality development                                                                   | ............................................. 16                                                             |
| 2.5. Non-clinical aspects                                                                                                 | ............................................................................................ 16              |
| 2.5.1. Ecotoxicity/environmental risk assessment .........................................................                | 16                                                                                                           |
| 2.6. Clinical aspects                                                                                                     | .................................................................................................. 17        |
| 2.6.1. Introduction ....................................................................................................  | 17                                                                                                           |
| 2.6.2. Clinical pharmacology                                                                                              | ...................................................................................... 17                    |
| 2.6.3. Discussion on clinical pharmacology                                                                                | ................................................................... 29                                       |
| 2.6.4. Conclusions on clinical pharmacology .................................................................             | 31                                                                                                           |
| 2.6.5. Clinical efficacy                                                                                                  | ............................................................................................... 31           |
| 2.6.6. Discussion on clinical efficacy ............................................................................       | 44                                                                                                           |
| 2.6.7. Conclusions on the clinical efficacy .....................................................................         | 45                                                                                                           |
| 2.6.8. Clinical safety .................................................................................................. | 45                                                                                                           |
| 2.6.9. Discussion on clinical safety                                                                                      | .............................................................................. 71                            |
| 2.6.10. Conclusions on the clinical safety .....................................................................          | 76                                                                                                           |
| 2.7. Risk Management Plan ........................................................................................        | 77                                                                                                           |
| 2.7.1. Safety concerns ...............................................................................................    | 77                                                                                                           |
| 2.7.2. Pharmacovigilance plan ....................................................................................        | 77                                                                                                           |
| 2.7.3. Risk minimisation measures ..............................................................................          | 78                                                                                                           |
| 2.7.4. Conclusion ......................................................................................................  | 79                                                                                                           |
| 2.8. Pharmacovigilance ..............................................................................................     | 79                                                                                                           |
| 2.8.1. Pharmacovigilance system                                                                                           | ................................................................................ 79                          |
| 2.8.2. Periodic Safety Update Reports submission requirements                                                             | ..................................... 79                                                                     |
| 2.9. Product information                                                                                                  | ............................................................................................ 80              |
| 2.9.1. User consultation                                                                                                  | ............................................................................................. 80             |

<div style=\"page-break-after: always\"></div>

3. Benefit-Risk Balance

..............................................................................

3.1.1. Main clinical studies

3.2. Favourable effects

80

.........................................................................................

80

..............................................................................................

3.3. Uncertainties and limitations about favourable effects

3.4. Unfavourable effects

80

.............................................

80

...........................................................................................

3.5. Uncertainties and limitations about unfavourable effects

3.6. Effects Table

80

.........................................

82

......................................................................................................

3.7. Benefit-risk assessment and discussion

82

.................................................................

3.7.1. Importance of favourable and unfavourable effects

3.7.2. Balance of benefits and risks

82

..............................................

82

.............................................................................

3.7.3. Additional considerations on the benefit-risk balance

3.8. Conclusions

83

...........................................

83

.......................................................................................................

4. Recommendations

83

.................................................................................

83

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ADA

Anti-drug antibody

AE

Adverse event

AJCC

American Joint Committee on Cancer

AUC(0-336h)

Area under the concentration-time curve from 0 to 336 hours

AUC(TAU)

Area under the concentration-time curve over the dosing interval

BMS

Bristol Myers Squibb

cHL

Classical Hodgkin's lymphoma

CHMP

Committee for Medicinal Products for Human Use

CHO

Chinese hamster ovary

CI

Confidence interval

Cmax

Maximum (or peak) concentration

CMC

Chemistry, Manufacturing, and Controls

CPAs

Critical performance attributes

CPP

Critical process parameter

CRC

Colorectal cancer

CO

Clinical Overview

CSR

Clinical Study Report

Ctau

Observed concentration at the end of a dosing interval

Ctrough

Observed nivolumab serum trough concentration

CTC

Common Terminology Criteria

DBL

Database lock

DC

Discontinuation

dMMR

Mismatch repair deficient

eCTD

Electronic Common Technical Document

OC

Oesophageal cancer

EMA

European Medicines Agency

EPCBs

End of Production Cell Banks

OSCC

Oesophageal squamous cell carcinoma

EU

European Union

FPFV

First patient first visit

GCP

Good Clinical Practice

GEO

Geometric

GEJC

Gastro-oesophageal junction cancer

HCP

Host Cell Protein

HR

Hazard ratio

hrs

Hours

HuMAb

human monoclonal immunoglobulin G4 (IgG4) antibody

ICH

International Council for Harmonisation

IEC

Independent Ethics Committee

IgG

Immunoglobulin G

IMAE

Immune-mediated adverse event

IPC

In-process control

INN

International Nonproprietary Name

IRB

Institutional Review Board

IRT

Interactive response technology

IV

Intravenous

LIVCA

Limit of In Vitro Cell Age

MAA

Marketing Authorization Application

MAX

Maximum

MCB

Master Cell Bank

MedDRA

Medical Dictionary for Regulatory Activities

MIN

Minimum

MSI-H

Microsatellite instability-high

N.A.

Not applicable

NAb

Neutralizing antibody

NSCLC

Non-small cell lung cancer

PAs

Performance attributes

PAM

Post-authorization measures

PD-1

Programmed cell death protein 1

PD-L1

Programmed death - ligand 1

PK

Pharmacokinetic

PP

Persistent Positive

PP

Process parameters

PPQ

Process Performance Qualification

PRS

Primary Reference Standard

PT

Preferred term

Q1, Q3

Quartile 1, quartile 3

Q2W

Once every two week dosing

Q4W

Once every four week dosing

RCB

Research cell bank

RCC

Renal cell carcinoma

RFS

Recurrence-free survival

SAE

Serious adverse event

SCCHN

Squamous cell carcinoma of head and neck

SOC

System organ class

SOP

Standard Operating Procedure

Tmax

Time at which maximum concentration (Cmax) occurs

TSE

Transmissible spongiform encephalopathy

UC

Urothelial carcinoma

UF/DF

Ultrafiltration/Diafiltration

US

United States

Vd

Volume of distribution

VF

Viral Filtration

WCB

Working Cell Bank

WRS

Working Reference Standard

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

Bristol-Myers Squibb Pharma EEIG submitted on 26 April 2023 an extension of the marketing authorisation.

Extension application to introduce a new recombinant Chinese hamster ovary (CHO) host cell line and a new manufacturing process of the active substance (Process D).

The RMP (version 34) is updated in accordance. In addition, the MAH took the opportunity to update the Annex II in the PI.

Consequentially, a few manufacturers of the biological active substance have been removed from Annex II of the PI.

- Lonza Biologics, Inc. (USA)
- Samsung Biologics Co. Ltd. (Korea)
- Lotte Biologics USA, LLC (USA)

## 1.2. Legal basis, dossier content

## The legal basis for this application refers to:

Article 19 of Commission Regulation (EC) No 1234/2008 and Annex I of Regulation (EC) No 1234/2008, (1) - Extensions of marketing authorisations

## 1.3. Information on Paediatric requirements

Not applicable

## 1.4. Information relating to orphan market exclusivity

## 1.4.1. Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did submit a critical report addressing the possible similarity with authorised orphan medicinal products.

## 1.5. Scientific advice

The MAH received scientific advice from the CHMP on 22 February 2018 (EMEA/H/SA/2253/6/2018/III) on quality and clinical aspects.

## 1.6. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Carolina Prieto Fernandez

<div style=\"page-break-after: always\"></div>

The Rapporteur appointed by the PRAC was:

## PRAC Rapporteur: Martin Huber

| The application was received by the EMA on                                                                                                                                             | 26 April 2023     |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| The procedure started on                                                                                                                                                               | 18 May 2023       |
| The CHMP Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on                                                                                           | 10 August 2023    |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC and CHMP members on                                                                                           | 16 August 2023    |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                               | 31 August 2023    |
| The CHMP agreed on the consolidated List of Questions to be sent to the MAH during the meeting on                                                                                      | 14 September 2023 |
| The MAH submitted the responses to the CHMP consolidated List of Questions on                                                                                                          | 21 October 2023   |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Questions to all CHMP and PRAC members on                        | 22 November 2023  |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                               | 30 November 2023  |
| The CHMP agreed on a list of outstanding issues in writing to be sent to the MAH on                                                                                                    | 14 December 2023  |
| The MAH submitted the responses to the CHMP List of Outstanding Issues on                                                                                                              | 20 December 2023  |
| The CHMP Rapporteurs circulated the Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on                                         | 10 January 2024   |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to OPDIVO on | 25 January 2024   |
| The CHMP adopted a report on similarity of OPDIVO with name of the authorised orphan medicinal product on                                                                              | 25 January 2024   |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Problem statement

Nivolumab drug substance for commercial manufacturing is currently produced using an approved Process C, which utilizes the Master Cell Bank (MCB) that serves as the global clinical and commercial supply of nivolumab.

At the time of the initial marketing authorisation application (MAA) for nivolumab, the MAH committed to establish a new MCB for long-term commercial active substance manufacturing.

In order to meet the quality commitment the MAH has developed a new recombinant Chinese hamster ovary (CHO) host cell line for commercial manufacture of nivolumab, together with an optimized drug substance manufacturing process (Process D). Process D has been developed for the manufacture of nivolumab at the registered manufacturing site, located in Dublin, Ireland, to increase process robustness and enhance overall process yield while maintaining product quality. There is no change to the drug substance (DS) formulation, final concentration, container closure or storage conditions.

With the submission of this Extension Application, there is no change to the drug product (DP) manufacturers, DP formulation and DP manufacturing process and overall flow of the process remains the same between Process C and Process D. The new drug substance manufacturing Process D is intended to replace the current manufacturing Process C for nivolumab.

## 2.2. About the product

Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody (HuMAb), which binds to the programmed death-1 (PD-1) receptor and blocks its interaction with PD-L1 and PD-L2. The PD-1 receptor is a negative regulator of T-cell activity that has been shown to be involved in the control of T-cell immune responses. Engagement of PD-1 with the ligands PD-L1 and PD-L2, which are expressed in antigen presenting cells and may be expressed by tumours or other cells in the tumour microenvironment, results in inhibition of T-cell proliferation and cytokine secretion. Nivolumab potentiates T-cell responses, including anti-tumour responses, through blockade of PD-1 binding to PDL1 and PD-L2 ligands.

Opdivo is currently approved in the EU for the treatment of patients with melanoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma (MPM), renal cell carcinoma (RCC), classical Hodgkin lymphoma (cHL), squamous cell cancer of the head and neck (SCCHN), urothelial carcinoma, colorectal cancer (CRC), oesophageal squamous cell carcinoma (OSCC), oesophageal or gastrooesophageal junction cancer and gastric, gastro-oesophageal junction or oesophageal adenocarcinoma.

## 2.3. Type of Application and aspects on development

This procedure for the nivolumab manufacturing process change is based on data from the Phase 1 biocomparability Study CA2098FC.

## Scientific advice

The MAH received scientific advice on 22 February 2018 (EMEA/H/SA/2253/6/2018/III) on quality and clinical aspects and a follow-up scientific advice on 24 February 2021 (EMA/SA/0000074196).

<div style=\"page-break-after: always\"></div>

## 2.4. Quality aspects

## 2.4.1. Introduction

The finished product is presented as concentrate for solution for infusion, containing 10 mg/ml of nivolumab as active substance.

Other ingredients are: sodium citrate dihydrate, sodium chloride, mannitol (E421), pentetic acid (diethylenetriaminepentaacetic acid), polysorbate 80 (E433), sodium hydroxide, hydrochloric acid and water for injections.

The product is available in the following presentations: 40 mg/4 mL (10 mg/mL), 100 mg/10 mL (10 mg/mL), 120 mg/12 mL (10 mg/mL) and 240 mg/24 mL (10 mg/mL).

Nivolumab active substance is currently produced in Chinese hamster ovary (CHO) cells using an approved manufacturing Process C, that uses the current approved Master Cell Bank (MCB). At the time of the initial marketing authorisation (MA) for OPDIVO (nivolumab), the applicant Bristol-Myers Squibb Company (BMS) committed to establish a new MCB for long-term commercial active substance manufacturing.

With the intention to fulfil the quality recommendation, BMS has developed a new recombinant CHO host cell line for manufacture of nivolumab, together with an optimised active substance manufacturing Process D, to increase process robustness and enhance overall process yield while maintaining comparable product quality.

## 2.4.2. Active Substance

## 2.4.2.1. General Information

The INN name of the active substance is nivolumab. Nivolumab is a fully human monoclonal antibody (mAb) of the IgG4 class consisting of four polypeptide chains; two identical heavy chains of 440 amino acids and two identical kappa light chains of 214 amino acids, which are linked through inter-chain disulfide bonds. The heavy chain includes a S221P mutation, which is known to impart increased stability to IgG4 antibodies.

Nothing changes in section 3.2.S.1 in relation with product manufactured with current Process C and new Process D.

## 2.4.2.2. Manufacture, process controls and characterisation

## Manufacturer

This extension application is being submitted to fulfil the quality commitment, and to transition to a new cell line with related active substance manufacturing Process D, for nivolumab manufactured at the currently approved manufacturing site, Swords Laboratories Unlimited Company t/a Bristol-Myers Squibb Cruiserath Biologics, located in Ireland.

With this procedure, the following manufacturers of the biological active substance have been removed from Annex II of the Product Information:

- Lonza Biologics, Inc. (USA)

- Samsung Biologics Co. Ltd. (Korea)

- Lotte Biologics USA, LLC (USA).

<div style=\"page-break-after: always\"></div>

## Description of manufacturing process and process controls

Process D utilises a new cell line, chemically defined media (containing no hydrolysates or animalsourced components) and has higher yield compared to the current process, Process C.

The overall flow of the unit operations, i.e., vial thaw, inoculum expansion, cell culture, harvest followed by downstream purification remains the same as the current approved process. Nivolumab is manufactured in production bioreactors. One production bioreactor produces one unique active substance batch. Active substance batches are not combined at the active substance stage. There is no change to the active substance formulation, final concentration, or storage condition.

## Control of materials

No materials of animal or human origin are used in the nivolumab active substance manufacturing Process D. Compendial and non-compendial materials used in the manufacturing process are purchased from qualified vendors. Non-compendial materials are controlled by specifications for each raw material.

To replace the current cell line, a new cell line for nivolumab active substance manufacturing was established that is clonally derived. Details of the development of this clonal cell line are provided. The same host cell line was used for the new clonal cell line. In the generation of the new Master Cell Bank (MCB), a new expression plasmid was created to produce the light and heavy chains of nivolumab different from the previously used in the original nivolumab marketing authorisation application. The Applicant was requested to explain and justify why a new expression plasmid is required. The Applicant clarified that the introduction of a new expression plasmid is to align this product with others in their platform technology. The MCBs and WCBs are re-evaluated every 5 years and tested according to acceptance criteria.

## Control of critical steps and intermediates

An in-process control (IPC) strategy was defined for the nivolumab active substance manufacturing process that is not site-specific but does differentiate in regard to site-specific equipment or procedures. The IPC strategy utilises a tiered set of in-process action and acceptable ranges to ensure the consistent monitoring and control of the nivolumab active substance process. Critical process parameters (CPPs) and critical performance attribute are well described. The limits for in-process holds were established via a combination of biochemical stability and product vessel microbial ingress (vessel hold time) studies. The clearance of process-related impurities in the manufacturing process is also described.

## Process validation

The nivolumab process performance qualification (PPQ) campaign qualified the nivolumab Process D performance for the media preparation, upstream, downstream, buffer preparation, and active substance handling at the approved manufacturing site (BMS-Cruiserath). The PPQ active substance batches produced at manufacturing-scale met release acceptance criteria in effect at the time of PPQ and also conform to the commercial specification described in this application.

Additional data from scale-down and manufacturing-scale studies were obtained to support PPQ.

## Manufacturing process development

The in-process control strategy for the nivolumab manufacturing process was established based on toxicological assessments, process development, manufacturing-scale impurity mapping, stability testing, and manufacturing-scale experience. Identification and justification of CPPs, process parameters (PPs), critical performance attributes (CPAs), and performance attributes (PAs) are

<div style=\"page-break-after: always\"></div>

described. The biochemical stability of process intermediates was evaluated at scale-down using inprocess material from nivolumab Process D produced at intermediate manufacturing-scale.

Development of the manufacturing process was conducted to ensure that critical quality attributes (CQAs) of the molecule were maintained within acceptable ranges. Identification and assessment of potential CQAs is described.

Process D is the process designation given to the next generation active substance manufacturing process which was developed utilising new cell line. Additional changes have been made to increase upstream productivity and downstream throughput. Comparability of active substance quality has been established through release testing, extended characterisation testing, and a stress degradation study of the active substance batches manufactured at BMS-Cruiserath using the next generation Process D with active substance manufactured using the current commercial Process C.

To support the transition of nivolumab active substance commercial manufacturing from Process C to Process D, BMS has conducted both clinical biocomparability and analytical comparability studies. In addition, two further analytical comparability studies are provided: (i) Process D commercial-scale comparability versus Process C, and (ii) Process D commercial-scale comparability versus Process D intermediate-scale. All such data supports the transition from the former Process C to the new Process D which will be used in the future.

Together, the clinical biocomparability data from CA2098FC and the analytical comparability data support the conclusion that the implementation of Process D active substance manufacturing will not have an adverse impact on the quality, safety and efficacy of nivolumab injection active product.

## Characterisation

There is no change in section Elucidation of Structure and other Characteristics in relation to product manufactured with previous Process C.

For process-related impurities, all potential impurities are common between Process C with the exception of one, which is a new media additive for Process D. In the case of product-related impurities, there are no modifications, due to the analytical comparability between nivolumab Process D and Process C, and since there are no changes to formulation or protein concentration, such conclusion remains valid for nivolumab Process D.

## 2.4.2.3. Specification, analytical procedures, reference standards, batch analysis, and container closure

## Specifications

The specifications for release and stability testing of nivolumab active substance (Process D) are considered acceptable. Specification for release and stability testing of nivolumab active substance include tests for appearance, quantity, pH, purity, identity, potency, host cell protein, bacterial endotoxins, and bioburden.

## Justification of specification

The Applicant justifies the specifications and compares those for Process C with the new Process D. A summary of the chronology of events that established the nivolumab active substance specification prior to Process D is also provided, including the initial Process C Specification and its lifecycle updates.

## Analytical procedures

The analytical methods used for control of nivolumab Process D active substance are presented and summaries of each non-compendial method procedure are provided. There are also method histories of

<div style=\"page-break-after: always\"></div>

analytical methods used for release and stability testing of nivolumab active substance batches throughout product development.

## Batch analysis

The Applicant provided detailed results of analytical testing for the active substance batches manufactured from Processes D batches at intermediate and commercial scales. Min-max ranges for the tested parameters were summarised and they met the specifications for both scales.

## Nitrosamines

A 'Nitrosamine Risk Assessment Summary - Drug Substance' is included in the dossier. A theoretical risk was identified from one of the excipients, pentetic acid (DTPA); however, the level of nitrosamine impurities is below a level of concern and the risk level is negligible to low and no specific testing is required.

## Reference standards of materials

Reference Standard was established as the reference standard prior to PPQ, and served as the initial Working Reference Standard (WRS) for release and stability testing of commercial lots. As the Primary Reference Standard (PRS) it is now used to qualify subsequent WRSs that are used for routine testing. The methods and acceptance criteria for qualification of WRS are presented. Further justification for acceptance criteria for qualification of WRS in regards to quantity/identity and potency was provided upon request. The stability of the WRS will be assessed annually by trend analysis.

The Reference Standard was prepared using Process B active substance; finished product manufactured from this lot was used in pivotal clinical trials for lung cancer and melanoma and thus provides a direct link to clinical experience.

## Container closure

There is no change to the container closure system. Process D active substance is stored in the same bioprocess bag as the Process C active substance.

## 2.4.2.4. Stability

Previous stability studies with Process C supported the current approved active substance shelf-life of 36 months at the recommended storage condition of 2°C to 8°C and protected from light.

Additionally, stability studies have been performed using active substance manufactured using Process D, at the intermediate-scale (one of these batches was used the Process D finished product batch used to establish biocomparability with the CA2098FC clinical study). These studies are also complete, with real-time stability data at the long-term, 2°C to 8°C, condition available through 36 months.

Minor change was observed for photostability studies at room temperature or room light or for temperature cycling studies for Process C active substance, and given that analytical comparability was demonstrated between Process D and Process C, the studies were not repeated for Process D active substance.

To support the transition to Process D, stability studies have been initiated using active substance manufactured using Process D. Samples were stored in 50-mL bioprocess containers representative of the larger bioprocess containers used for active substance storage. Real-time stability data at the longterm (2ºC to 8ºC) are available through 12 months for  a number of batches. Accelerated (25ºC/40%RH) stability studies are now complete through 6 months for the same batches. All results met the proposed acceptance criteria through the study period, and all stability profiles align with

<div style=\"page-break-after: always\"></div>

those of the historical Process C batches and the Process D batches (intermediate scale) batches. As expected, slight changes were observed at the accelerated conditions. Stress (40ºC/75%RH) stability studies were conducted on the PPQ batches through 3 months, showing greater changes than observed for the accelerated studies, which are not unexpected at the stress condition. However, the stability profiles for all attributes are aligned with those of historical Process C batches, as well as the Process D (intermediate scale) batches.

A protocol for long-term (up to 36 months), accelerated (up to 6 months), and stress (up to 3 months) stability studies is presented. The Applicant commits to the completion of all ongoing long-term stability studies on nivolumab active substance batches according to that protocol. The Applicant also commits to place one batch annually thereafter into the post-approval stability program.

The Applicant requests that the stability data presented here, along with the active substance comparability, support the proposal to retain the currently approved Process C shelf-life of 36 months for Process D active substance manufactured at the approved facility, stored at 2ºC to 8ºC and protected from light. This is accepted.

## 2.4.3. Finished Medicinal Product

## 2.4.3.1. Description of the product and Pharmaceutical Development

## Description of the product

There are no changes in this section and the finished product is prepared in these four presentations: 40 mg/4 mL (10 mg/mL), 100 mg/10 mL (10 mg/mL), 120 mg/12 mL (10 mg/mL) and 240 mg/24 mL (10 mg/mL). The four presentations have the same formulation and protein concentration, and are only different in terms of fill volumes and vial sizes. Nivolumab injection is formulated in sodium citrate, sodium chloride, mannitol, pentetic acid, with polysorbate 80.

## Pharmaceutical development

For finished product manufacturing, there are no changes to the currently approved nivolumab injection manufacturing process. Therefore, the active substance comparability data also supports that finished product manufactured with Process D active substance is comparable to finished product manufactured with Process C active substance. To further support that finished product quality is not impacted by this change in the active substance manufacturing process, a supplemental analytical comparability evaluation of finished product release data was performed.

The pre-change comparator group consisted of multiple commercial batches manufactured with Process C active substance batches including all four presentations. The post-change data set consists of the PPQ batches (one batch of each presentation) manufactured with Process D active substance (representative of the quality of Process D sourced finished product manufactured at any of the approved finished product manufacturing sites). The comparative release data confirm that Process D sourced finished product is comparable to Process C sourced finished product across all approved finished product manufacturing sites.

Combined with the active substance analytical comparability data and with the finished product comparative stability data, it can be concluded that there is no adverse impact on nivolumab finished product due to the change from Process C active substance to the new Process D active substance.

<div style=\"page-break-after: always\"></div>

## 2.4.3.2. Manufacture of the product and process controls

## Manufacturers and manufacturing process

There are no changes, to the finished product manufacturing sites, or finished product manufacturing process with this Process D introduction. There is no change in the formulation and composition.

## Process validation/verification

Since the finished product process and formulation are identical for both Process C and Process D sourced finished product, the PPQ was completed at one manufacturing site based on a bracketing approach, with one finished product validation batch per presentation (40 mg/4 mL, 100 mg/10 mL, 120 mg/12 mL, and 240 mg/24 mL). The results were satisfactory without major deviations and they serve to qualify Process D active substance for use to manufacturing all Process D sourced finished product presentations at the approved manufacturing sites.

## 2.4.3.3. Product specification, analytical procedures, batch analysis

## Specifications

The specifications for release and stability testing of Process D sourced finished product are considered acceptable. The specifications for release and stability testing of Process D sourced finished product include tests for appearance, semi-quantitative visible particles, quantity, pH, polysorbate 80, osmolality, particulate matter, extractable volume, purity, identity, potency, host cell protein, bacterial endotoxins, sterility and container closure system.

With the introduction of Process D sourced finished product, the only significant change proposed is to remove endotoxin and sterility from the stability specification (container closure integrity test (CCIT) is performed in lieu of sterility for stability testing, and endotoxin does not increase on stability).

For three attributes, minor changes are made to the specification for Process D sourced finished product compared to the specification for Process C sourced finished product: appearance, quantity and endotoxin (there is no change to the acceptance criteria).

## Analytical procedures and reference standards

The analytical procedures used for control of Process D sourced finished product and the method histories are presented.

A new quantity method was validated and is introduced for Process D sourced finished product testing. For all other methods, the existing method validations performed to support testing of Process C sourced finished product also support use of the same methods for Process D sourced finished product.

## Batch analyses

The Applicant provided detailed results of analytical testing for the PPQ Process D sourced finished product batches and also the clinical/stability batch used for the biocomparability study.

## Nitrosamines

A 'Nitrosamine Risk Assessment Summary - Drug Product' is included in the dossier. The conclusion was that the risk level is negligible to low and that there are no actionable risks identified for the presence of nitrosamines in the finished product.

## Container closure

No changes are introduced in this section.

<div style=\"page-break-after: always\"></div>

## 2.4.3.4. Stability of the product

The finished product (10 mg/mL) is manufactured using Process C active substance and the results from the completed and on-going studies support a shelf-life of 36 months at the recommended storage condition of 2°C to 8°C, protected from light.

Stability studies of finished product formulated with Process D active substance made at intermediate bioreactor-scale are complete at real-time, long-term, 2°C to 8°C, condition through 36 months.

Since minor changes were observed for Process C, and given that analytical comparability was demonstrated between Process D and Process C active substance, photostability and freeze/thaw temperature cycling studies were not repeated for Process D.

To support the transition to Process D, stability studies have been initiated using PPQ batches of finished product (10 mg/mL) using Process D active substance. Stability studies are being conducted on a few batches of finished product  at the long-term (2°C to 8°C), accelerated (25°C/60% RH) and stress (40°C/75% RH) storage conditions. The finished product was packaged in the same packaging components that are used for the current approved commercial product.

At the long-term (2°C to 8°C) and accelerated (25°C/60% RH) storage conditions, stability test results from the finished product PPQ batches meet the acceptance criteria for all attributes through the 3month and 2-month timepoints, respectively, and are aligned with historical data from finished product manufactured using approved commercial Process C active substance and Process D sourced finished product (using intermediate scale active substance). At the stress condition (40°C/75% RH), the results through the 2-month timepoints are consistent with the historical data from Process C sourced finished product and Process D sourced finished product (using intermediate scale active substance).

A protocol for long-term (up to 36 months), accelerated (up to 6 months), and stress (up to 3 months) stability studies is presented. The Applicant commits to the completion of all ongoing long-term stability studies on nivolumab finished product batches according to that protocol. The Applicant also commits to place one batch annually thereafter into the post-approval stability program for each calendar year that commercial manufacturing occurs. The post-approval stability protocol is presented in the dossier.

The Applicant requests that the stability data presented, along with the finished product comparability studies, support the proposal to retain the currently approved Process C sourced finished product shelf-life of 36 months for Process D sourced finished product, stored at 2ºC to 8ºC and protected from light. This is accepted.

## 2.4.3.5. Adventitious agents

In order to minimise the risk of transmissible spongiform encephalopathy (TSE), no raw material of animal origin (primary source) was used in the manufacture and cryopreservation of the research cell bank (RCB), MCB and WCB for nivolumab. The nivolumab active substance manufacturing process from WCB does not use any material of animal or human origin.

The TSE risk is considered negligible.

Viral testing and characterization was performed for the cell banks. In the bulks pre-harvest material critical performance attributes were bioburden, mycoplasma, adventitious virus and Minute virus of mice (MVM).

Viral clearance studies were conducted using a panel of model viruses with a wide range of physiochemical characteristics. Scale-down studies were performed to evaluate the capacity of orthogonal

<div style=\"page-break-after: always\"></div>

steps with the capacity to inactivate or remove potential adventitious viral agents. The calculated viral safety assessment is considered acceptable.

## 2.4.4. Discussion and conclusions on chemical, pharmaceutical and biological aspects

Nivolumab active substance is currently produced using an approved manufacturing Process C, that uses the approved MCB cell line. At the time of the initial marketing authorisation for OPDIVO (nivolumab), Bristol-Myers Squibb Company (BMS) committed to establish a new MCB for long-term commercial active substance manufacturing. With the intention to fulfil the quality recommendation, BMS has developed a new recombinant CHO host cell line  for manufacture of nivolumab, together with an optimised active substance manufacturing Process D, to increase process robustness and enhance overall process yield while maintaining comparable product quality.

The quality dossier submitted is well organised and provides comprehensive information regarding the new development of manufacturing Process D. There were no major objections. Only a few other concerns were raised during the evaluation procedure and were adequately addressed.

The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

## 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way. Data have been presented to give reassurance on viral/TSE safety.

## 2.4.6. Recommendation(s) for future quality development

Not applicable

## 2.5. Non-clinical aspects

No new non-clinical data have been submitted with this application.

## 2.5.1. Ecotoxicity/environmental risk assessment

Nivolumab is a protein composed of natural amino acids expected to biodegrade in the environment and not be a significant risk. Nivolumab is therefore exempt from preparation of an Environmental Risk Assessment under the 'Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use' (EMEA/CHMP/S/4447/00).

<div style=\"page-break-after: always\"></div>

## 2.6. Clinical aspects

## 2.6.1. Introduction

The transition of nivolumab drug substance manufacturing Process C to new optimized Process D (using new cell line), is supported by a clinical Phase 1 Study CA2098FC in adjuvant melanoma patients to assess biocomparability between the material from both drug substance manufacturing Process C and Process D.

## GCP aspects

The clinical trial was performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trial conducted outside the community was carried out in accordance with the ethical standards of Directive 2001/20/EC.

## · Tabular overview of clinical studies

| StudyType            | Study Identifier; Report Location in CTD                                                                                                                            | Primary Study Objective                                                                     | Study Design                                                                                                                                                                                                                             | Test Product(s); Dosage Regimen; Routeof Administration                                                                                                                                                                                                                                                                               | Numberof SubjectsTreated                              | StudyPopulation                                                                                                                       | Study Status,Typeof Report                                                                                                                                                                                                                                                                                                                                                  |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PivotalClinicalStudy | PivotalClinicalStudy                                                                                                                                                | PivotalClinicalStudy                                                                        | PivotalClinicalStudy                                                                                                                                                                                                                     | PivotalClinicalStudy                                                                                                                                                                                                                                                                                                                  | PivotalClinicalStudy                                  | PivotalClinicalStudy                                                                                                                  | PivotalClinicalStudy                                                                                                                                                                                                                                                                                                                                                        |
| Bioequivalence       | Study identifier: CA2098FC (NCT03980314) Report location: Primary CSR: Module5.3.5.1; Addendum01 toPrimary CSR:Module 5.3.5.1; Erratumto Primary CSR: Module5.3.5.1 | To compare thePK(AUC [0-336h]at Week1,Day1 andWeek17, Dayl]of ProcessD relativeto ProcessC. | Phase1, randomized, double-blind study. Subjectswere randomized 1:1to nivolumab Process C(Arm A)or Process D (ArmB)and stratified by: -AJCC Staging (8th edition) [Stage IIla/b/c/d orIV] -Weight categories(<70 kg,70 to90 kg, and>90kg | ArmA:NivoProcessC 3mg/kgIVQ2Wfor Week1toWeek17 followedby480mgIV Q4WforWeek19to Week51 3mg/kgIVQ2Wfor ArmB:NivoProcessD Week1toWeek17 followedby480mgIV Q4WforWeek19to Week51 Allsubjectswere treateduntilrecurrence, unacceptable toxicity, withdrawal ofconsent, completionof1yearof treatment,orstudyend, whicheveroccurred first. | Total:261 -ArmA (Process C):129 -ArmB (Process D):132 | Subjects≥18years oldwith histologically confirmedcompletely resectedStage IIla/b/c/dorStageIV (AJCC Staging,8th edition)NED melanoma. | Study status:Ongoing Typeofreports: Primary CSR(includes primary endpoint[PK], secondary endpoints [safety, immunogenicity and PK],andexploratory endpoints [efficacy and PK1): Addendum01to Primary CSRa (includes updated analyses of secondary andexploratory endpoints,excluding PK); ErratumtoPrimary CSR(includesrevised Appendix2.3 [important protocol deviationsl) |

Abbreviations:AJCC:AmericanJointCommitteeonCancer;AUC（0-336h):Areaundertheconcentration-timecurvefrom0to336hours;CSR:clinicalstudy report;IV:intravenous;NED:noevidence of disease;nivo:nivolumab;PK:pharmacokinetics;QxW:everyxwecks

## 2.6.2. Clinical pharmacology

## 2.6.2.1. Pharmacokinetics

## Quantitation of Nivolumab in Human Serum

## Method validation

Method ICD 416 is an electrochemiluminescent (ELC) assay and was used to analyse the human serum samples that were obtained for PK evaluations from Study CA2098FC. .

<div style=\"page-break-after: always\"></div>

## Sample analysis

The quantification of nivolumab in human serum samples from Study CA2098FC was performed by ECL method over a quantitative range of 0.2 μg/mL and 6.5 μg/mL. Each run consisted of one set of standards [0.100 (anchor), 0.200, 0.300, 1.000, 2.500, 4.000, 5.50 0 and 6.500 μg/mL], two sets of three QCs (0.600, 1.50 and 4.80 μg/mL) and three sets of DQCs (for study samples that required dilution).

Sample analysis started on 01 July 2020 and was completed on 29 April 2021. Overall, 176 out of 178 runs were accepted (98.7%). Two runs were rejected, one due to unacceptable QC samples and the other one due to unacceptable matrix blanks.

Multiple samples were received and analysed according to protocol. From the  samples analysed, the majority was reported, but a few samples were not reported or were pending analysis. One sample shipment was received in a thawed condition, and for this reason, those samples were classified as 'not reported'.

The between-run precision (%CV) and accuracy (%Bias) of the calibration curve standards and of the QCs met the acceptance criteria.

Samples were reassayed per protocol/SOP.

Incurred sample reanalysis was performed on 11.2% of samples, and for 99.8% of samples the relative percent difference (RPD) of the original and repeat results was ≤ ±30%.

No temperature excursions were reported. The maximum storage time was 848 days at -80ºC, and the validated stability of nivolumab for method ICD 416 is 2373 days at -80  C.

## Detection of Anti-Nivolumab Antibodies in Human Serum

## Method validation

For ADA analysis, method ICDIM 140 was used. This is a qualitative bridging ECL immunoassay performed using bead extraction with acid dissociation on the MSD platform.

The detection of ADA is based on a three-tiered testing approach (screen, confirm, and titer), as described in the table below.

<div style=\"page-break-after: always\"></div>

Table 1: Three-tiered testing for the detection of ADA

| Analysis conducted according to      | Bioanalytical Plan11                                                                                                                                   |
|--------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| PPDMethod Number                     | ICDIM 140 V 2.04 (Appendix B)                                                                                                                          |
| PPD Method Titlea                    | AnElectrochemiluminescenceMethodfor the DetectionofAnti-BMS-936558inDiseaseState Human Serum                                                           |
| Method Validation Project Code       | JRY21,2,3,4,5,6,7,8,9,10                                                                                                                               |
| Tier 1: Screening Cut Point (ACP)    | Samples with raw responses at or above the assay cut point (1.52*Mean NC Response) are considered potentially positive for anti-BMS-936558 antibodies. |
| Tier 2: Confirmatory Cut Point (CCP) | Samples are confirmed positive if suppression ≥ 77.2%.                                                                                                 |
| Tier 3: Titer Cut Point (TCP)        | Samples are titered until a raw response below the sample TCP (2.11*Mean NC Response) is obtained.                                                     |
| ValidatedStabilityParameters         | ValidatedStabilityParameters                                                                                                                           |
| Freeze/ThawStability                 | Ten cycles, thawed at room temperature and frozen at -80°C                                                                                             |
| Room Temperature Stability           | 24 hours at room temperature                                                                                                                           |

- Footer, Page 1 of 21: ICDIM 140 Version 2.04
- Critical Reagents Table,Page 6 of21:Use ofTag-BMS-936558six months or more after aliquoting is acccptable as long as plate specific method acceptance criteria continue to be met.Assayperformance should be monitored closelyfor trends in NC raw signal to alert reviewer to possible performance issues that warrant aliquoting a new vial.
- Reportable titer = reciprocal of highest dilution detected at or above the sample TCP. If lowcst diluted sample tested is below the TCP,the titerresult is reported as1.
- Samplesanalyzedwithinvalidatcdstabilityparamcters.

## Sample analysis

Human serum samples from Study CA2098FC were analysed for anti-BMS-936558 antibodies. Sample analysis started on 02 July 2020 and was completed in 05 April 2021. A total of 62 runs were performed, and 60 of them were accepted (96.8%).

Multiple samples were received. Of those, majority was analysed and reported. Some samples were not analysed per protocol/SOP, and one sample was pending analysis when the report was issued.

Prior to the analysis of study samples, positive and negative control samples were prepared and qualified according to protocol. All negative controls, positive controls, confirmatory controls, titer controls, and study samples were analysed in duplicate wells.

In the screening assay, some samples were identified as 'potential positive'. Of those several were negative in the confirmatory assay, whilst some were classified as positive. Of those, a few samples had insufficient volume for the titer assay.

Reasons for sample reassay were according to protocol/SOP.

An evaluation of the false positive screening rate was conducted during this study.

## Detection of Anti-Nivolumab Neutralising Antibodies in Human Serum

## Method validation

Method VSDCBA was used for the detection of BMS-936558 (nivolumab) neutralizing antibodies (NAbs).

It is expected that all anti-drug antibody (ADA) positive clinical serum samples will contain a high concentration of BMS-936558, resulting in potential interference in the NAb assay. In this assay, anti-

<div style=\"page-break-after: always\"></div>

BMS-936558 NAb positive controls (low, high positive, and an extraction control containing drug) are analyzed on each plate.

Samples are stored at a nominal temperature of -80 °C (-90 °C to -60 °C) prior to analysis. This assay requires a minimum 100 μL human serum aliquot for analysis.  Samples at or below the assay cut point will be characterized as having neutralizing antibodies present.

The plate map is designed in such a way that each single well on preparatory plate will be duplicated on bioassay plate.

All drug controls, positive controls, and study samples are analyzed in duplicate wells. Based on the results of the validation, the acceptance criteria for sample analysis was specified in the protocol.

## Sample analysis

Multiple samples from study CA2098FC were received and of those, some samples that were confirmed positive for ADA and had sufficient volume for the titer assay were analysed for NAb.

A total of 6 runs were performed and were acceptable according to pre-defined criteria.

No sample reassay was required and no deviations were reported.

Regarding neutralising activity results, some samples were reported as 'not neutralising', whereas for a few samples the result was not recorded (NRR) due to insufficient sample volume for analysis.

## Bioequivalence

## Study CA2098FC: A Randomized, Double-Blind, Parallel, Phase 1 Study to Compare the Pharmacokinetics of Nivolumab Process D to Nivolumab Process C after Complete Resection of Stage IIIa/b/c/d or Stage IV Melanoma

## Methodology

The study was divided into a Screening Period; a Treatment Period consisting of Arm A and Arm B (described below); and a Follow-up Period. The nivolumab drug product used in this study was manufactured from Process C and Process D drug substance, respectively.

· Arm A: Process C 3 mg/kg IV Q2W for Week 1 to Week 17 followed by 480 mg IV Q4W for Week 19 to Week 51

· Arm B: Process D 3 mg/kg IV Q2W for Week 1 to Week 17 followed by 480 mg IV Q4W for Week 19 to Week 51

Subjects were randomly assigned within stratified AJCC Staging (8th edition) [Stage IIIa/b/c/d or IV] and weight categories (&lt; 70 kg, 70 to 90 kg, and &gt; 90 kg) in a 1:1 ratio to receive either Process C or Process D. Overall, 129 subjects were randomized to Arm A (Process C), and 132 subjects were randomized to Arm B (Process D).

All subjects were treated until recurrence of disease, unacceptable toxicity, or subject withdrawal of consent, with a maximum of 1 year of treatment, or study termination by the Sponsor, whichever occurred first. The study design schematic is presented in Figure 1.

<div style=\"page-break-after: always\"></div>

Figure 1: Study Design Schematic

<!-- image -->

This study was conducted at 32 investigational sites in 13 countries (Argentina, Australia, Brazil, Chile, France, Ireland, Italy, Mexico, New Zealand, Poland, Romania, Spain, and United States).

The study was initiated on 24-Jun-2019 and is still ongoing.

Objectives and outcomes/endpoints

Primary and secondary objectives and endpoints for study CA2098FC are described below.

Table 2: Primary and secondary objectives and endpoints

| Objectives                                                        | Endpoints                                                                                                                                              |
|-------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary                                                           |                                                                                                                                                        |
| To compare the PK of Process D relative to Process C.             | AUC(TAU)(0-336h) at Week 1 Day 1 (after first dose) and AUC(TAU)(0-336h) at Week 17 Day 1 (after multiple doses)                                       |
| Secondary                                                         |                                                                                                                                                        |
| To characterize the PK of ProcessDand Process C.                  | Cmax and Ctau at Week 1 Day 1 after first dose Cmax, Ctau, clearance, and volume of distribution at Week 17 Day 1 after multiple doses Ctrough         |
| To assess the immunogenicity of Process Dand Process C.           | Incidence and frequency of anti-nivolumab antibodies and neutralizing antibodies                                                                       |
| To assess the safety and tolerability of Process D and Process C. | Safety (including but not limited to): AEs, SAEs, AEs leading to discontinuation, deaths, and clinical laboratory abnormalities per CTCAE, version 5.0 |

## Test and reference products

Subjects received Process C or Process D nivolumab at a dose of 3 mg/kg as a 30-minute infusion on Day 1 of each treatment cycle Q2W for Week 1 to Week 17 and a flat dose of 480 mg Q4W for Week 19 to Week 51 until recurrence, unacceptable toxicity, withdrawal of consent, completion of 1 year of treatment, or the study ends, whichever occurred first. Subjects received 3 mg/kg dose based on body weight, which was assessed at each visit. All doses were rounded up to the nearest milligram per institutional standard.

<div style=\"page-break-after: always\"></div>

There were no dose escalations or reductions of nivolumab allowed. Subjects were dosed no less than 12 days from the previous dose during Q2W cycles and no less than 25 days during Q4W cycles. Premedications were not recommended for the first dose of nivolumab.

The investigational products used in this study are summarised below.

Table 3: Details on investigational products used in study CA2098FC

| Product Description and Dosage Form                      | Strength          |
|----------------------------------------------------------|-------------------|
| Nivolumab (BMS-936558-01) SolutionforInjection (Process  | 100 mg (10 mg/mL) |
| Nivolumab(BMS-936558-01) SolutionforInjection (Process D | 100 mg (10 mg/mL) |

## Sampling times

Nivolumab PK blood samples were collected at 0:00 (pre-dose), 0:30 (end of infusion), 4:00, 24:00, 48:00, 96:00 and 168:00 hours after start of nivolumab infusion. ADA blood samples were also collected at pre-dose times (Week 1 Day 1 and Week 17 Day 1).

Additionally, pre-dose PK blood samples and ADA blood samples were collected on Week 3 Day 1, Week 19 Day 1, week 35 Day 1 and Week 51 Day 1 (Table below).

Table 4: Pharmacokinetic and ADA sampling schedule

| Study Day of SampleCollection   | Event   | TimeRelativetoStartof NivolumabInfusion (hr:min)   | NivolumabPK Blood Sample   | NivolumabADA Blood Sample   |
|---------------------------------|---------|----------------------------------------------------|----------------------------|-----------------------------|
| Weck 1 Day 1                    | Predose | 0:00                                               | X                          | X                           |
| Weck 1 Day 1                    | EOra    | 0:30                                               | X                          |                             |
| Weck 1 Day 1                    |         | 4:00                                               | X                          |                             |
| Weck 1 Day 2                    |         | 24:00                                              | X                          |                             |
| Weck 1 Day 3                    |         | 48:00                                              | X                          |                             |
| Weck 1 Day 5                    |         | 96:00                                              | xb                         |                             |
| Weck 2 Day 1                    |         | 168:00                                             | X                          |                             |
| Weck 3 Day 1                    | Predose | 0:00                                               | X                          | X                           |
| Weck 17 Day 1                   | Predose | 0:00                                               | X                          | X                           |
| Weck 17 Day 1                   | EO1a    | 0:30                                               | X                          |                             |
| Weck 17 Day 1                   |         | 4:00                                               | X                          |                             |
| Weck 17Day 2                    |         | 24:00                                              | X                          |                             |
| Weck 17 Day 3                   |         | 48:00                                              | X                          |                             |
| Weck 17Day 5                    |         | 00:96                                              | xb                         |                             |
| Weck 18 Day 1                   |         | 168:00                                             | X                          |                             |
| Weck 19 Day 1                   | Predose | 0:00                                               | X                          | X                           |
| Weck 35 Day 1                   | Predose | 0:00                                               | X                          | X                           |
| Weck 51 Day 1                   | Predose | 0:00                                               | X                          | X                           |

<div style=\"page-break-after: always\"></div>

## Pharmacokinetic parameters

PK parameters for nivolumab were derived by non-compartmental analysis methods using serum concentration versus time data following the first and last dose administration of nivolumab 3 mg/kg IV Q2W (Week 1, Day 1 and Week 17, Day 1, respectively). Actual times were used for all analyses.

Geometric mean, %CV, N, mean, SD, min, max, and median were presented by treatment group for Cmax, Tmax, AUC(0-336h) [AUC(TAU)], and Ctau, after the first dose (Week 1) and after multiple doses (Week 17); for CLT, Vz, AI\\_AUC, and T-HALF-eff, only after multiple doses (Week 17). AI\\_AUC was based on the ratio of AUC(TAU) after multiple doses (Week 17) to that after the first dose (Week 1). Ctrough values were summarized separately from the other PK parameters using geometric mean, %CV, N, mean, SD, min, max, and median, across all cycles where predose PK samples were collected. In addition, scatterplots of Ctrough vs week were provided overlaid by the geometric mean values, for each treatment.

Within a dosing interval, the Cmax and Tmax were recorded directly from experimental observations. The AUC(TAU) was calculated by log- and linear-trapezoidal summations or linear up/log down method in Phoenix WinNonlin ™ (version 8.2).

For the purpose of calculating PK parameters, predose concentrations that were less than the assay's LLOQ and concentrations prior to the first quantifiable concentration that were less than the LLOQ were set to zero, and all other concentrations less than LLOQ were set to missing.

## Statistical analysis

A linear fixed effect model with treatment, AJCC staging and weight category (as recorded in the IRT) as fixed effects was fitted to the log-transformed PK parameters AUC(0-336h) at Week 1, Day 1 and at Week 17, Day 1 for use in estimation of effects and construction of CIs. To assess biocomparability of Process D to Process C, point estimates and the 2-sided 90% CIs for treatment differences on the log scale was exponentiated to obtain estimates for ratios of geometric means and respective 90% CIs for nivolumab AUC(0-336h) at Week 1, Day 1 and at Week 17, Day 1 on the original scale. Biocomparability of Process D to Process C was concluded if the 90% CIs for the ratios of geometric means for nivolumab AUC(0-336h) at Week 1, Day 1 and at Week 17, Day 1 are contained within 0.8 to 1.25 limits.

## Subject disposition

The enrolment period was approximately 15 months from 24-Jun-2019 to 25-Sep-2020. 341 subjects were enrolled, and 261 subjects were randomized and treated (129 to the nivolumab Process C group and 132 to the nivolumab Process D group).

<div style=\"page-break-after: always\"></div>

Table 5: Summary of demographic characteristics

|                                           | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)   |
|-------------------------------------------|--------------------------|--------------------------|--------------------------|
|                                           | Process C N = 129        | Process D N = 132        | Total N = 261            |
| AGE (YEARS)                               |                          |                          |                          |
| N                                         | 129                      | 132                      | 261                      |
| MEAN                                      | 55.8                     | 54.2                     | 55.0                     |
| MEDIAN                                    | 57.0                     | 57.0                     | 57.0                     |
| MIN，MAX                                   | 25 , 81                  | 20 , 87                  | 20，87                    |
| SD                                        | 13.6                     | 15.4                     | 14.5                     |
| AGE CATEGORIZATION 1 (%)                  |                          |                          |                          |
| < 65 YEARS                                | 88 (68.2)                | 89 ( 67.4)               | 177 ( 67.8)              |
| >= 65 YEARS                               | 41 ( 31.8)               | 43 ( 32.6)               | 84 ( 32.2)               |
| AGE CATEGORIZATION 2 (%)                  |                          |                          |                          |
| < 75 YEARS                                | 123 ( 95.3)              |                          | 245 ( 93.9)              |
| >= 75 YEARS                               | 64.7)                    |                          | 16 (6.1)                 |
| SEX (%)                                   |                          |                          |                          |
| MALE                                      | 87 (67.4)                | 78 (59.1)                | 165 (63.2)               |
| FEMALE                                    | 42 ( 32.6)               | 54 ( 40.9)               | 96 ( 36.8)               |
| RACE (%)                                  |                          |                          |                          |
| WHITE                                     | 126 ( 97.7)              | 127 (96.2)               | 253 ( 96.9)              |
| NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER | 0                        | 1 0.8)                   | (0.4)                    |
| OTHER                                     | 3 ( 2.3)                 | 4 ( 3.0)                 | 2.7                      |
| WEIGHT (KG)                               |                          |                          |                          |
| N                                         | 129                      | 132                      | 261                      |
| MEAN                                      | 82.1                     | 80.8                     | 81.4                     |
| MEDIAN                                    | 81.0                     | 78.6                     | 79.7                     |
| MIN，MAX                                   | 52 144                   | 50;140 16.5              | 50,144 17.5              |
| SD                                        | 18.5                     |                          |                          |
| WEIGHT CATEGORIZATION (CRF)(%)            |                          |                          |                          |
| <70KG                                     | 33 3( 25.6)              | 33 (25.0)                | 66 (25.3)                |
| 70TO90KG                                  | 53 50.4)                 | 51.53                    | 133 51.0)                |
| >90 KG                                    | 24.0)                    | 83 23.5)                 | 62 23.8)                 |

Sourcc:Table S.3.2.1

Table 6: Analysis p opulation

| Population                      | Description                                                                                                                                                                                                                                                                                                                                                                                                                            | Total Number of Subjects   |
|---------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|
| All Enrolled Subjects           | All subjects who sign an informed consent form and are registered into the IRT.                                                                                                                                                                                                                                                                                                                                                        | 341                        |
| All Randomized Subjects         | All subjects who are randomized to any treatment arm in the study.                                                                                                                                                                                                                                                                                                                                                                     | 261                        |
| All Treated Subjects            | All subjects who receive at least 1 dose of nivolumab                                                                                                                                                                                                                                                                                                                                                                                  | 261                        |
| PK Subjects                     | All treated subjects with available PK concentration-time data.                                                                                                                                                                                                                                                                                                                                                                        | 261                        |
| Evaluable PK Subjects           | The Evaluable PK Subjects is a subset of the PK Subjects. The Evaluable PK Subjects includes all subjects in the PK Subjects with adequate dosing and adequate PK profiles for accurate estimation of PK parameters. All available derived PK parameter values will be included in the PK data set and reported, but only subjects in the Evaluable PK Population will be included in the summary statistics and statistical analysis. | 240a                       |
| ImmunogenicityEvaluableSubjects | All treated subjects who have a baseline and at least 1 post baseline immunogenicity assessment.                                                                                                                                                                                                                                                                                                                                       | 241                        |

Source: Table S.2.5 (all enrolled subjects), Table S.2.6A (all randomized subjects), Table S.2.7 (all treated subjects), Appendix 4.6.2 (PK subjects), Table S.9.1 (evaluable PK subjects), Table S.7.10 (ADA Summary)

Numbers of evaluable PK subjects vary for different PK parameters. For primary endpoint AUC(TAU), there are 240 evaluable PK subjects at Week 1, and 195 evaluable PK subjects at Week 17. Numbers of evaluable PK subjects for other PK parameters by treatment group are provided in Table S.9.1.

<div style=\"page-break-after: always\"></div>

While 261 patients had available PK concentration-time data, only 240 subjects were considered as PK evaluable patients by the MAH (i.e. subjects with adequate dosing and PK profiles).

Table 7: Summary of reasons for subjects without AUC (TAU) values in the statistical analysis

<!-- image -->

|                                                                                                   | Process C N = 127                                                                                 | Process N = 132                                                                                   | Total N = 259                                                                                     |
|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| WEEK 1                                                                                            | WEEK 1                                                                                            | WEEK 1                                                                                            | WEEK 1                                                                                            |
| SUBJECTS WITH EVALUABLE AUC(TAU)(%)                                                               | 121 (95.3)                                                                                        | 119 (90.2)                                                                                        | 240 (92.7)                                                                                        |
| SUBJECTSWITHOUT EVALUABLE AUC(TAU)(%)                                                             | 6(4.7)                                                                                            | 13 ( 9.8)                                                                                         | 19 (7.3)                                                                                          |
| REASON(%)                                                                                         | REASON(%)                                                                                         | REASON(%)                                                                                         | REASON(%)                                                                                         |
| AUC(TAU)EXTRAPOLATIONGREATERTHAN3O%                                                               | 4 (3.1)                                                                                           | 8 (6.1)                                                                                           | 12 (4.6)                                                                                          |
| INCOMPLETEPROFILE                                                                                 | 0                                                                                                 | 2 2 (1.5)                                                                                         | 2 (0.8)                                                                                           |
| PROFILE MISSING POTENTIAL TmaX                                                                    | 1 (0.8)                                                                                           | 0                                                                                                 | 1 (0.4)                                                                                           |
| OTHER*                                                                                            | 1 (0.8)                                                                                           | 3 (2.3)                                                                                           | 4 (1.5)                                                                                           |
| WEEK 17                                                                                           | WEEK 17                                                                                           | WEEK 17                                                                                           | WEEK 17                                                                                           |
| SUBJECTS WITH EVALUABLE AUC(TAU)(%)                                                               | 93 (73.2)                                                                                         | 102 (77.3)                                                                                        | 195 (75.3)                                                                                        |
| SUBJECTS WITHOUT EVALUABLE AUC(TAU)(%)                                                            | 34 (26.8)                                                                                         | 30 (22.7)                                                                                         | 64 (24.7)                                                                                         |
| REASON(%)                                                                                         | REASON(%)                                                                                         | REASON(%)                                                                                         | REASON(%)                                                                                         |
| AUC(TAU)EXTRAPOLATIONGREATERTHAN3O%                                                               | 11 (8.7)                                                                                          | 14 (10.6)                                                                                         | 25 (9.7)                                                                                          |
| INCOMPLETEPROFILE                                                                                 | 0                                                                                                 | 0                                                                                                 | 0                                                                                                 |
| PROFILE MISSING POTENTIAL TmaX                                                                    | 1 (.0.8)                                                                                          | 0                                                                                                 | 1 (.0.4)                                                                                          |
| OTHER*                                                                                            | 22 (17.3)                                                                                         | 16 (12.1)                                                                                         | 38 3(14.7)                                                                                        |
| * Other means not enough PK concentration data for Auc(TAu)to be derived at week 1 or at week 17. | * Other means not enough PK concentration data for Auc(TAu)to be derived at week 1 or at week 17. | * Other means not enough PK concentration data for Auc(TAu)to be derived at week 1 or at week 17. | * Other means not enough PK concentration data for Auc(TAu)to be derived at week 1 or at week 17. |
| ProgramSource:BMS_GBS\\CA209\\WYA33304\\Biostatistics\\Production\\Tables\\PA\\rt-pk-aucmis.sas          | ProgramSource:BMS_GBS\\CA209\\WYA33304\\Biostatistics\\Production\\Tables\\PA\\rt-pk-aucmis.sas          | ProgramSource:BMS_GBS\\CA209\\WYA33304\\Biostatistics\\Production\\Tables\\PA\\rt-pk-aucmis.sas          | 07MAR2023:13:51                                                                                   |

## Pharmacokinetic results

In the primary analysis performed with treatment, AJCC staging and weight category as fixed effects, AUC(TAU) geometric mean ratios (90% CI) were of 1.012 (0.984, 1.041) and 0.998 (0.951, 1.047) at Week 1, Day 1 and at Week 17, Day 1, respectively (table below).

Table 8: Statistical Analysis of PK parameters

<!-- image -->

An additional analysis was performed with only treatment as a fixed effect. In this analysis, Week 1, Day 1 and Week 17, Day 1 AUC(TAU) geometric mean ratios (90% CI) were of 1.013 (0.983, 1.043) and 1.002 (0.955, 1.051).

Plots of mean (+SD) nivolumab serum concentrations vs time by treatment at Week 1 and Week 17 are presented below.

<div style=\"page-break-after: always\"></div>

Figure 2: Mean (+SD) nivolumab serum concentrations vs time by treatment at Week 1

Week 1

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 3: Mean (+SD) nivolumab serum concentrations vs time by treatment at Week 17

## Week 17

<!-- image -->

Figure S.4.6.4

Trcatment Description: ARM A: Process C, 3 mg/kg Q2W + 480 mg Q4W; ARM B: Proccss D, 3 mg/kg Q2W + 480 mg Q4W.

Note: &lt; LLOQ = Less than lower limit of quantitation (O.200 μg/mL).

<div style=\"page-break-after: always\"></div>

Table 9: Summary of nivolumab PK parameters by treatment on Week 1, Day 1 and Week 17, Day 1

| PARAMETER STATISTIC              | Process C               | Process D               |
|----------------------------------|-------------------------|-------------------------|
| Week 1 Day 1                     |                         |                         |
| Cmax (ug/mL)                     |                         |                         |
| GEO.MEAN [N] (%CV)               | 84.6 [125] (139)        | 78.8 [130] (60)         |
| Tmax (h)                         |                         |                         |
| MEDIAN [N] (MIN-MAX)             | 4.00 [125] (0.300-21.6) | 3.92 [130] (0.417-24.1) |
| AUC (TAU)  (ug*h/mL)             |                         |                         |
| GEO.MEAN [N]                     | 12880 [121] (16)        | 13046 [119] (12)        |
| (%CV)                            |                         | 25.3 [121]              |
| Ctau (ug/mL) GEO.MEAN [N] (%CV)  | 25.5 [122] (16)         | (16)                    |
| Week 17 Day 1                    |                         |                         |
| Cmax (ug/mL) GEO.MEAN [N] (%CV)  | 178 [105] (64)          | (21)                    |
|                                  |                         | 167 [117]               |
| MEDIAN [N]                       | 4.00_[105]              |                         |
| Tmax (h)                         |                         |                         |
| (MIN-MAX)                        | (0.383-24.7)            | 4.00_[117] (0.450-24.6) |
| AUC (TAU) (ug*h/mL) GEO.MEAN [N] |                         |                         |
| (%CV) Ctau (ug/mL)               | 39282_[93] (18)         | 39345_[102] (19)        |
| GEO.MEAN [N] (%CV)               | (21)                    | 88.0,[102] (23)         |
|                                  | 89.4. [94]              |                         |
| CLT (mL/min) GEO.MEAN [N]        | 0.103_[93] (30)         | 0.101_[102]             |
|                                  |                         | (35)                    |
| (%CV)                            |                         | 601 [95]                |
| T-HALFeff (h)                    |                         |                         |
| MEAN [N]                         | 603[90]                 | (136.7)                 |
| (SD)                             | (139.6)                 |                         |
| Vz_ (L)                          |                         |                         |
| GEO.MEAN [N]                     | 4.82_ [98]              | 4.80 [111]              |
| (%CV)                            | (33)                    | (55)                    |
| AI AUC                           |                         |                         |
| GEO.MEAN [N]                     | 3.04_[88]               | 2.98_[95]               |
|                                  |                         | (20)                    |
| (%CV)                            | (20)                    |                         |

Source:Table S.9.1

Following the first round of assessment, the MAH provided new comparability data including the subjects that were initially excluded due to AUCextrap greater than 30% and profile missing potential Tmax. A new biocomparability analysis was carried out, which included patients with AUC(TAU) extrapolated greater than 30% (12 patients in Week 1 and 25 patients in Week 17) and profiles with missing Tmax (1 patient in Week 1 and 1 patient in Week 17). The results of the new biocomparability analysis are shown.

Table 10: Statistical Analysis of BMS-936558 Pharmacokinetic Parameters Expanded PK Participants

<!-- image -->

| Protocol:CA2098FC       |                                     |                                     |                                     |                                     |                                     |                                     |                           | Page 1 of 2               |                  |
|-------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|---------------------------|---------------------------|------------------|
| Week 1 Day1(0-336h)     | FK parameter = AUC (TAU) ）(ug*h/mL) | FK parameter = AUC (TAU) ）(ug*h/mL) | FK parameter = AUC (TAU) ）(ug*h/mL) | FK parameter = AUC (TAU) ）(ug*h/mL) | FK parameter = AUC (TAU) ）(ug*h/mL) | FK parameter = AUC (TAU) ）(ug*h/mL) | On OriginalScale          | On OriginalScale          | On OriginalScale |
|                         | OnNaturalLogarithmicScale           | OnNaturalLogarithmicScale           | OnNaturalLogarithmicScale           | OnNaturalLogarithmicScale           | OnNaturalLogarithmicScale           | OnNaturalLogarithmicScale           | OnNaturalLogarithmicScale | OnNaturalLogarithmicScale |                  |
| IREATMENTAND COMPARISON | ADJUSTEDMEAN                        | STANDARD ERROR                      | DE                                  | T                                   | Pr > |T|                            | 90%CI                               | ADJUSTED GEO MEAN         | 90%CI                     |                  |
| Process                 | 9.466                               | 0.016                               | 248.0                               | 577.22                              | <.0001                              | (9.439,9.493)                       | 12916.272                 | (12571.241, 13270.771)    |                  |
| Process D               | 9.471                               | 0.016                               | 248.0                               | 594.02                              | <.0001                              | (9.444,9.497) (-0.023,0.032）        | 12975.076                 | (12637.989, 13321.155)    |                  |
| ProcessDvs Process C    | 0.005                               | 0.017                               | 248.0                               | 0.27                                | 0.7854                              |                                     | 1.005                     | (0.977, 1.033)            |                  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

## 2.6.3. Discussion on clinical pharmacology

Analytical methods ICD 416, ICDIM 140 and VSDCBA were validated to quantitate nivolumab concentrations, detect ADA, and characterise NAb in human serum, respectively. Overall, the applied methods are acceptable according to ICH M10 Guideline, and no major concerns arise.

The MAH was asked to justify why few samples for the quantification of nivolumab and one ADA sample were pending analysis. It was agreed that the overall integrity and validity of the PK analysis for Study CA2098FC are not affected by these few missing data.

Some samples from Study CA2098FC were confirmed positive for ADA and had sufficient volume for the titer assay. Those  samples were analysed for neutralising activity, and majority of them were reported as 'not neutralising' according to pre -specified criteria. A few samples were not reported due to insufficient sample volume. Thus, there is no evidence of formation of NAb.

## Study CA2098FC

Study CA2098FC is a randomized, double-blind, parallel, phase 1 study submitted to assess the biocomparability of Process D vs Process C. Subjects were randomly assigned within stratified AJCC Staging (8th edition) [Stage IIIa/b/c/d or IV] and weight categories (&lt; 70 kg, 70 to 90 kg, and &gt; 90 kg) in a 1:1 ratio to receive either Process C or Process D.

The parallel design is considered adequate due to the long half-life of nivolumab (25 days), as this avoids the long wash-out period of a cross-over design.

The monitoring activities included on-site monitoring visits, un-blinded in-person or remote visits, offsite monitoring visits and central monitoring.

The chosen primary PK parameters were AUC(TAU) after the first dose (Week 1 Day 1) and AUC(TAU) after multiple doses (Week 17 Day 1), and this is in line with the recommendations of the EMA Guideline on similar biological medicinal products containing monoclonal antibodies. Similarly, secondary endpoints were Cmax and Ctau, and Ctrough. This is acceptable according to the aforementioned Guideline.

Subjects received Process C or Process D nivolumab at a dose of 3 mg/kg as a 30-minute infusion on Day 1 of each treatment cycle Q2W for Week 1 to Week 17 and a flat dose of 480 mg Q4W for Week 19 to Week 51 until recurrence, unacceptable toxicity, withdrawal of consent, completion of 1 year of treatment, or the study ends, whichever occurred first.

Information  regarding  the  manufacturing  date,  expiry  date  and  certificates  of  analysis  for  the investigational products used in study CA2098FC has been provided.

The selection of batches for Process C did not follow a specific criteria, and the choice was based on supply chain availability. Instead, for Process D, a batch that was deemed analytically comparable to Process C was selected. This approach is considered acceptable.

<div style=\"page-break-after: always\"></div>

Additionally, in accordance with EMA Clinical pharmacology and pharmacokinetics Q&amp;A Question 7.1, the protein content of the test and reference product should be determined beforehand and analysed using the same bioanalytical method. During the procedure the MAH confirmed that the same analytical method was used.

According to the Guideline on similar biological medicinal products containing monoclonal antibodies, the chosen sampling times should enable the characterisation of the concentration-time profiles both after the first dose and at steady state. Nivolumab was initially infused every 2 weeks, and PK samples were collected up to 336 hours (14 days) after start of nivolumab infusion. Even though these sampling times do not cover the half-life of nivolumab (25 days), this is acceptable considering that they are the longest possible according to the posology of the study treatment.

PK parameters for nivolumab were derived by non-compartmental analysis methods using serum concentration versus time data. Actual times were used for all analyses and this is acceptable according to the EMA Guideline on the Investigation of Bioequivalence. The AUC(TAU) was calculated by log- and linear-trapezoidal summations or linear up/log down method in Phoenix WinNonlin ™ (version 8.2).

## Population analysed

The enrolment period was approximately 15 months from 24-Jun-2019 to 25-Sep-2020. 341 subjects were enrolled, and 261 subjects were randomized and treated (129 to the nivolumab Process C group and 132 to the nivolumab Process D group).

According to the EMA Guideline on the Investigation of Bioequivalence, for parallel design studies, treatment groups should be comparable in all known variables that may affect the PK of the active substance. This is an essential pre-requisite to give validity to the results from such studies. For this study, demographic characteristics such as sex, age, race and weight were similar between both treatment groups.

Initially, even though 261 patients had available PK concentration-time data, only 240 patients at Week 1 and 195 patients at Week 17 were considered as evaluable PK subject population by the MAH, and thus included in the statistical PK analysis for this bioequivalence study. The reasons for the exclusion of certain patients from the PK analysis were provided by the MAH, however, two reasons for exclusion were considered unacceptable (AUC0-TAU extrapolated &gt;30% and profile missing potential Tmax). Therefore, the MAH was asked to repeat the statistical PK analysis, including the aforementioned excluded subjects (see below).

## Pharmacokinetic results

In the first analysis, nivolumab Process C and Process D were found to be biocomparable as the AUC(0-336 h) geometric mean ratios (90% CI) were 1.012 (0.984, 1.041) and 0.998 (0.951, 1.047) at Week 1 and Week 17, respectively. However, in order to draw definitive conclusions regarding the bioequivalence of the new nivolumab Process D to the currently approved nivolumab Process C, the MAH was asked to repeat the biocomparability analysis including the subjects with an AUC0-TAU extrapolated &gt;30% and including profiles missing potential Tmax.

In this new biocomparability analysis, Process C and Process D were also found to be biocomparable as the AUC(0-336 h) geometric mean ratios (90% CI) were 1.005 (0.977, 1.033) and 0.995 (0.952, 1.040) at Week 1 and Week 17, respectively.

<div style=\"page-break-after: always\"></div>

## 2.6.4. Conclusions on clinical pharmacology

In conclusion, PK results support demonstration of biocomparability between nivolumab Process C and Process D.

## 2.6.5. Clinical efficacy

## 2.6.5.1. Main study

## Study CA2098FC: A Randomized, Double-Blind, Parallel, Phase 1 Study to Compare the Pharmacokinetics of Nivolumab Process D to Nivolumab Process C after Complete Resection of Stage IIIa/b/c/d or Stage IV Melanoma

## Methods

## · Study Participants

All subjects were required to be ≥ 18 years old of age or age of majority at the time of informed consent and have:

- Either Stage IIIa/b/c/d or Stage IV (AJCC Staging, 8th edition) histologically confirmed melanoma that was completely surgically resected to be eligible. All melanomas, except ocular/uveal melanoma, regardless of primary site of disease were allowed; mucosal melanomas were eligible. Subjects must have been surgically rendered free of disease with negative margins on resected specimens.
- -If Stage III melanoma (whether Stage IIIa, IIIb, IIIc, or IIId) at the time of diagnosis, the subject must have demonstrated clinical or radiographic evidence of regional metastases, either in the regional lymph nodes or locoregional metastases manifesting as satellite or intransit metastases, or microsatellites discovered at the time of microscopic evaluation of the primary tumor diagnostic biopsy. The pathology report for Stage IIIa, IIIb, IIIc, and IIId must have been reviewed, signed, and dated by the investigator.
- -If Stage IV melanoma, the pathology report confirming negative margins must have been reviewed, dated, and signed by the investigator prior to randomization.
- -For CNS lesion(s) at the time of diagnosis, documentation indicating that there had been complete resection of CNS lesion(s) was sufficient as confirmation of negative margins.
- Complete resection must have been performed within 12 weeks prior to randomization.
- Formalin-fixed paraffin embedded tissue block (preferably obtained within 12 weeks prior to enrollment) or 10 to 20 unstained tumor tissue slides (preferably sectioned within 12 weeks of enrollment). If a minimum of 10 slides was not obtainable, submission of fewer slides was acceptable in some circumstances following discussion with the Sponsor. Slides were sent to a central laboratory for biomarker analysis. Subjects must not have received any intervening systemic anticancer therapy between date that the submitted tumor tissue was obtained and enrollment. Biopsy was excisional, incisional, or core needle.
- Note: Fine needle aspiration was unacceptable for submission. Biopsies of bone lesions that did not have a soft tissue component were also unacceptable for submission.

Imaging studies included CT or MRI scans of the chest, abdomen, pelvis, and all known sites of resected disease in the setting of Stage IIIa/b/c/d or Stage IV disease, and brain MRI or CT (brain CT

<div style=\"page-break-after: always\"></div>

was allowable if MRI was contraindicated or if there was no known history of resected brain lesions). Subjects with equivocal lymph nodes ( ≥ 10 mm and ≤ 15 mm in a short axis) were eligible if confirmation with histology/cytology was available. If risk of biopsy was too high or biopsy was not feasible, 2 sequential CT or MRI scans, showing no progressive and measurable disease, or PET/CT demonstrating no fluorodeoxyglucose uptake, were acceptable. The second scan must have occurred at least 4 weeks after the initial scan.

## · Treatments

See section 2.6.2.1

## · Objectives

See section 2.6.2.1

## · Outcomes/endpoints

## See section 2.6.2.1

Efficacy was assessed using the recurrence-free survival (RFS) endpoint as an exploratory endpoint.

## · Sample size

Biocomparability of the Process D cell line relative to Process C is concluded if the 90% Cis for the ratio of geometric means for nivolumab AUC(TAU)(0-336h) at Week 1, Day 1 (after first dose) and at Week 17, Day 1 (after multiple doses) are contained within the equivalence interval: 80% to 125%.

If AUC(TAU) of Process D is 11% greater or 10% less than AUC(TAU) of Process C, then 83 participants per treatment arm would provide 97% or 90% power with respect to AUC(TAU)(0-336h) at Week 1, Day 1 (after first dose) and at Week 17, Day 1 (after multiple doses), respectively, to conclude equivalence between the 2 manufacturing processes. The overall power would be at least 87%.

Accounting for 35% of participants data being not evaluable for statistical analysis due to dropouts, dose delays, insufficient sampling, etc., a total of 254 participants (127 per each arm) were estimated to be randomized and dosed to ensure that 83 participants per arm complete all relevant procedures.

## · Randomisation and Blinding (masking)

This was a double-blind study. Subjects were randomly assigned within stratified AJCC Staging (8th edition) [Stage IIIa/b/c/d or IV] and weight categories (&lt; 70 kg, 70 to 90 kg, and &gt; 90 kg) in a 1:1 ratio to receive either Process C or Process D.

## · Statistical methods

The efficacy of Process D and Process C in terms of RFS is an exploratory endpoint.

The RFS analyses were conducted in randomized subjects. RFS was programmatically determined based on the disease recurrence date provided by the investigator and is defined as the time between the date of randomization and the date of first recurrence (local, regional, or distant metastasis), new primary melanoma (including melanoma in situ), or death (whatever the cause), whichever occurred first. A subject who died without reported recurrence was considered to have recurred on the date of death. For subjects who remained alive and whose disease had not recurred and without new primary disease, RFS was censored on the date of last evaluable disease assessment. For those subjects who remained alive and had no recorded post-randomization disease assessment, RFS was censored on the day of randomization.

The hazard ratio and corresponding 2-sided 95% CI was estimated using a Cox proportional hazards

<div style=\"page-break-after: always\"></div>

model, with treatment group as a single covariate, stratified by AJCC staging and weight category (as recorded in the IRT). RFS curves, RFS medians with 95% CIs, and RFS rates at 6, 12, 18, and 24 months, with 95% CIs were estimated using Kaplan-Meier methodology.

Sensitivity analyses of RFS were also performed:

- RFS stratified analysis using stratification factors as obtained from the baseline CRF pages (instead of IRT). This analysis was performed only if at least one stratification factor (Weight category or AJCC staging) at randomization (as per IRT) and baseline was not concordant for at least 10% of all randomized subjects.
- RFS analysis using a 2-sided, un-stratified Cox proportional hazards model with treatment as the single covariate was conducted.
- RFS analysis for subjects with no relevant deviation. This analysis was conducted only if there were more than 10% subjects with relevant protocol deviations.

For additional details on statistical methods, see section 2.6.2.1.

## Results

## · Participant flow

At the time of DBL, 341 subjects were enrolled, and 261 subjects were randomized and treated (129 to the nivolumab Process C group and 132 to the nivolumab Process D group).

At the time of DBL, there were no subjects continuing treatment in either treatment arm.

Table 11: Subject Disposition - All Enrolled, Randomized, and Treated Subjects

| Status ()                                                                               | Process C   | Process D   | Total       |
|-----------------------------------------------------------------------------------------|-------------|-------------|-------------|
| ENROLLED                                                                                |             |             | 341 (100.0) |
| RANDOMIZED OR ENIERING TREATMENT PERIOD                                                 | 129         | 132         | 261 (76.5)  |
| NOTRANDOMIZEDOR ENTERING TREATMENTPERIOD                                                |             |             | 80 23.5)    |
| REASONFORNOTRANDOMIZEDORENTERINGTREATMENTPERIOD                                         |             |             |             |
| SUBJECTWITHDREWCONSENT                                                                  |             |             | 12 3.5)     |
| LOSTTO FOLLOW-UP                                                                        |             |             | 1 0.3)      |
| SUBJECT NOIONGER MEETS STUDY CRITERIA                                                   |             |             | 60 17.6)    |
| OTHER                                                                                   |             |             | 7 2.1)      |
|                                                                                         | 129 (100.0) | 132 (100.0) | 261 (100.0) |
| CONTINUINGINTHETREATMENTPERIOD                                                          | 0           | 0           | 0           |
| COMPLETEDTHETREATMENTPERIOD                                                             | 79 61.2)    | 88 3(66.7)  | 167 (64.0)  |
| NOT CONTINUING IN THETREATMENT PERIOD                                                   | 50 (38.8)   | 44 ( 33.3)  | 94 ( 36.0)  |
| REASON FORNOT CONTINUING INTHETREATMENT PERIOD                                          |             |             |             |
| SUBJECTREQUESTTODISCONTINUESTUDYTREAIMENT                                               | 2 1.6)      | 0.8)        |             |
| SUBJECT NO IONGER MEETS STUDY CRITERIA                                                  | 0           | 0.8)        | 1 0.4)      |
| DISEASE PROGRESSION                                                                     | 1 0.8)      | 0           | 1 0.4)      |
| STUDY DRUG TOXICITY                                                                     | 16 12.4)    | 23 (17.4)   | 39 14.9)    |
| ADVERSE EVENTUNRELATEDTOSTUDYDRUG                                                       | 2 1.6)      | 2 1.5)      | 4 1.5)      |
| DISEASE RECURRENCE                                                                      | 27 20.9)    | 15 11.4)    | 42 16.1)    |
| OTHER                                                                                   | 2 1.6)      | 2 1.5)      | 4 1.5)      |
| NOT CONTINUING IN THE TREATMENT PERIOD DUE TO COVID-19                                  | 0.8)        | 1（ 0.8)     | 2( 0.8)     |
| ADVERSEEVENTUNRELATEDTOSTUDYDRUG                                                        | 0.8)        | 0           | 0.4)        |
| OTHER                                                                                   | 0           | 1 0.8)      | 0.4)        |
| CONTINUING IN THE STUDY                                                                 | 112 ( 86.8) | 118 ( 89.4) | 230 ( 88.1) |
| NOT CONTINUING IN THE STUDY                                                             | 17 (13.2)   | 14 ( 10.6)  | 31 (11.9)   |
| REASON FOR NOT CONTINUING IN THE STUDY                                                  |             |             |             |
| DEATH                                                                                   | 15 ( 11.6)  | 14 (10.6)   | 29 ( 11.1)  |
| SUBJECTWITHDREWCONSENT                                                                  | 2 (1.6)     | 0           | 2( 0.8)     |
| NOT CONTINUING INTHE STUDY DUE TOCOVID-19 REASONFORNOTCONTINUINGINTHESTUDYDUETOCOVID-19 | 0           | 1（ 0.8)     | 1 ( 0.4)    |
| DEATH                                                                                   |             |             | 1(          |
|                                                                                         |             | 1（ 0.8)     | 0.4)        |

Note: Percentages based on subjects entering period.

## · Recruitment

The enrolment period was approximately 15 months, from 24-Jun-2019 to 25-Sep-2020.

<div style=\"page-break-after: always\"></div>

The study was conducted in 12 countries including: Australia, Brazil, Chile, France, Ireland, Italy, Mexico, New Zealand, Poland, Romania, Spain, and United States. The LPLV and DBL of the study occurred on 14 October 2021 and 18-February 2022, respectively.

Minimum follow-up was 15.7 months, and median follow-up was 25.9 months (range: 15.7, 31.8).

## · Conduct of the study

## Protocol amendments

The original protocol for this study was dated 10 Dec 2018. As of the 18 Feb 2022 DBL, there were 2 global protocol revisions, 6 administrative letters and 1 clarification memo. The protocol amendment revision 02 was dated 24 Sep 2021.

Table 12: Summary of Key Changes to Protocol CA2098FC

| Document (Amendment) /Date        | Summary of Key Changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |   Planned Sample Size |   Subjects Randomized at time of Protocol Amendment |
|-----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|-----------------------------------------------------|
| Revised Protocol 01 25-0ct-2019   | Modified to remove language requiring complete lymph node dissection with lymph node positive disease to align with practice and guideline changes. Modified minimum number of slides required Allowed adjuvant radiation therapy after resection of large nodal metastases or extra nodal extension. PBMC language was removed from the protocol text and Table 9.8-1. Receptor occupancy test included to compare thebiologicaleffectofthenivolumabproduced byProcess C with the nivolumab produced by Process D. Blood will be drawn at the same time as PK sampling at the following time points: W1D1 pre-dose and 4 hours post-dose and W17D1 pre-dose and 4 hours post-dose. Changes as per Administrative Letter 01 and 02 and ClarificationMemo01. |                   254 |                                                  66 |
| Protocol Amendment 02 24-Sep-2021 | Aligned safety language based on CTCAE v5 safety reportmgpurposes Removed male contraception requirements Clarified the blinding/unblinding section Mademinor wording modifications to secondary endpoint Included changesaspreviouslycommunicated in AdministrativeLetters 03,04,05,06                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                   254 |                                                 261 |

<div style=\"page-break-after: always\"></div>

Important protocol deviations

Table 13: Summary of important protocol deviations - all enrolled subjects

| ProtocolDeviationClassification ProtocolDeviationSpecifications                                                                              |   No. of Subjects |
|----------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| Total IPDs                                                                                                                                   |                35 |
| Trial Procedures                                                                                                                             |                23 |
| Repetitive and/or systemicnon-important protocol deviationsfortumor assessments not performed within the specified scheduled.                |                 8 |
| Failure to collect PK samples for planned PK time points as specified in the protocol.                                                       |                 4 |
| Failure to collect PK samples for planned PK timepoint due to COVID                                                                          |                 2 |
| Pregnancy Tests not performed as per protocol specified schedule.                                                                            |                 2 |
| Tumor assessment scans not performed as per specified schedule.                                                                              |                 4 |
| Failuretoperform theSurvivalFollow upvisit 1withinthe timelines                                                                              |                 1 |
| FailuretoperformtheFollowupvisit 2withinthetimelines                                                                                         |                 1 |
| Re-consent containing updatedrisk language or updated safety information not signed                                                          |                 1 |
| Safety Reporting                                                                                                                             |                 6 |
| Tumor Assessment not performed as per timelines specified in the protocol                                                                    |                 3 |
| Failure to notify BMS of all SAEs (initial report) in accordance with the time period required by the protocol and/or applicable regulation. |                 2 |
| Follow-up visit 1 and/or 2 not performed.                                                                                                    |                 1 |
| Informed Consent and/or Ethics(IEC/IRB)                                                                                                      |                 7 |
| with delay.                                                                                                                                  |                 7 |

inadvertently re-entered in the source listing.

Source: Appendix 2.3

Relevant protocol deviations

Relevant Protocol Deviations (RPD) are IPDs that could affect the interpretability of key study results, are programmable deviations from clinical database and are protocol specific.

Table 14: Relevant protocol deviations - all randomized subjects

|                                                         | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)   |
|---------------------------------------------------------|--------------------------|--------------------------|--------------------------|
|                                                         | Process C N = 129        | ProcessD N = 132         | Total N=261              |
| SUBJECTSWITHATLEASTONEIEVIATION                         | 27 (20.9)                | 30 (22.7)                | 57 (21.8)                |
| ATENIRANCE                                              |                          |                          |                          |
| SUBJECTSMISSINGATIEASTONEINCTUSIONOREXCIUSIONCRITERION  | 5 ( 3.9)                 | 8 (6.1)                  | 13 ( 5.0)                |
| ON-TREATMENT                                            |                          |                          |                          |
| NIVOLUMABAIMINISIRATIONERROR<75OR>125OFTHEPLANNEDDOSAGE | 6 ( 4.7)                 | 8 (6.1)                  | 14 ( 5.4)                |
| IESSTHAN12DAYSFROMFREVIOUSDOSEDURINGQ2WCYCIES           | 7 (5.4)                  | 3 (2.3)                  | 10 ( 3.8)                |
| IESSTHAN25DAYSFROMFREVIOUSDOSEDURINGQ4WCYCIES           | 4 (3.1)                  | 3 (2.3)                  | 7 (2.7)                  |
|                                                         | 7 (5.4)                  | 9 (6.8)                  | 16 (6.1)                 |
| MORETHAN42DAYSFROMFREVIOUSDOSEDUETOCOVID                | 1 (0.8)                  | 3 (2.3)                  | 4 (1.5)                  |

Source:TableS.2.4

## · Baseline data

For a summary of demographic characteristics, see section 2.6.2.1.

<div style=\"page-break-after: always\"></div>

Baseline disease characteristics

Table 15: Baseline disease characteristics summary - all randomized subjects

|                                           | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)   |
|-------------------------------------------|--------------------------|--------------------------|--------------------------|
|                                           | Process C N = 129        | Process D N = 132        | Total N = 261            |
| AJUC 8.0 STAGING                          |                          |                          |                          |
| IIIA/B/C/D                                | 117 ( 90.7)              | 115 ( 87.1)              | 232 ( 88.9)              |
| AI                                        | 12 (9.3)                 | 17 ( 12.9)               | 29 ( 11.1)               |
| ECOGFERFORMANCESTATUS                     |                          |                          |                          |
| 0                                         | 122 ( 94.6)              | 124 ( 93.9)              | 246 ( 94.3)              |
| 1                                         | 7 (5.4)                  | 8 (6.1)                  | 15 (5.7)                 |
| FRIOR RADIOIHERAPY                        |                          |                          |                          |
| YES                                       | 3 (2.3)                  | 4 (3.0)                  | 7 (2.7)                  |
| NO                                        | 126 ( 97.7)              | 128 ( 97.0)              | 254 ( 97.3)              |
| BASELINE LDH IEVEL                        |                          |                          |                          |
| <=1.5 XUIN                                | 127 ( 98.4)              | 132 (100.0)              | 259 ( 99.2)              |
| > 1.5 X UN                                | 2 ( 1.6)                 | 0                        | 2 (0.8)                  |
| REGION                                    |                          |                          |                          |
| US/WEST EU                                | 55 ( 42.6)               | 49 ( 37.1)               | 104 ( 39.8)              |
| EAST EU                                   | 7(5.4)                   | 10 (7.6)                 | 17 (6.5)                 |
| AUS/NZ                                    | 38 ( 29.5)               | 35 ( 26.5)               | 73 ( 28.0)               |
| CENIRAL/SOUTHAMERICA                      | 29 ( 22.5)               | 38 (28.8)                | 67 ( 25.7)               |
| BASELINEPD-L1+ STATUS BASEDON A 1&CUT OFF |                          |                          |                          |
| > 1%                                      | 61 ( 47.3)               | 68 ( 51.5)               | 129 ( 49.4)              |
| < 1%                                      | 37 ( 28.7)               | 40 ( 30.3)               | 77 ( 29.5)               |
| INDETERMINATE                             | 6 (4.7)                  | 8 (6.1)                  | 14 (5.4)                 |
| NOT EVALUABLE                             | 25 (19.4)                | 16 ( 12.1)               | 41 ( 15.7)               |
| > 5%                                      | 42 ( 32.6)               | 44 ( 33.3)               | 86 (33.0)                |
| <5%                                       | 56 ( 43.4)               | 64 ( 48.5)               | 120 ( 46.0)              |
| INDETERMINATE                             | 6 (4.7)                  | 8 (6.1)                  | 14 (5.4)                 |
| NOTEVALUABLE                              | 25 (19.4)                | 16 (12.1)                | 41 ( 15.7)               |
| DISEASE STAGEAT DIAGNOSIS                 |                          |                          |                          |
| IIIA                                      | 18 ( 14.0)               | 17 ( 12.9)               | 35 (13.4)                |
| IIIB/C/D                                  | 99 ( 76.7)               | 98 ( 74.2)               | 197 ( 75.5)              |
| AI                                        | 12 (9.3)                 | 17 ( 12.9)               | 29 (11.1)                |
| DISEASE STAGE AT DIAGNOSIS                |                          |                          |                          |
| IIIA.                                     | 18 ( 14.0)               | 17 ( 12.9)               | 35 (13.4)                |
| IIIB                                      | 32 ( 24.8)               | 32 ( 24.2)               | 64 ( 24.5)               |
| IIIC                                      | 64 ( 49.6)               | 60 ( 45.5)               | 124 ( 47.5)              |
| IIID                                      | 3 (2.3)                  | 6 (4.5)                  | 9 (3.4)                  |
| AI                                        | 12 (9.3)                 | 17 ( 12.9)               | 29 ( 11.1)               |

<div style=\"page-break-after: always\"></div>

## MELANOMA TNM CLASSIFICATION

| METASTASIS MO   | 109 ( 84.5)      | 113 ( 85.6)     | 222 ( 85.1)       |
|-----------------|------------------|-----------------|-------------------|
| MlA             | 2 (1.6)          | 8 (6.1)         | 10 (3.8)          |
| MlA.(0)         | 2 (1.6)          | 1( 0.8)         | 3 (1.1)           |
| MlA(1)          | 1 (0.8)          | 1（ 0.8)         | 2 (0.8)           |
| MIB             | 2（ 1.6)          | 4( 3.0)         | 6( 2.3)           |
| MB(0)           | 2 (1.6)          | 2（ 1.5)         | 4( 1.5)           |
| MC(0)           | 1 ( 0.8)         | 0               | 1( 0.4)           |
| MID             | 1( 0.8)          | 0               | 1（ 0.4)           |
| MD(1)           | 0                | 1( 0.8)         | 1（ 0.4)           |
| MX              | 4 ( 3.1)         | 2( 1.5)         | 6 (2.3)           |
| UNKNOWN         | 5 (3.9)          | 0               | 5 (1.9)           |
| NOIES           |                  |                 |                   |
| NO              | 6 (4.7)          | 9 (6.8)         | 15 (5.7)          |
| NL              | 8(6.2)           | 9 (6.8)         | 17 (6.5)          |
| NLA.            | 33 (25.6)        | 36 ( 27.3)      | 69 (26.4)         |
| NIB             | 23 (17.8)        | 20 ( 15.2)      | 43 ( 16.5)        |
| NIC             | 6 (4.7)          | 5 (3.8)         | 11 ( 4.2)         |
| N2              | 3 (2.3)          | 2 ( 1.5)        | 5 (1.9)           |
| N2A             | 9 (7.0)          | 15 (11.4)       | 24 (9.2)          |
| N2B             | 16 (12.4)        | 10（ 7.6)        | 26 (10.0)         |
| N2C             | 7(5.4)           | 4( 3.0)         | 11 ( 4.2)         |
| N3              | 5 ( 3.9)         | 7（ 5.3)         | 12（ 4.6)          |
| N3A.            | 1(0 0.8)         | 4( 3.0)         | 5 (1.9)           |
| N3B             | 4 (3.1)          | 1( 0.8)         | 5 (1.9)           |
| N3C             | 5 ( 3.9)         | 6( 4.5)         | 11 (4.2)          |
| NX              | 3 (2.3)          | 4( 3.0)         | 7 (2.7)           |
| TUMOR           |                  |                 |                   |
| T0              | 8 (6.2)          | 6 (4.5)         | 14 (5.4)          |
| T1              | 2 ( 1.6)         | 1 (0.8)         | 3 ( 1.1)          |
| T1A             | 7(5.4)           | 10 (7.6)        | 17 (6.5)          |
| T1B             | 6 (4.7)          | 3 (2.3)         | 9 (3.4)           |
| T2              | 1 (0.8)          | 1 (0.8)         | 2 (0.8)           |
| T2A             | 24 (18.6)        | 18 ( 13.6)      | 42 ( 16.1)        |
| T2B             | 4 (3.1)          | 6 (4.5)         | 10 (3.8)          |
| T3              | 1 (0.8)          | 1 (0.8)         | 2 (0.8)           |
| T3A             | 10 (7.8)         | 19 ( 14.4)      | 29 (11.1)         |
| T3B             | 18 (14.0)        | 15 ( 11.4)      | 33 ( 12.6)        |
| T4 T4A          | 2 (1.6) 12 (9.3) | 1 (0.8) 9 (6.8) | 3 ( 1.1) 21 (8.0) |
| T4B             | 25 (19.4)        | 30 ( 22.7)      | 55 ( 21.1)        |
| TIS             | U                | 27 1.5)         | (8:0)7            |
| TX              | 8 (6.2)          | 10（ 7.6)        | 18 (6.9)          |
| UNKNOWN         | 1 (0.8)          | 0               | 1 (0.4)           |
| BRAINMETASTASIS |                  |                 |                   |
| YES             | 1 (0.8)          | 2 (1.5)         | 3 ( 1.1)          |
| NO              | 128 ( 99.2)      | 130 ( 98.5)     | 258 ( 98.9)       |
| BRAFSTATUS      |                  |                 |                   |
| MITANT          | 43 ( 33.3)       | 34 ( 25.8)      | 77 ( 29.5)        |
| WILD-TYFE       | 17 ( 13.2)       | 31 ( 23.5)      | 48 (18.4)         |
| NOT REEORTED    | 69 ( 53.5)       | 67 ( 50.8)      | 136 ( 52.1)       |

Source: Table S.3.2.7

<div style=\"page-break-after: always\"></div>

## Previous treatments

Table 16: Prior cancer therapy summary - all randomized subjects

|                                                | Number of Subjects ($)   | Number of Subjects ($)   | Number of Subjects ($)   | Number of Subjects ($)   | Number of Subjects ($)   |
|------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                                                | Process C N = 129        | Process D N = 132        | Total N = 261            | Total N = 261            |                          |
| FRIOR SURGERY RELATED TO CANCER                |                          |                          |                          |                          |                          |
| YES                                            | 129 (100.0)              | 132 (100.0)              | 261 (100.0)              |                          |                          |
| NO                                             | 0                        | 0                        | 0                        |                          |                          |
| FRIORRADIOTHERAPY                              |                          |                          |                          |                          |                          |
| YES                                            | 3 (2.3)                  | 4 (3.0)                  | 7 (2.7)                  |                          |                          |
| NO                                             | 126 ( 97.7)              | 128 ( 97.0)              | 254 ( 97.3)              |                          |                          |
| FRIOR SYSTEMICCANCER THERAPY RELATED TO CANCER |                          |                          |                          |                          |                          |
| YES                                            | 3 (2.3)                  | 1 ( 0.8)                 | 4 (1.5)                  |                          |                          |
| NO                                             | 126 ( 97.7)              | 131 ( 99.2)              | 257 ( 98.5)              |                          |                          |

Source:Table S.3.3.5

## · Numbers analysed

See section 2.6.2.1.

## · Outcomes and estimation

As of the 18-Feb-2022 DBL for the Addendum 01 to the CA2098FC Primary CSR (minimum follow-up of 15.7 months), the efficacy profile of nivolumab Process D was comparable to Process C based on RFS results in all randomized subjects as well as RFS results in PD-L1 positive subjects, and subjects with no relevant protocol deviations.

<div style=\"page-break-after: always\"></div>

Table 17: Efficacy Results - All Randomized Subjects - CA2098FC (Addendum 01 CSR DBL: 18-Feb-2022)

|                                                        | Minimum Follow-up: 15.7 months   | Minimum Follow-up: 15.7 months   |
|--------------------------------------------------------|----------------------------------|----------------------------------|
|                                                        | Nivolumab Process C              | Nivolumab Process D              |
| RFS - All Randomized Subjects                          | N= 129                           | N= 132                           |
| Events, n / Subjects, n (%)                            | 47 / 129 (36.4)                  | 43 / 132 (32.6)                  |
| Median RFS, monthsa (95% CI)                           | N.A. (27.27 - N.A.)              | N.A. (29.80 - N.A.)              |
| HRb (95% CI)                                           | 0.81 (0.53 - 1.23)               | 0.81 (0.53 - 1.23)               |
| RFS - Tumor cell PD-Ll Positive (PD-Ll ≥l%o) Subjectsc | N=61                             | N = 68                           |
| Events, n / Subjects, n (%)                            | 24 / 61 (39.3)                   | 21 / 68 (30.9)                   |
| Median RFS, monthsa (95% CI)                           | 27.60 (16.72 -N.A.)              | N.A. (N.A - N.A)                 |
| HRb (95% CI)                                           | 0.75 (0.42 - 1.36)               | 0.75 (0.42 - 1.36)               |
| RFS - Subjects with no Relevant Protocol Deviation     | N=102                            | N=102                            |
| Events, n Subjects, n (%)                              | 38 / 102 (37.3%)                 | 31/102 (30.4%)                   |
| Median RFS, months* (95% CI)                           | N.A (27.27 - N.A)                | NA (NA - NA.)                    |
| HRb (95% CI)                                           | 0.75 (0.46 - 1.21)               | 0.75 (0.46 - 1.21)               |
| RFS -All Randomized Subjects, Unstratified Analysis    | N=129                            | N=132                            |
| Events, n Subjects, n (%)                              | 47 / 129 (36.4%)                 | 43 / 132 (32.6%)                 |
| Median RFS, monthsa (95% CI)                           | NA (27.27 - N.A)                 | N.A (29.80 - N.A)                |
| HRb (95% CI)                                           | 0.84 (0.56 - 1.28)               | 0.84 (0.56 - 1.28)               |
| RFS Ratea(95% CI) - All Randomized Subjects            | N= 129                           | N= 132                           |
| 6-Months                                               | 80.6 (72.6, 86.4)                | 87.9 (81.0, 92.4)                |
| 12-Months                                              | 74.3 (65.8, 81.0)                | 76.5 (68.3, 82.9)                |
| 18-Months                                              | 66.7 (57.6, 74.2)                | 72.1 (63.4, 79.0)                |
| 24-Months                                              | 64.2 (54.9, 72.1)                | 66.5 (57.2, 74.3)                |

Source: Table 7.1-1 of the Addendum 01 to the CA2098FC Primary CSR

<div style=\"page-break-after: always\"></div>

Table 18: Reason for Censoring, Recurrence-Free Survival - All Randomized subjects

|                                                                                                                                              | Process C N = 129                           | Prooess D N = 132                           |
|----------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|
| NUMBER OF EVENIS (4)                                                                                                                         | 47( 36.4)                                   | 43 ( 32.6)                                  |
| TYPE OF EVENIS (G)                                                                                                                           |                                             |                                             |
| REUURRENCE DISDASE AT BASELINE DISTANT RECURRENCE REGIONALNODE RETURRENCE LOCAL REJURRENCE                                                   | 45 (34.9) 0 23 17.8) 5 3.9) 13 10.1) 4 3.1) | 39 (29.5) 1 0.8) 21 15.9) 9 6.8) 4.5 1.5) 0 |
| DEATH                                                                                                                                        | 2 (1.6)                                     | 4 (3.0)                                     |
| NUMBER OF SUBJECIS CENEORED ($)                                                                                                              | 82 (63.6)                                   | 89(67.4)                                    |
| NEWPRIMARYMELANOMA IN SITU NEWFRIMARYINVASIVEMELPNOMA                                                                                        | 0                                           |                                             |
| CENEORED ON DATE OF RANIOMIZATION CENSORED ON DATE OELAST DISEASE ASSESSMENT ON-STUDY OR LAST ASSESSMENT FRIORTO SUESEQUENTANTICANCERTHERAPY | 0 82 (63.6) 0                               | 0 89(67.4)                                  |
| RECEIVED SUBSDQUENT ANTI CANCER THERADY(1)                                                                                                   |                                             | 0                                           |
| RECEIVED SUBSEQUENT SYSIEMIC THERAPY RECEIVED SUBSEQUENT RADIOIHERAPY                                                                        |                                             | 0                                           |
| RDCEIVEDSURSEOUENTSURGERY                                                                                                                    | 0                                           | 0                                           |
| SEOOND NON-MELANOMA FRIMARY CANCER (2) STILL ON-TREATMENT IN FOLIOW-UP                                                                       | 61                                          |                                             |
|                                                                                                                                              | 1.6)                                        | 0.8) 88 (66.7)                              |
|                                                                                                                                              | 61.2)                                       |                                             |
|                                                                                                                                              | 0.81                                        |                                             |
| OEF STUDY                                                                                                                                    | 0                                           |                                             |
| WITHLREW CONSENT                                                                                                                             |                                             |                                             |
| LOST TO FOLLOW-UP                                                                                                                            |                                             |                                             |
| 0                                                                                                                                            | 0                                           | 0                                           |
| 0.8) D                                                                                                                                       |                                             |                                             |
| 00                                                                                                                                           | 00                                          | 00                                          |
| OTHER                                                                                                                                        | OTHER                                       | OTHER                                       |

Source: Table S.5.3

(l) Disease assessments and death if any, oceuring after start of subsequent anti-cancer therapy or second non-melanoma primary cancer are not considered.

(2) Includes subjects, regardless of treatment status, who received subsequent anti-cancer therapy or experienced second non-melanoma primary cancer without a prior reported RFS event. Those subjects were censored at the last evaluable disease assessment prior to/on stat date of subsequent anti-cancer therapy or second non-melanoma primary cancer.

Figure 4: KM plot of Recurrence-Free-Survival - All randomized subjects

<!-- image -->

ProcessD overProcess C-hazard ratio(95%Cl):0.81(0.53,1.23).p-value:0.3282

<div style=\"page-break-after: always\"></div>

Statistical model for hazard ratio and p-value: Stratified Cox proportional hazard model and stratified log-rank test.

Symbols represent censored observations.

## Immunogenicity results

## Nivolumab Process C

Of the 118 nivolumab ADA-evaluable subjects in the nivolumab Process C treatment group, 5 (4.2%) subjects were nivolumab ADA-positive at baseline, and 3 (2.5%) subjects were nivolumab ADApositive after the start of treatment.

- No subjects were considered persistent positive or developed neutralizing antibody.
- The highest titer value observed among nivolumab ADA-positive subjects was 32, which occurred in 1 subject. All other titers were low, ranging from 1 to 16.

## Nivolumab Process D

Of the 123 nivolumab ADA-evaluable subjects in the nivolumab Process D treatment group, 5 (4.1%) subjects were nivolumab ADA-positive at baseline, and 8 (6.5%) subjects were nivolumab ADApositive after the start of treatment.

- 2 (1.6%) subjects were considered persistent positive, and no subjects developed neutralizing antibodies.
- The highest titer value observed among nivolumab ADA-positive subjects was 8, which occurred in 2 subjects. All other titers were low, ranging from 1 to 4.

Table 19: Anti-Drug Antibody assessments summary - All immunogenicity evaluable subjects with baseline and at least one post-baseline assessment

| Subject ADA Status (%)      | Process C N = 118   | Process D N = 123   |
|-----------------------------|---------------------|---------------------|
| BASELINE ADA POSITIVE       | 5 ( 4.2)            | 5 (4.1)             |
| ADA POSITIVE                | 3 ( 2.5)            | 8 (6.5)             |
| PERSISTENT POSITIVE (PP)    | 0                   | 2 1.6)              |
| NOT PP LAST SAMPLE POSITIVE | 1 (0.8)             | １５ 0.8)             |
| OTHER POSITIVE              | 2 (1.7)             | 4.1)                |
| NEUTRALIZING POSITIVE       | 0                   | 0                   |
| ADA NEGATIVE                | 115 (97.5)          | 115 (93.5)          |

Source: Table S.7.10

Note: Post-baseline assessments are assessments reported after initiation of treatment.

Baseline ADA Positive: A subject with baseline ADA-positive sample;

ADA Positive: A subject with at least one ADA-positive sample relative to baseline (ADA negative at baseline or ADA titer to be at least 4-fold or greater [≥] than baseline positive titer) at any time after initiation of treatment;

Persistent Positive: ADA-positive sample at 2 or more consecutive time points, where the first and last ADA-positive samples are at least 16 weeks apart;

Not PP-Last Sample Positive: Not persistent but with ADA-positive sample at the last sampling time point;

Other Positive: Not persistent but some ADA-positive samples with the last sample being negative;

Neutralizing Positive: At least one ADA-positive sample with neutralizing antibodies detected post-baseline;

ADA Negative: A subject with no ADA-positive sample after initiation of treatment.

## Onset and duration of immunogenicity

The assessment of onset and duration of anti-nivolumab ADAs was based on a small number of participants who became nivolumab ADA-positive after the start of treatment with either Process C or

<div style=\"page-break-after: always\"></div>

Process D. The median time to first detection of ADAs to nivolumab was similar between nivolumab Process C and Process D. The median duration of ADAs to nivolumab was somewhat longer for nivolumab Process D versus Process C.

Table 20: Onset and duration of Anti-Drug Antibodies to nivolumab - all treated subjects with ADA-positive status for whom ADA is not detected at baseline

| Kinetics of ADA                                                                                                  |                     | Process C N=3                |                        | Process D N=8   |
|------------------------------------------------------------------------------------------------------------------|---------------------|------------------------------|------------------------|-----------------|
| TIME TOFIRST DETECTION OF ADA TONIVOLUMAB N MEDIAN (Q1，Q3)，WEEKS MIN, MAX                                        | 3                   | 2.29 (2.14, 29.14) 2.1, 29.1 | 8 2.14 (2.14, 2.0,     | 2.36) 7.3       |
| DURATION OF ADA TONIVOLUMAB N MEDIAN (95 CI)， WEEKS MIN, MAX                                                     | 3 8.07 (2.14, N.A.) | 0.1*, 14.0                   | 8 14.29 (13.86, 34.14) | 0.1*, 56.3*     |
| NUMBER OF DOSES BEFORE FIRST DETECTION OF ADA TO NIVOLUMAB N MEDIAN (MIN, MAX)                                   | 3 1.0 (1, 8)        |                              | 8 1.0 (1, 1)           |                 |
| NUMBER OF DOSES AFTER FIRST DETECTION OF ADA TO NIVOLUMAB N MEDIAN (MIN, MAX) TOTAL NUMBER OF DOSES OF NIVOLUMAB | 3                   | 10.0 (2, 17)                 | 8                      | 13.0 (7, 17)    |
| N MEDIAN (MIN, MAX)                                                                                              | 3                   | 18.0 (3, 18)                 | 8                      | 14.0 (8, 18)    |

Source: Table S.7.12

Onset of ADA refers to the time period between the first dose of the treatment and the first instance of ADA detection. Duration of ADA is defined as the time from the first on-study ADA-positive date to the first ADA-negative date after the last on-study ADA-positive date. Duration of ADA is estimated by Kaplan-Meier method. Subjects who do not have an ADA-negative date after the last on-study ADA-positive date is censored on the date of their last ADA-evaluable assessment.

Excluded those participants with baseline ADA-positive sample and had an increased titer at post-baseline since this type of immune response differs mechanistically.

*Censored observation.

N.A.: Not Applicable.

## Effect of immunogenicity on efficacy

## Nivolumab Process C

Based on assessment of the presence of ADAs vs RFS, some subjects positive for nivolumab ADAs continued treatment with clinical benefit, and there was no apparent trend showing an effect of positive ADA on the efficacy of nivolumab Process C.

Among the 3 nivolumab ADA-positive subjects, 2 were censored in follow-up with no events reported, and 1 subject had a distant reoccurrence of disease. The ADA titers among the 3 subjects with nivolumab ADAs ranged from 1 to 32.

## Nivolumab Process D

Based on assessment of the presence of ADAs vs RFS, some subjects positive for nivolumab ADAs continued treatment with clinical benefit, and there was no apparent trend showing an effect of positive ADA on the efficacy of nivolumab Process D.

Among the 8 nivolumab ADA-positive subjects, 5 were censored in follow-up with no events reported, 1 subject had a distant reoccurrence of disease, 1 subject had a local occurrence of disease, and death was reported for 1 subject after 10.5 months of RFS. The ADA titers among the 8 subjects with nivolumab ADAs ranged from 1 to 8.

<div style=\"page-break-after: always\"></div>

## · Summary of main efficacy results

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 21: Summary of efficacy for trial CA2098FC

| Title : A Randomized, Double-Blind, Parallel, Phase 1 Study to Compare the Pharmacokinetics of Nivolumab Process D to Nivolumab Process C after Complete Resection of Stage IIIa/b/c/d or Stage IV Melanoma   | Title : A Randomized, Double-Blind, Parallel, Phase 1 Study to Compare the Pharmacokinetics of Nivolumab Process D to Nivolumab Process C after Complete Resection of Stage IIIa/b/c/d or Stage IV Melanoma                       | Title : A Randomized, Double-Blind, Parallel, Phase 1 Study to Compare the Pharmacokinetics of Nivolumab Process D to Nivolumab Process C after Complete Resection of Stage IIIa/b/c/d or Stage IV Melanoma                       | Title : A Randomized, Double-Blind, Parallel, Phase 1 Study to Compare the Pharmacokinetics of Nivolumab Process D to Nivolumab Process C after Complete Resection of Stage IIIa/b/c/d or Stage IV Melanoma                       | Title : A Randomized, Double-Blind, Parallel, Phase 1 Study to Compare the Pharmacokinetics of Nivolumab Process D to Nivolumab Process C after Complete Resection of Stage IIIa/b/c/d or Stage IV Melanoma                       |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                              | CA2098FC ClinicalTrials.gov Identifier: NCT03980314                                                                                                                                                                               | CA2098FC ClinicalTrials.gov Identifier: NCT03980314                                                                                                                                                                               | CA2098FC ClinicalTrials.gov Identifier: NCT03980314                                                                                                                                                                               | CA2098FC ClinicalTrials.gov Identifier: NCT03980314                                                                                                                                                                               |
| Design                                                                                                                                                                                                        | Phase 1, randomized, double-blinded study to compare the PK of Process D nivolumab to Process C nivolumab administered after complete resection of Stage IIIa/b/c/d or Stage IV melanoma in subjects with no evidence of disease. | Phase 1, randomized, double-blinded study to compare the PK of Process D nivolumab to Process C nivolumab administered after complete resection of Stage IIIa/b/c/d or Stage IV melanoma in subjects with no evidence of disease. | Phase 1, randomized, double-blinded study to compare the PK of Process D nivolumab to Process C nivolumab administered after complete resection of Stage IIIa/b/c/d or Stage IV melanoma in subjects with no evidence of disease. | Phase 1, randomized, double-blinded study to compare the PK of Process D nivolumab to Process C nivolumab administered after complete resection of Stage IIIa/b/c/d or Stage IV melanoma in subjects with no evidence of disease. |
| Design                                                                                                                                                                                                        | Duration of main phase: Duration of Run-in phase:                                                                                                                                                                                 | Duration of main phase: Duration of Run-in phase:                                                                                                                                                                                 | From 24-Jun-2019. Ongoing. Not applicable Not applicable                                                                                                                                                                          | From 24-Jun-2019. Ongoing. Not applicable Not applicable                                                                                                                                                                          |
| Design                                                                                                                                                                                                        | Duration of Extension phase:                                                                                                                                                                                                      | Duration of Extension phase:                                                                                                                                                                                                      |                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                   |
| Hypothesis                                                                                                                                                                                                    | Exploratory                                                                                                                                                                                                                       | Exploratory                                                                                                                                                                                                                       | Exploratory                                                                                                                                                                                                                       | Exploratory                                                                                                                                                                                                                       |
| Treatments groups                                                                                                                                                                                             | Process C                                                                                                                                                                                                                         | Process C                                                                                                                                                                                                                         | Process C nivolumab (3 mg/kg IV Q2W for Week 1 to Week 17 followed by 480 mg IV Q4W for Week 19 to Week 51), up to 1 year. N=129                                                                                                  | Process C nivolumab (3 mg/kg IV Q2W for Week 1 to Week 17 followed by 480 mg IV Q4W for Week 19 to Week 51), up to 1 year. N=129                                                                                                  |
| Treatments groups                                                                                                                                                                                             | Process D                                                                                                                                                                                                                         | Process D                                                                                                                                                                                                                         | Process D nivolumab (3 mg/kg IV Q2W for Week 1 to Week 17 followed by 480 mg IV Q4W for Week 19 to Week 51), up to 1 year. N=132                                                                                                  | Process D nivolumab (3 mg/kg IV Q2W for Week 1 to Week 17 followed by 480 mg IV Q4W for Week 19 to Week 51), up to 1 year. N=132                                                                                                  |
| Endpoints and definitions                                                                                                                                                                                     | Exploratory endpoint                                                                                                                                                                                                              | RFS                                                                                                                                                                                                                               | Time between the date of randomization and the date of first recurrence (local, regional, or distant metastasis), new primary melanoma (including melanoma in situ), or death (whatever the cause), whichever occurred first.     | Time between the date of randomization and the date of first recurrence (local, regional, or distant metastasis), new primary melanoma (including melanoma in situ), or death (whatever the cause), whichever occurred first.     |
| Database lock                                                                                                                                                                                                 | 18 February 2022                                                                                                                                                                                                                  | 18 February 2022                                                                                                                                                                                                                  | 18 February 2022                                                                                                                                                                                                                  | 18 February 2022                                                                                                                                                                                                                  |
| Results and Analysis                                                                                                                                                                                          | Results and Analysis                                                                                                                                                                                                              | Results and Analysis                                                                                                                                                                                                              | Results and Analysis                                                                                                                                                                                                              | Results and Analysis                                                                                                                                                                                                              |
| Analysis description                                                                                                                                                                                          | Exploratory Analysis                                                                                                                                                                                                              | Exploratory Analysis                                                                                                                                                                                                              | Exploratory Analysis                                                                                                                                                                                                              | Exploratory Analysis                                                                                                                                                                                                              |
| Analysis population and time point description                                                                                                                                                                | All randomized subjects: 261 subjects                                                                                                                                                                                             | All randomized subjects: 261 subjects                                                                                                                                                                                             | All randomized subjects: 261 subjects                                                                                                                                                                                             | All randomized subjects: 261 subjects                                                                                                                                                                                             |
| Descriptive statistics and estimate variability                                                                                                                                                               | Treatment group                                                                                                                                                                                                                   | Process C                                                                                                                                                                                                                         | Process C                                                                                                                                                                                                                         | Process D                                                                                                                                                                                                                         |
| Descriptive statistics and estimate variability                                                                                                                                                               | Number of subject                                                                                                                                                                                                                 | 129                                                                                                                                                                                                                               | 129                                                                                                                                                                                                                               | 132                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability                                                                                                                                                               | RFS (median, months)                                                                                                                                                                                                              | NR                                                                                                                                                                                                                                | NR                                                                                                                                                                                                                                | NR                                                                                                                                                                                                                                |
| Descriptive statistics and estimate variability                                                                                                                                                               | 95% CI                                                                                                                                                                                                                            | (27.27, NR)                                                                                                                                                                                                                       | (27.27, NR)                                                                                                                                                                                                                       | (29.80, NR)                                                                                                                                                                                                                       |
| Effect estimate per comparison                                                                                                                                                                                | Exploratory endpoint: RFS                                                                                                                                                                                                         | Comparison groups                                                                                                                                                                                                                 | Comparison groups                                                                                                                                                                                                                 | Process C vs. Process D                                                                                                                                                                                                           |
| Effect estimate per comparison                                                                                                                                                                                | Exploratory endpoint: RFS                                                                                                                                                                                                         | Hazard Ratio (HR)                                                                                                                                                                                                                 | Hazard Ratio (HR)                                                                                                                                                                                                                 | 0.81                                                                                                                                                                                                                              |
| Effect estimate per comparison                                                                                                                                                                                | Exploratory endpoint: RFS                                                                                                                                                                                                         | 95% CI                                                                                                                                                                                                                            | 95% CI                                                                                                                                                                                                                            | 0.53, 1.23                                                                                                                                                                                                                        |
| Effect estimate per comparison                                                                                                                                                                                | Exploratory endpoint: RFS                                                                                                                                                                                                         | P-value                                                                                                                                                                                                                           | P-value                                                                                                                                                                                                                           | Not applicable (descriptive)                                                                                                                                                                                                      |

## 2.6.5.2. In vitro biomarker test for patient selection for efficacy

Not applicable

<div style=\"page-break-after: always\"></div>

## 2.6.5.3. Analysis performed across trials (pooled analyses and meta-analysis)

Not applicable

## 2.6.5.4. Supportive study(ies)

Not applicable

## 2.6.6. Discussion on clinical efficacy

## Design and conduct of clinical studies

The basis of this submission is Study CA2098FC, a randomized, double-blind, parallel, Phase 1 study aimed to demonstrate biocomparability of Process C IV nivolumab to Process D IV nivolumab in 261 patients with stage IIIa/b/c/d or stage IV melanoma after complete resection. The primary endpoints of this study were AUC (tau) (0-336h) at week 1 day 1 (after first dose) and AUC (tau) (0-336h) at week 17 day 1 (after multiple doses).

Subjects were randomized 1:1 to receive nivolumab Process C (Arm A) or nivolumab Process D (Arm B) and randomization was stratified by AJCC Staging (8th edition) [Stage IIIa/b/c/d or IV] and weight categories (&lt; 70 kg, 70 to 90 kg, and &gt; 90 kg).

The target study population included subjects ≥ 18 years old with histologically confirmed completely resected Stage IIIa/b/c/d or Stage IV (AJCC Staging, 8 th  edition) melanoma with no evidence of disease. The target population was agreed by the CHMP during a SA (EMEA/H/SA/2253/6/2018/III).

The only efficacy endpoint included in this study was 'recurrence-free-survival (RFS)', and was an exploratory endpoint. Therefore, the results mentioned below are only descriptive in nature and are considered as supportive.

Median follow-up was 25.9 months (range: 15.7, 31.8), with a minimum follow-up of 15.7 months. Data base lock was 18 February 2022. Although in terms of efficacy assessment a longer follow-up might have been informative, in this context this follow-up is considered acceptable.

Relevant protocol deviations were reported with a similar frequency in both arms: 20.9% in Process C and 22.7% in Process D.

Overall, the design and conduct of the study are considered acceptable. It should be noted that in the CHMP SA provided in 2018 (EMEA/H/SA/2253/6/2018/III) no efficacy issue was addressed.

## Efficacy data and additional analyses

A total of 261 patients were randomized, 129 to the Process C arm and 132 to the Process D arm. This number of patients is deemed adequate, considering that the primary objective of this clinical trial was to compare the PK of both processes, and that efficacy was only considered as supportive.

No relevant differences were observed between treatment arms in terms of baseline demographics. Median age was 57 years in both arms, most patients were males (67.4% in Process C and 59.1% in Process D) and white (97.7% in Process C and 96.2% in Process D). Similarly, no differences were observed in baseline disease characteristics. The majority of patients had IIIa/b/c/d stage in both arms (90.7% in Process C and 87.1% in Process D). Only 2.3% of patients in Process C and 3% of patients in Process D received prior radiotherapy and all patients had prior surgery related to cancer (as per protocol). Most patients did not receive prior systemic cancer therapy related to cancer (97.7% in Process C vs. 99.2% in Process D). Overall, treatment arms were also balanced in terms of PDL-1 status: 47.3% of patients in Process C and 51.5% in Process D had PDL-1 expression ≥ 1%. There was

<div style=\"page-break-after: always\"></div>

a higher proportion of patients with BRAF mutation in Process C compared to Process D (33.3% vs 25.8%). Apart from that no major differences were identified between treatment arms. Thus, considering all this, it can be concluded that both treatment arms were overall well-balanced in terms of baseline characteristics.

No statistically significant differences were observed between both arms in terms of efficacy. The HR for RFS in all randomized subjects was 0.81 (95% CI: 0.53-1.23), with 47 events (36.4%) reported in Process C vs. 43 events (32.6%) in Process D. Median RFS was not reached in either arm. Similar results were observed in patients with PDL-1 ≥1%: the HR was 0.75 (95% CI: 0.42-1.36), with 24 events (39.3%) reported in Process C vs. 21 events (30.9%) in Process D. In this case median RFS was reached in Process C (27.60 months [95% CI: 16.72 - NR]). The HR in subjects with no relevant protocol deviations was 0.75 (95%CI: 0.46-1.21), with 38 events (37.3%) reported in Process C vs. 31 events (30.4%) in Process D. RFS in all randomized subjects (unstratified analysis) was also similar: the HR was 0.84 (95% CI: 0.56-1.28), with 47 events (36.4%) in Process C vs. 43 events (32.6%) in Process D.

RFS rates in all randomized subjects were similar in both arms, or even slightly higher in Process D when compared with Process C: at 6 months 80.6 (95% CI: 72.6, 86.4) in Process C vs. 87.9 (95% CI: 81.0, 92.4) in Process D; at 12 months 74.3 (95% CI: 65.8, 81.0) in Process C vs. 76.5 (95% CI: 68.3, 82.9) in Process D; at 18 months 66.7 (95% CI: 57.6, 74.2) in Process C vs. 72.1 (95% CI: 63.4, 79.0) in Process D; and at 24 months 64.2 (95% CI: 54.9, 72.1) in Process C vs. 66.5 (95% CI: 57.2, 74.3) in Process D.

Immunogenicity incidence was higher in the Process D arm than in the Process C arm: in Process D there were 8 (6.5%) ADA-positive patients vs. 3 (2.5%) ADA-positive patients in Process C. The median duration of nivolumab ADAs was longer in Process D than in Process C: 14.29 (95% CI: 13.86, 34.14) weeks in Process D vs. 8.07 (95% CI: 2.14, NA) weeks in Process C. No patients in either arm developed neutralizing ADAs (see discussion on clinical safety). Overall, it does not appear that immunogenicity had an impact on efficacy results.

Therefore, based on the above-mentioned results, no relevant differences appear in terms of efficacy between Process C and Process D; although, as previously mentioned, these results are only descriptive and therefore no firm conclusions can be drawn.

## 2.6.7. Conclusions on the clinical efficacy

No relevant differences have been observed in RFS between patients randomized to Process C and patients randomized to Process D, suggesting that the efficacy between both processes might be similar. However, it should be noted that the efficacy data provided are only descriptive, as the primary endpoints of this study were PK endpoints (see 2.6.4).

## 2.6.8. Clinical safety

The primary safety data presented to support the nivolumab drug substance manufacturing process change application (from the current approved Process C to a newly optimized Process D) is based on the pivotal clinical biocomparability Study CA2098FC.

The primary safety data, is, therefore, based on 129 subjects treated with nivolumab Process C and 132 subjects treated with nivolumab Process D. To further support the safety data collected from Study CA2098FC, additional exposure-adjusted analyses were conducted for all-causality unique select AEs to contextualize numerically higher incidence of some select AE categories noted in nivolumab Process D compared to nivolumab Process C. Additionally, the MAH has performed a non-exposure

<div style=\"page-break-after: always\"></div>

adjusted descriptive analysis of drug-related select AEs within 30 days of last dose, to further address the differences observed in certain select AEs and cardiac disorders events with nivolumab Process D compared with nivolumab Process C.

## 2.6.8.1. Patient exposure

A majority of subjects treated with nivolumab dosed at 3 mg/kg IV Q2W, received 90% to &lt; 110% of the planned dose intensity, 114 (88.4%) and 113 (85.6%) in Process C and Process D, respectively. A higher proportion was seen during the phase with nivolumab dosed at 480 mg IV Q4W: (100 [95.2%]) and (112 [95.7%]) in Process C and Process D, respectively.

One subject in Process D, treated with nivolumab dosed at 3 mg/kg IV Q2W, had a relative dose intensity greater than or equal to 110%, while none were reported in the Process C arm. The median number of doses received was 9 for both Process C and Process D for subjects during the phase of nivolumab dosed at 3 mg/kg IV Q2W as well as the phase of nivolumab dosed at 480 mg IV Q4W.

The median duration of therapy was 11.53 and 11.55 months for subjects in both Process C and Process D, respectively.

Table 22: Cumulative dose and relative dose intensity summary - all treated subjects

|                                       | Process C N = 129   | Process D N = 132   |
|---------------------------------------|---------------------|---------------------|
| Treatment:Nivolumab3 mg/kg IV Q2W     |                     |                     |
| NUMBEROFSUBJECTSWHORECEIVEDDOSES      | 129 (100.0)         | 132 (100.0)         |
| NUMBEROFDOSESRECEIVED                 |                     |                     |
| MEAN (SD)                             | 8.4 (1.5)           | 8.5 (1.6)           |
| MEDIAN (MIN - MAX)                    | 9.0 ( 2 -9)         | 9.0( 1 -' 9)        |
| CUMULATIVE DOSE (MG/KG)               |                     |                     |
| MEAN (SD)                             | 25.1 ( 4.5)         | 25.5 ( 4.9)         |
| MEDIAN (MIN - MAX)                    | 27.0 ( 6 - 27)      | 27.0 ( 3 - 34)      |
| RELATIVE DOSE INTENSITY (*)           |                     |                     |
| >= 110%                               |                     | 1 (0.8)             |
| 90%10<110%                            | 114 88.4)           | 113 (85.6)          |
| 70%10<90%                             |                     | 18 (13.6) 0         |
| 50%TO<70%                             |                     | 0                   |
| <50%                                  |                     |                     |
| Treatment: Nivolumab480mg IV Q4W      |                     |                     |
| NUMBER OF SUBJECTS WHO RECEIVED DOSES | 105 ( 81.4)         | 117 ( 88.6)         |
| NUMBEROFDOSESRECETVED                 |                     |                     |
| MEAN (SD)                             | 7.9 (2.3)           | 7.9 (2.2)           |
| MEDIAN (MIN - MAX)                    | 9.0 (1 -9)          | 9.0 (1-9)           |
| CUMULATIVE DOSE (MG)                  |                     |                     |
| MEAN (SD)                             | 3768.7 (1099.7)     | 3802.3 (1046.2)     |
| MEDIAN (MIN - MAX)                    | 4320.0 (480 - 4320) | 4320.0 (480 - 4320) |
| RELATIVE DOSE INTENSITY (%)           |                     |                     |
| > 110%                                | 0                   | 0                   |
| 90%T0<110%                            | 100 ( 95.2)         | 112 ( 95.7)         |
| 70%10<90%                             | 5 (4.8)             | 5 (4.3)             |
| 50%TO<70%                             | 0                   | 0                   |
| < 50%                                 | 0                   | 0                   |

Source: Table S.4.1

Note: Percentages are computed out of the total number of subjects who received doses.

<div style=\"page-break-after: always\"></div>

Table 23: Duration of study therapy summary - all treated subjects

|                                               | Process C N = 129   | Process D N = 132   |
|-----------------------------------------------|---------------------|---------------------|
| DURATION OF THERAPY  (MONTHS) MEAN (MIN, MAX) | 9.23 (0.5, 14.8)    | 9.84 (0.0, 14.8)    |
| MEDIAN                                        | 11.53               | 11.55               |
| >3MONTHS (%)                                  | 112 ( 86.8)         | 121 ( 91.7)         |
| 6 MONTHS (%)                                  | 99(76.7)            | 110 (83.3)          |
| > 9MONTHS (%)                                 | 88 (68.2)           | 99 ( 75.0)          |
| > 12 MONTHS (%)                               | 15 ( 11.6)          | 20 ( 15.2)          |

Source:Table S.4.61

## Interruption or delay of study therapy

In both arms of the study, most subjects received all doses of the study medications without an infusion interruption or dose delay.

## Dose delays:

The number of subjects with at least one dose delay was 50 (38.8%) and 58 (43.9%) in Process C and Process D, respectively. The most common reason for dose delays of treatment in both arms of the study was due to AEs. The number of subjects with at least one dose delay due to COVID-19 was 9 (7.0%) and 11 (8.3%) in Process C and Process D, respectively.

## Infusion interruptions:

The number of subjects with at least one infusion interruption was 2 (1.6%) and 8 (6.1%) in Process C and Process D, respectively.

Table 24: Dose delays and infusion interruptions of study therapy - all treated subjects

|                                                                                  | Process C N = 129   | Process D N = 132   |
|----------------------------------------------------------------------------------|---------------------|---------------------|
| SUBJECTS WITH AT LEAST ONE DOSE DELAYED (%)                                      | 50 ( 38.8)          | 58 ( 43.9)          |
| NUMBEROFDOSEDELAYEDPERSUBJECT                                                    |                     |                     |
| 0                                                                                | 79 (61.2)           | 74 (56.1)           |
| 1                                                                                | 38 (29.5)           | 38 (28.8)           |
| 2                                                                                | 8 (6.2)             | 18 (13.6)           |
| 3                                                                                | 3 (2.3)             | 2 (1.5)             |
| >=                                                                               | 1 (0.8)             | 0                   |
| TOTAL NUMBER OF DOSE DELAYED/ TOTAL NUMBER OF DOSES RECEIVED (A)                 | 67/1780 (3.8)       | 80/1921 ( 4.2)      |
| REASON FOR DOSE DELAY (B)                                                        |                     |                     |
| ADVERSE EVENT                                                                    | 42 ( 62.7)          | 44 ( 55.0)          |
| OTHER                                                                            | 24 ( 35.8)          | 33 ( 41.3)          |
| NOT REPORTED                                                                     | 1 (1.5)             | 3(3.8)              |
| LENGTH OF DOSE DELAY (B)                                                         |                     |                     |
| 4 - 7 DAYS                                                                       | 22 ( 32.8)          | 39 (48.8)           |
| 8 - 14 DAYS                                                                      | 30 (44.8)           | 22 ( 27.5)          |
| 15 -42 DAYS                                                                      | 11 ( 16.4)          | 17 ( 21.3)          |
| > 42 DAYS                                                                        | 4 (6.0)             | 2 (2.5)             |
| SUBJECTS WITH AT LEAST ONE DOSE DELAYED DUE TO COVID-19 (*)                      | 9 (7.0)             | 11 (8.3)            |
| TOTAL NUMBER OF DOSE DELAYED DUE TO COVID-19/ TOTAL NUMBER OF DOSES RECEIVED (A) | 9/1780 (0.5)        | 11/1921 ( 0.6)      |
| REASON FOR DOSE DELAY DUE TO COVID-19 (C)                                        |                     |                     |
| ADVERSEEVENT OTHER                                                               |                     | 7 63.6) 4 36.4)     |
| NOT REPORTED                                                                     | 0                   | 0                   |
| SUBJECTS WITH AT LEAST ONE INFUSION INTERRUPTED (%)(D)                           | 2 (1.6)             | 8 (6.1)             |
| NUMBER OF INEUSIONS INTERRUPIED PER SUBJECT (%)(D) 0                             | 127 ( 98.4)         | 124 4 (93.9)        |
| 1                                                                                | 2 1.6)              | 5 3.8)              |

<div style=\"page-break-after: always\"></div>

<!-- image -->

Note:Adosewasconsideredasactuallydelayedif thedelayisexceeding3daysfornivolumab.

(A) Total number of doses received is excluding first dose.

(B)Percentagesarecomputedoutofthetotalnumberofdosesdelayed.

(C) Percentages are computed out of the total number of doses delayed due to CoVID-19.

(D）IntheProcessDarm,onesubjectwithinterruptionreasonof\"Other\"wasactually\"INFUSIONRELATEDHYPERSENSITIVITYREACTION\" andremappedto\"HYPERSENSITIVITYREACTION\"

(E)Percentages are computed outof the total number of doses interrupted bytreatment group.

Source: Table S.4.2.1 (dose delay summary) of the CA2098FC Addendum to the Primary CSR and Table S.4.2.2 (dose interruptions) in Appendix 1.

Table 25: 'Other reasons' of infusion interruptions in the nivolumab Process D arm CA2098FC

| Subject   | Cycle                                                           | \"other Reasons\" of infusion interruptions°                                                                                                                                                                          |
|-----------|-----------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Subject A | Week 3 Day 1                                                    | Infusion reaction back pain                                                                                                                                                                                         |
| Subject B | Week3 Day 1 Week 7 Day 1 Week 9 Day 1 Week 11 Day 1 Week13Day 1 | Infusion-related hypersensitivity reaction Infusion-relatedhypersensitivityreaction Infusion-related hypersensitivity reaction Infusion-related hypersensitivity reaction Infusion-related hypersensitivityreaction |
| Subject C | Week3Day1 Week 17 Day 1                                         | Lumbar pain Backpainandrash-maculopapular                                                                                                                                                                           |
| Subject D | Week 1 Day 1                                                    | Lumbar pain                                                                                                                                                                                                         |
| Subject E | Week31Day1 Week39Day1                                           | Cardiac arrythmia Cardiac arrythmia                                                                                                                                                                                 |

Source: refer to Appendix 4.1 of the CA2098FC Addendum 01 to the Primary CSR3

## Adverse events leading to dose delays

Any-grade all-causality AEs leading to dose delay (within 30 days of last dose) were reported in 37 (28.7%) subjects in the nivolumab Process C treatment group and 39 (29.5%) subjects in the nivolumab Process D treatment group. Grade 3-4 AEs leading to dose delay were reported in 5 (3.9%) subjects in the nivolumab Process C treatment group and 8 (6.1%) subjects in the nivolumab Process D treatment group.

The most frequently reported all-causality AEs leading to dose delay were:

- Nivolumab Process C: ALT increased (4.7%), hyperthyroidism (3.1%), AST increased and diarrhoea (2.3% each), and faecal calprotectin increased and COVID-19 (1.6% each).
- Nivolumab Process D: COVID-19 (3.8%), diarrhoea (3.0%), hyperthyroidism and asthenia (2.3% each), and AST increased, herpes zoster, nausea, and hyperbilirubinemia (1.5% each).

Any-grade drug-related AEs leading to dose delay (within 30 days of last dose) were reported in 25 (19.4%) subjects in the nivolumab Process C treatment group and 21 (15.9%) subjects in the nivolumab Process D treatment group. Grade 3-4 AEs leading to delay were reported in 5 (3.9%) subjects in the nivolumab Process C treatment group and 2 (1.5%) subjects in the nivolumab Process D treatment group.

The most frequently reported drug-related AEs leading to dose delay were:

<div style=\"page-break-after: always\"></div>

- Nivolumab Process C: ALT increased (4.7%), hyperthyroidism (3.1%), AST increased (2.3%), and diarrhoea (1.6%).
- Nivolumab Process D: diarrhoea (3.0%), ALT increased, hyperthyroidism, and asthenia (2.3% each), and AST increased, nausea, and hyperbilirubinemia (1.5% each).

Table 26: Adverse events leading to dose delay in ≥ 1% of all treated subjects in any treatment

|                                                       | Process C N = 129   | Process C N = 129   | Process C N = 129   | Process D N = 132   | Process D N = 132   | Process D N = 132   |
|-------------------------------------------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| System Organ Class (%) Preferred Tenm ($)             | Any Gracde          | Gracle 3-4          | Gradle 5            | Any Grade           | Grade 3-4           | Grade 5             |
| TOTALSUBJECTSWIIHANEVENT                              | 37 (28.7)           | 5 (3.9)             | 0                   | 39 (29.5)           | 8 (6.1)             | 0                   |
| Investigations                                        | 12 (9.3)            | (0.8)               | 0                   | 4 (3.0)             | 0                   | 0                   |
| Alanine aminotransferase increased                    | 6 (4.7)             | (0.8)               | 0                   | 1 (0.8)             | 0                   | 0                   |
| Aspartate aminotransferase increased                  | 3 (2.3)             | 1 (0.8)             | 0                   | 2 (1.5)             | 0                   | 0                   |
| Faecal calprotectin increased                         | 2 (1.6)             | 0                   | 0                   | 0                   |                     | 0                   |
| Infections and infestations COVID-19                  | 5 (3.9) (1.6)       | 0                   | 0                   | 13 ( 9.8)           | 3 (2.3) 1 (0.8)     | 0                   |
| Herpes zoster                                         | 20                  | 0 0                 | 0 0                 | 52 3.8) (1.5)       |                     | 0                   |
|                                                       | 5 3.9)              |                     |                     |                     | 0                   | 0                   |
| Endocrine cisorders                                   |                     | 0                   | 0                   | 4 (3.0)             | (0.8)               | 0                   |
| Hyperthyroiclism                                      | 4 3.1)              | 0                   | 0                   | 3 ( 2.3)            | 1 (0.8)             | 0                   |
| Gastrointestinal cisorders                            | 3 (2.3)             | 0                   | 0                   | 9 (6.8)             | 0                   | 0                   |
| Diarrhoea                                             | 3 ( 2.3)            | 0                   | 0                   | 4( 3.0)             | 0                   | 0                   |
| Nausea                                                | 0                   | 0                   | 0                   | 2 (1.5)             | 0                   | 0                   |
| General disorders and acministration site conclitions | 4 ( 3.1)            | 1 (0.8)             | 0                   | 4 (3.0)             | 0                   | 0                   |
| Asthenia                                              | 1 (0.8)             | 1 (0.8)             | 0                   | 3 (2.3)             | 0                   | 0                   |
| Hepatobiliary cisorders                               | 0                   | 0                   | 0                   | 3 (2.3)             | 1 (0.8)             | 0                   |
| Hyperbilirubinaemia                                   | 0                   | 0                   | 0                   | 2 (1.5)             | 0                   | 0                   |

Source:TableS.6.4.2.3

MedDRA Version 24.1.CTC Version 5.0.

Note: Includes events reported between first dose and 30 days after last dose of study therapy.

Table 27: Drug-related adverse events leading to dose delay in ≥ 1% of all treated subjects in any treatment

|                                                       | Process C N = 129   | Process C N = 129   | Process C N = 129   | Process D N = 132   | Process D N = 132   | Process D N = 132   |
|-------------------------------------------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| System Organ Class (%) Preferred Tenm ($)             | Any Grade           | Grade 3-4           | Grade 5             | Any Gradle          | Grade 3-4           | Grade 5             |
| TOTALSUBJECTSWIIHANEVENT                              | 25 (19.4)           | 5 (3.9)             | 0                   | 21 (15.9)           | 2 (1.5)             | 0                   |
| Investigations                                        | 11 (8.5)            | 1 (0.8)             | 0                   | (2.3)               | 0                   | 0                   |
| Alanine aminotransferase increased                    | 6( 4.7)             | 1 ( 0.8)            |                     | (0.8)               |                     | 0                   |
| Aspartate aminotransferase Increased                  | 3 (2.3)             | 1 (0.8)             | 0                   | 2 (1.5)             | 0                   | 0                   |
| Endocrine disorders                                   | 5  (3.9)            | 0                   | 0                   | 4 (3.0)             | 1 (0.8)             | 0                   |
| Hyperthyroiclism                                      | 4 (3.1)             | 0                   |                     | 3 (2.3)             | 1 (0.8)             | 0                   |
| Gastrointestinal cisorders                            | 2 (1.6)             | 0                   | 0                   | B (6.1)             | 0                   | 0                   |
| Diarrhoea                                             | 20 1.6)             | 0                   | 0                   | 4 (3.0)             | 0                   | 0                   |
| Nausea                                                |                     | 0                   | 0                   | 2 (1.5)             | 0                   | 0                   |
| General cisorders and acministration site conclitions | 2 (1.6)             | 1 (0.8)             | 0                   | 3 (2.3)             |                     | 0                   |
| Asthenia                                              | 1 (0.8)             | 1 (0.8)             | 0                   | 3 (2.3)             |                     | 0                   |
| Hepatobiliary clisorders                              | 0                   | 0                   | 0                   | 2 (1.5)             | 00                  | 0                   |
| Hyperbilirubinaemia                                   |                     | 0                   | 0                   | 2 (1.5)             |                     | 0                   |

Source:Table S.6.4.2.4

MedDRA Version 24.1.CTC Version5.0.

Note: Includes events reported between first dose and 30 days after last dose of study therapy.

<div style=\"page-break-after: always\"></div>

## 2.6.8.2. Adverse events

Table 28: Summary of safety - all treated subjects - CA2098FC

|                                         | Number of Subjects (%)       | Number of Subjects (%)       | Number of Subjects (%)      | Number of Subjects (%)      |
|-----------------------------------------|------------------------------|------------------------------|-----------------------------|-----------------------------|
| SafetyParameters                        | NivolumabProcess C (N = 129) | NivolumabProcess C (N = 129) | NivolumabProcess D (N =132) | NivolumabProcess D (N =132) |
| Deaths                                  | 15 (11.6)                    | 15 (11.6)                    | 14 (10.6)                   | 14 (10.6)                   |
| PrinaryReasonforDeath                   |                              |                              |                             |                             |
| Disease                                 | 13 (10.1)                    | 13 (10.1)                    | 10 (7.6)                    | 10 (7.6)                    |
| Study Drug Toxicity                     | 0                            | 0                            | 1 (0.8)                     | 1 (0.8)                     |
| Unknown                                 | 0                            | 0                            | 1 (0.8)                     | 1 (0.8)                     |
| Othera                                  | 2 (1.6)                      | 2 (1.6)                      | 2 (1.5)                     | 2 (1.5)                     |
|                                         | Any Grade                    | Grade 3-4                    | Any Grade                   | Grade 3-4                   |
| All-causality SAEs                      | 15 (11.6)                    | 9 (7.0)                      | 20 (15.2)                   | 17 (12.9)                   |
| Drug-related SAEs                       | 9 (7.0)                      | 7 (5.4)                      | 7 (5.3)                     | 6 (4.5)                     |
| All-causality AEs leading to DC         | 20 (15.50)                   | 8 (6.2)                      | 20 (15.2)                   | 9 (6.8)                     |
| Drug-related AEs leading to DC          | 15 (11.6)                    | 5 (3.9)                      | 18 (13.6)                   | 8 (6.1)                     |
| All-causalityAEs                        | 124 (96.1)                   | 23 (17.8)                    | 126 (95.5)                  | 37 (28.0)                   |
| Drug-related AEs                        | 114 (88.4)                   | 13 (10.1)                    | 111 (84.1)                  | 17 (12.9)                   |
| ≥ 15% Drug-related AEs in Any Treatment |                              |                              |                             |                             |
| Rash                                    | 22 (17.1)                    | 1 (0.8)                      | 28 (21.2)                   | 1 (0.8)                     |
| Pruritis                                | 21 (16.3)                    | 0                            | 32 (24.2)                   | 0                           |
| Fatigue                                 | 31 (24.0)                    | 0                            | 35 (26.5)                   | 0                           |
| Diarrhea                                | 15 (11.6)                    | 0                            | 22 (16.7)                   | 2 (1.5)                     |
| Hypothyroidism                          | 26 (20.2)                    | 0                            | 24 (18.2)                   | 0                           |
| Hyperthyroidism                         | 23 (17.8)                    | 0                            | 21 (15.9)                   | 1 (0.8)                     |
| Arthralgia                              | 23 (17.8)                    | 0                            | 18 (13.6)                   | 1 (0.8)                     |
| All-causality Select AEs by Category    |                              |                              |                             |                             |
| Skin                                    | 55 (42.6)                    | 2 (1.6)                      | 76 (57.6)                   | 1 (0.8)                     |
| Endocrine                               | 45 (34.9)                    | 4 (3.1)                      | 38 (28.8)                   | 4 (3.0)                     |
| Gastrointestinal                        | 31 (24.0)                    | 1 (0.8)                      | 40 (30.3)                   | 4 (3.0)                     |
| Hepatic                                 | 26 (20.2)                    | 1 (0.8)                      | 35 (26.5)                   | 4 (3.0)                     |
| Renal                                   | 6 (4.7)                      | 0                            | 8 (6.1)                     | 0                           |
| Pulmonary                               | 4 (3.1)                      | 0                            | 4 (3.0)                     | 0                           |
| Hypersensitivity/Infusion Reactions     | 2 (1.6)                      | 0                            | 8 (6.1)                     | 0                           |
| Drug-related Select AEs by Category     |                              |                              |                             |                             |
| Skin                                    | 52 (40.3)                    | 2 (1.6)                      | 74 (56.1)                   | 1 (0.8)                     |
| Endocrine                               | 43 (33.3)                    | 2 (1.6)                      | 37 (28.0)                   | 3 (2.3)                     |

<div style=\"page-break-after: always\"></div>

| Gastrointestinal                                                                                                      | 18 (14.0)                                                                                                             | 1 (0.8)                                                                                                               | 24 (18.2)                                                                                                             | 4 (3.0)                                                                                                               |
|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|
| Hepatic                                                                                                               | 18 (14.0)                                                                                                             | 1 (0.8)                                                                                                               | 25 (18.9)                                                                                                             | 3 (2.3)                                                                                                               |
| Pulmonary                                                                                                             | 4 (3.1)                                                                                                               | 0                                                                                                                     | 3 (2.3)                                                                                                               | 0                                                                                                                     |
| Renal                                                                                                                 | 3 (2.3)                                                                                                               | 0                                                                                                                     | 3 (2.3)                                                                                                               | 0                                                                                                                     |
| Hypersensitivity/Infusion Reactions                                                                                   | 2 (1.6)                                                                                                               | 0                                                                                                                     | 8 (6.1)                                                                                                               | 0                                                                                                                     |
| All-causalityNon-endocrineIMAEswithin100daysof lastdose where Immune Modulating Merlication was Initiated by Category | All-causalityNon-endocrineIMAEswithin100daysof lastdose where Immune Modulating Merlication was Initiated by Category | All-causalityNon-endocrineIMAEswithin100daysof lastdose where Immune Modulating Merlication was Initiated by Category | All-causalityNon-endocrineIMAEswithin100daysof lastdose where Immune Modulating Merlication was Initiated by Category | All-causalityNon-endocrineIMAEswithin100daysof lastdose where Immune Modulating Merlication was Initiated by Category |
| Rash                                                                                                                  | 13 (10.1)                                                                                                             | 2 (1.6)                                                                                                               | 17 (12.9)                                                                                                             | 2 (1.5)                                                                                                               |
| Diarrhea/Colitis                                                                                                      | 6 (4.7)                                                                                                               | 3 (2.3)                                                                                                               | 7 (5.3)                                                                                                               | 5 (3.8)                                                                                                               |
| Hepatitis                                                                                                             | 3 (2.3)                                                                                                               | 0                                                                                                                     | 8 (6.1)                                                                                                               | 4 (3.0)                                                                                                               |
| Pneumonitis                                                                                                           | 3 (2.3)                                                                                                               | 0                                                                                                                     | 3 (2.3)                                                                                                               | 1 (0.8)                                                                                                               |
| Nephritis and Renal Dysfunction                                                                                       | 2 (1.6)                                                                                                               | 0                                                                                                                     | 3 (2.3)                                                                                                               | 0                                                                                                                     |
| Hypersensitivity                                                                                                      | 1 (0.8)                                                                                                               | 0                                                                                                                     | 2 (1.5)                                                                                                               | 0                                                                                                                     |
| All-causality Endocrine IMAEs within 100 days of last dose by Category                                                | All-causality Endocrine IMAEs within 100 days of last dose by Category                                                | All-causality Endocrine IMAEs within 100 days of last dose by Category                                                | All-causality Endocrine IMAEs within 100 days of last dose by Category                                                | All-causality Endocrine IMAEs within 100 days of last dose by Category                                                |
| Adrenal insufficiency                                                                                                 | 2 (1.6)                                                                                                               | 1 (0.8)                                                                                                               | 3 (2.3)                                                                                                               | 1 (0.8)                                                                                                               |
| Hypothyroidism/Thyroiditis                                                                                            | 28 (21.7)                                                                                                             | 0                                                                                                                     | 27 (20.5)                                                                                                             | 0                                                                                                                     |
| Hypothyroidism                                                                                                        | 27 (20.9)                                                                                                             | 0                                                                                                                     | 26 (19.7)                                                                                                             | 0                                                                                                                     |
| Hyperthyroidism                                                                                                       | 23 (17.8)                                                                                                             | 0                                                                                                                     | 21 (15.9)                                                                                                             | 1 (0.8)                                                                                                               |
| Thyroiditis                                                                                                           | 3 (2.3)                                                                                                               | 0                                                                                                                     | 1 (0.8)                                                                                                               | 0                                                                                                                     |
| Diabetes Mellitus                                                                                                     | 2 (1.6)                                                                                                               | 2 (1.6)                                                                                                               | 3 (2.3)                                                                                                               | 2 (1.5)                                                                                                               |
| Hypophysitis                                                                                                          | 1 (0.8)                                                                                                               | 0                                                                                                                     | 2 (1.5)                                                                                                               | 0                                                                                                                     |
| All-causality OESIs within 100 days of last dose by Category                                                          | All-causality OESIs within 100 days of last dose by Category                                                          | All-causality OESIs within 100 days of last dose by Category                                                          | All-causality OESIs within 100 days of last dose by Category                                                          | All-causality OESIs within 100 days of last dose by Category                                                          |
| Myositis/Rhabdomyolysis                                                                                               | 1 (0.8)                                                                                                               | 0                                                                                                                     | 1 (0.8)                                                                                                               | 1 (0.8)                                                                                                               |
| Uveitis                                                                                                               | 1 (0.8)                                                                                                               | 0                                                                                                                     | 1 (0.8)                                                                                                               | 0                                                                                                                     |
| Myocarditis                                                                                                           | 0                                                                                                                     | 0                                                                                                                     | 2 (1.5)                                                                                                               | 2 (1.5)                                                                                                               |
| Pancreatitis                                                                                                          | 0                                                                                                                     | 0                                                                                                                     | 2 (1.5)                                                                                                               | 1 (0.8)                                                                                                               |

MedDRA Version 24.1. CTC Version 5.0.

Note: All events were reported within 30 days after last dose of study therapy unless otherwise indicated.

The verbatim terms reported for the ^other' reasons of death with nivolumab Process C were sepsis secondary to the COVID-19 (147 days after the last dose) and cardiogenic shock (301 days after the last dose); with nivolumab Process D were sudden cardiac death (155 days after the last dose) and cardiogenic shock (477 days after the last dose).

## Common adverse events

The overall frequencies of any grade AEs (all causality and drug-related) [within 100 days of last dose] were comparable between the nivolumab Process D and Process C arms. Numerically higher frequencies of all-causality Grade 3-4 AEs were observed in the Process D vs. the Process C arm (44 [33.3%] subjects and 32 [24.8%] subjects, respectively) driven by small differences in some SOCs due to a few event PTs, though no specific patterns were noted with these events.

<div style=\"page-break-after: always\"></div>

Table 29: Adverse events by worst CTC grade in ≥ 5% of all treated subjects - CA2098FC

|                                                                                                                                              | Process C N = 129                    | Process C N = 129    | Process C N = 129   | Process D N = 132                         | Process D N = 132   | Process D N = 132   | Process D N = 132   | Process D N = 132   |
|----------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|----------------------|---------------------|-------------------------------------------|---------------------|---------------------|---------------------|---------------------|
| System Organ Class (%) Preferred Tenn (%)                                                                                                    | Any Grade                            | Grade 3-4            | Grade 5             | Any Grade                                 | Grade 3-4           | Grade 5             | Grade 5             | Grade 5             |
| TOTALSUBJECTSWITHANEVENT                                                                                                                     | 125 ( 96.9)                          | 32 (24.8)            | 0                   | 126 ( 95.5)                               | 44 ( 33.3)          | 0                   | 0                   | 0                   |
| General disorders and administration site conditions                                                                                         | 69 ( 53.5) 29.5)                     | 3 (2.3) 0            | 0 0 0 0             | 71 ( 53.8) 43                             | 0 0 0               |                     |                     |                     |
| Fatigue Asthenia                                                                                                                             | 34:10.5 7. 8)                        | 1.6)                 | 0                   | 32.6) :８9 13.6) 6.1) 6.8) 86 (65.2) 28.53 | 0:0                 | 0                   | 0                   | 0                   |
| Rash Dry skin vitiligo Rash maculo-papular                                                                                                   |                                      |                      | 0                   |                                           |                     |                     |                     |                     |
| Headache                                                                                                                                     | 10.9 3.9)                            | 200                  |                     |                                           |                     | 0 0 0:0             | 0 0 0:0             | 0 0 0:0             |
| Pyrexia  Oedema peripheral                                                                                                                   |                                      |                      |                     |                                           |                     |                     |                     |                     |
| Skin and subcutaneous tissue disorders                                                                                                       | 69 (53.5)                            | 3 2.3)               | 0 0                 |                                           | 2( 1.5)             |                     |                     |                     |
| Abdominal pain Vomiting Musculoskeletal and connective tissue disorders Arthralgia Myalgia Back pain Investigations Alanine aminotransferase | 14 LL 50 5(                          | 0.8)                 |                     | 697 63 2 17 54 21 1 ( 0.8)                | 0 0:0:0             | 0                   | 0                   | 0                   |
| increased Aspartate aminotransferase increased increased Weight decreased                                                                    | 40 20                                | 1 0.8) 0 1( 0.8) 0 0 |                     | 7 G跖                                      | 91                  |                     |                     |                     |
| Gastrointestinal disorders Diarrhoea Nausea Dry mouth Constipation                                                                           | 262.663 29:3                         | 8 （ 1 (              |                     | 1:3121515(                                | ０１０００ 0.8)          | 0 00 0              | 0 00 0              | 0 00 0              |
| Pruritus                                                                                                                                     |                                      |                      | 0 0 0               | 53128:3 13                                |                     |                     |                     |                     |
|                                                                                                                                              |                                      |                      | 0:0: 0              |                                           |                     |                     |                     |                     |
|                                                                                                                                              |                                      | 6                    |                     | 9.8)                                      |                     |                     |                     |                     |
|                                                                                                                                              | 48.8)                                | 4.7) 0.8)            | 0 0 0 0             |                                           |                     | 0 0                 | 0 0                 | 0 0                 |
|                                                                                                                                              | 缸矶９ 24.8) 10.9) 10.1)                |                      |                     | 28.8) 56.8)                               | 6.8)                | 0 0 0               | 0 0 0               | 0 0 0               |
|                                                                                                                                              | 8.5) 7.8)                            | 10000                | 0 0                 | 15.9) 11.4) 11.4) 4.5)                    | ９４２０００００            |                     |                     |                     |
|                                                                                                                                              | 11 10 10 7.8)                        |                      | 0                   | 6.8)                                      |                     | 000:                | 000:                | 000:                |
|                                                                                                                                              | 3 2.3)                               |                      | 0                   |                                           |                     | 0                   | 0                   | 0                   |
|                                                                                                                                              |                                      |                      |                     | 5.3)                                      |                     |                     |                     |                     |
| Gastrooesophageal reflux disease                                                                                                             | 61 (47.3)                            |                      | 0                   | 47.7)                                     | 3 ( 2.3)            | 0                   | 0                   | 0                   |
|                                                                                                                                              | 36 27.9) 10.9)                       |                      | 0 0                 | 22.0) 9.1)                                | 1 0.8) 0            | 0 0                 | 0 0                 | 0 0                 |
|                                                                                                                                              | 8.5)                                 |                      | 0                   | 12.9)                                     | 1 0.8)              | 0 0                 | 0 0                 | 0 0                 |
|                                                                                                                                              |                                      |                      | 0                   | (40.9)                                    | 4.5) 1 ( 0.8)       | 0                   | 0                   | 0                   |
|                                                                                                                                              | (38.8)                               | 6.2) 0.8)            | 0                   | (15.9)                                    | 1( 0.8)             |                     |                     |                     |
|                                                                                                                                              | 18 (14.0)                            | 1 0.8)               | 0                   | 17 (12.9)                                 |                     | 0                   | 0                   | 0                   |
| Blood thyroid stimulating homone                                                                                                             | 17 (13.2)                            |                      | 0                   |                                           | 0                   |                     |                     |                     |
|                                                                                                                                              | 7(5.4)                               | 0 1 0.8)             | 0                   | 5.3)                                      |                     | 0 0                 | 0 0                 | 0 0                 |
|                                                                                                                                              | 3.9) 31.0)                           | 4                    | 0 0 0               | 33.3)                                     |                     | 0                   | 0                   | 0                   |
| Nervous system disorders Dizziness                                                                                                           | 15.5) 7.8)                           | 3.1) 0:0             |                     | 3.8)                                      |                     | 0 0                 | 0 0                 | 0 0                 |
|                                                                                                                                              |                                      | 0:0                  | 0 0                 | 58 41.7) 6.1)                             | (8:0 6.8)           |                     |                     |                     |
| Infections and infestations COVID-19                                                                                                         | 396 30:3)                            |                      |                     |                                           | 2.3)                | 0                   | 0                   | 0                   |
|                                                                                                                                              |                                      | １００ 0.8)             | 0 0 0               |                                           | ３:０１                | 0                   | 0                   | 0                   |
| Endocrine disorders Hypothyroidism                                                                                                           |                                      |                      |                     | 7262                                      | 0.8) 4.5)           | 0 0                 | 0 0                 | 0 0                 |
| Hyperthyroidism                                                                                                                              | 373                                  | ５０0１ 3.9)            | 0                   | 24.2) 7.6 3.8)                            | ６０２１ （（ (8:9        | 0 0                 | 0 0                 | 0 0                 |
| Metabolism and nutrition disorders Decreased appetite Hyperglycaemia                                                                         | 30 77７ 23.3)                         | 0.8)                 |                     | 21.59 6.8)                                |                     | 0                   | 0                   | 0                   |
| Hyponatraemia                                                                                                                                | 5.4)                                 |                      |                     |                                           | 3 ( 2.3)            | 0                   | 0                   | 0                   |
|                                                                                                                                              | 26 (20.2)                            | 0                    | 0                   | 44 ( 33.3)                                |                     | 0                   | 0                   | 0                   |
| Respiratory, thoracic and mediastinal' disorders Cough                                                                                       | 11（ 8.5)                             | 0                    | 0                   | 15 (11.4)                                 | 1( 0.8)             | 0                   | 0                   | 0                   |
| Insomnia                                                                                                                                     | 17 11 ( 13:3 10                      | 0:0                  | 0 0                 | 8:3                                       | 00                  | 0 0                 | 0 0                 | 0 0                 |
|                                                                                                                                              |                                      |                      |                     | 14.4)                                     |                     |                     |                     |                     |
|                                                                                                                                              | 10 7.8) 3 2.3)                       | 0:0                  | 0 0                 | 9.1)                                      |                     | 0 0                 | 0 0                 | 0 0                 |
|                                                                                                                                              |                                      |                      | 0                   |                                           |                     |                     |                     |                     |
|                                                                                                                                              |                                      | 0.8) 0.8)            | 0                   |                                           |                     |                     |                     |                     |
| Psychiatric disorders                                                                                                                        |                                      |                      |                     | 78 12.9) 6.1)                             | 3123                | 0 0                 | 0 0                 | 0 0                 |
|                                                                                                                                              |                                      | 11                   |                     |                                           |                     |                     |                     |                     |
| Anaemia                                                                                                                                      | 7.8) 3.9)                            |                      |                     |                                           |                     | 10 5                | 10 5                | 10 5                |
|                                                                                                                                              | Blood and lymphatic system disorders |                      |                     |                                           |                     |                     |                     |                     |

MedDRA Version 24.1. CTC Version 5.0.

Note: Includes events reported between first dose and 100 days after last dose of study therapy.

Source: Table 8.8-1 in Addendum 01 to the CA2098FC Primary CSR1

<div style=\"page-break-after: always\"></div>

Table 30: Drug-related adverse events by worst CTC grade in ≥ 5% of all treated subjects CA2098FC

|                                                 | Process C N = 129   | Process C N = 129   | Process C N = 129   | Process D N = 132   | Process D N = 132   | Process D N = 132   |
|-------------------------------------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| System Organ Class (%) Preferred Term (%)       | Any Grade           | Grade 3-4           | Grade 5             | Any Grade           | Grade 3-4           | Grade 5             |
| TOTALSUBJECTSWITHANEVENT                        | 114 ( 88.4)         | 16 (12.4)           | 0                   | 112 (84.8)          | 22 (16.7)           | 0                   |
| Skin and subcutaneous tissue disorders          | 61 (47.3)           | 2（ 1.6)             | 0                   | 81 (61.4)           | 1（ 0.8)             | 0                   |
| Rash                                            | 22 17.1)            | 1 0.8)              | 0                   | 28 21.2)            | 1 （ 0.8)            | 0                   |
| Pruritus                                        | 21 16.3)            | 00                  | 0                   | 34 25.8)            | 0:0:                | 0                   |
| Dry skin                                        | 3.9)                |                     | 0                   | 9 6.8)              |                     | 0                   |
| vitiligo                                        | 3.9)                | 0                   | 0                   | 8 6.1)              | 0                   | 0                   |
| Rash maculo-papular                             | ５53 2.3)            | 0                   | 0                   | 13 9.8)             | 0                   | 0                   |
| General disorders and                           | 44 4(34.1)          | 2 1.6)              | 0                   | 51 ( 38.6)          | 0                   | 0                   |
| acministration site conditions Fatigue          | 32 (24.8)           | 0                   | 0                   | 35 (26.5)           | 0                   | 0                   |
| Asthenia                                        | 11 (8.5)            | 2 1.6)              | 0                   | 12 9.1)             | 0                   | 0                   |
| Gastrointestinal disorders                      | 39 ( 30.2)          | 5 3.9)              | 0                   | 46 ( 34.8)          | 9 ( 6.8)            | 0                   |
| Diarrhoea                                       | 18 14.0)            | 0.8)                | 0                   | 25 18.9)            | ( 3.0)              | 0                   |
| Dry mouth                                       | 12 9.3)             | 0:0                 | 0                   | 13 9.8)             | ４０１                 | 0                   |
| Nausea                                          | 9 7.0)              |                     | 0                   | 14 (10.6)           | 0.8)                | 0                   |
| Endocrine disorders                             | 37 (28.7)           | 1 0.8)              | 0                   | 36 ( 27.3)          | ( 1.5)              | 0                   |
| Hypothyroidism                                  | 27 ( 20.9)          | 0                   | 0                   | 25 (18.9)           | ２０１                 | 0                   |
| Hyperthyroidism                                 | 23 (17.8)           | 0                   | 0                   | (15.9)              | 0.8)                | 0                   |
| Musculoskeletal and connective tissue disorders | 35 5(27.1)          | 0                   | 0                   | 33 (25.0)           | 2 （ 1.5)            | 0                   |
| Arthralgia                                      | 25 (19.4)           | 0                   | 0                   | 19 14.4)            | 1 0.8)              | 0                   |
| Myalgia                                         | 9 (7.0)             | 0                   | 0                   | 10 7.6)             | 0                   | 0                   |
| Investigations                                  | 34 ( 26.4)          | 3.9)                | 0                   | 30 ( 22.7)          | 4 （ 3.0)            | 0                   |
| Alanine aminotransferase increased              | 12 (9.3)            | ii 0.8)             | 0                   | 17 (12.9)           | ii 0.8)             | 0                   |
| Aspartate aminotransferase increased            | 10 (7.8)            | 1( 0.8)             | 0                   | 13 (9.8)            | 1( 0.8)             | 0                   |
| Nervous system disorders                        | 16 (12.4)           | 0                   | 0                   | 14 (10.6)           | 0                   | 0                   |
| Headache                                        | 3(2.3)              | 0                   | 0                   | 8 (6.1)             | 0                   | 0                   |

MedDRA Version 24.1. CTC Version 5.0.

Note: Ineludes events reported between first dose and 100 days after last dose of study therapy.

Source: Table 8.8-2 in Addendum 01 to the CA2098FC Primary CSR1

## 2.6.8.3. Serious adverse events, deaths, and other significant events

## Serious adverse events (SAEs)

Among all treated subjects, the overall proportion of subjects with all-causality SAEs (within 100 days of last dose) was similar between the nivolumab Process C and Process D treatment groups, 24 (18.6%) vs. 28 (21.2%).

Among all treated subjects, the overall proportion of subjects with drug-related SAEs (within 100 days of last dose) was similar between the nivolumab Process C and Process D treatment groups, 11 (8.5%) vs. 9 (6.8%).

There were 2 SAEs of myocarditis attributed to study drug toxicity by the investigator in the nivolumab Process D treatment group. These 2 SAEs were G3 events and resolved in both subjects following steroid therapy instituted per the recommended guidelines.

<div style=\"page-break-after: always\"></div>

Table 31: SAEs reported in ≥ 1% of all treated subjects in any treatment

|                                                                     | Process C N = 129   | Process C N = 129   | Process C N = 129   | Process D N = 132   | Process D N = 132   | Process D N = 132   |
|---------------------------------------------------------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| System Organ Class () Preferred Tenm (%)                            | Any Grade           | Grade3-4            | Grade5              | Any Grade           | Grade3-4            | Grade5              |
| TOIALSUBJECTSWIIHANEVENT                                            | 24 (18.6)           | 16 (12.4)           | 0                   | 28 (21.2)           | 22 (16.7)           | 0                   |
| Respiratory, thoracic and mecliastinal cisorders                    | 3 (2.3)             | 0                   | 0                   | 2 (1.5)             | 2 (1.5)             | 0                   |
| Pneumonitis                                                         | 2 (1.6)             | 0                   | 0                   | 1 (0.8)             | 1 (0.8)             | 0                   |
| Neoplasms benigm, maligmant and unspecified (incl cysts and polyps) | 3 (2.3)             | 2  (1.6)            | 0                   | 3 (2.3)             | 2 (1.5)             | 0                   |
| Metastatic maligmant melancma                                       | 2 (1.6)             | 2 (1.6)             | 0                   | 2 (1.5)             | 2 (1.5)             | 0                   |
| Metabolismandlnutrition cisorders                                   | 1 ( 0.8)            | 1 (0.8)             | 0                   | 4 (3.0)             | 4 (3.0)             | 0                   |
| Diabetic ketoacidosis                                               | 1 (0.8)             | 1 1( 0.8)           | 0                   | 3 (2.3)             | 3 (2.3)             | 0                   |
| Carcliac cisorders                                                  | 1 (0.8)             | 1 (0.8)             | 0                   | 4 ( 3.0)            | 4 (3.0)             | 0                   |
| Myocarclitis                                                        | 0                   | 0                   | 0                   | 2 (1.5)             | 2 (1.5)             | 0                   |

Source:Table S.6.3.1.2.3

MedDRAVersion24.1.CTCVersion5.0

MedDRAVersion24.1.CTCVersion5.0

Note: Includes events reported between first dose and 100 days after last dose of study therapy.

Table 32: Drug-related SAEs reported in ≥ 1% of all treated subjects in any treatment

|                                                   | Process C N = 129   | Process C N = 129   | Process C N = 129   | Process D N = 132   | Process D N = 132   | Process D N = 132   |
|---------------------------------------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| System Organ Class () Preferred Tenm (&)          | Any Gradle          | Grade3-4            | Grade5              | Any Gradle          | Grade3-4            | Grade5              |
| TOTALSUBJECTSWIIHANEVENT                          | 11 (8.5)            | 8 (6.2)             | 0                   | 9 (6.8)             | 9 (6.8)             | 0                   |
| Respiratory, thoracic and mecliastinal clisorders | 2 (1.6)             | 0                   | 0                   | 1 (0.8)             | 1 (0.8)             | 0                   |
| Pneumonitis                                       | 2 (1.6)             | 0                   | 0                   | 1 (0.8)             | 1 (0.8)             | 0                   |
| Carcliac disordlers                               | 0                   | 0                   | 0                   | (2.3)               | 3 (2.3)             | 0                   |
| Myocarclitis                                      |                     | 0                   | 0                   | 2 (1.5)             | 2 (1.5)             | 0                   |

Source:TableS.6.3.1.2.4

MedDRAVersion24.1.CTCVersion5.0

MedDRAVersion24.1.CTCVersion5.0

Note: Includes events reported between first dose and 100 days after last dose of study therapy.

## Deaths

As of the 18-Feb-2022 DBL, death was reported in 15 (11.6%) subjects in the nivolumab Process C treatment group and 14 (10.6%) subjects in the nivolumab Process D treatment group. Disease progression was the most common cause of death.

Table 33: Death summary - all treated subjects

|                                                             | Prooess C N = 129   | Process D N = 132   | Total N = 261   |
|-------------------------------------------------------------|---------------------|---------------------|-----------------|
| NUMBEROFSUBJECTSWHODIED  (8)                                | 15 (11.6)           | 14 (10.6)           | 29 (11.1)       |
| FRIMARY REASON FOR DEATH (%) DISEASE                        | 13 10.1)            | 10 7.6) 112 0.8)    | 8.8)            |
| STUDY DRUG TOXICITY                                         | 0                   |                     | 0.4)            |
| UNKNONN                                                     | 0                   | 0.8)                | 0.4)            |
| OTHER                                                       | 2 1.6)              | 1.5)                | 1.5)            |
| NUMBEROFSUBJECTS WHODIED WITHIN 3O DAYS OF LAST DOSE (%)    | 0                   | 0                   |                 |
| NUMBEROF SUBJECTS WHO DIED WITHIN 10O DAYS OF LAST DOSE (6) | 0                   | 0                   | 0               |

Source:Table S.6.15

<div style=\"page-break-after: always\"></div>

## Deaths attributed to study drug toxicity

There was 1 death attributed to study drug toxicity by the investigator in the nivolumab Process D arm. The subject died (130 days after last dose of nivolumab Process D) due to multiple organ dysfunction considered to be related to treatment by investigator (but deemed not be treatment related by BMS).

## Deaths attributed to other reasons

The verbatim terms reported for the 'other reasons' were consistent with events expected in the population under study and none were considered related to study drug.

- Nivolumab Process C: sudden cardiac death (155 days after the last dose), cardiogenic shock (477 days after the last dose)
- Nivolumab Process D: sepsis secondary to the COVID-19 (147 days after the last dose), cardiogenic shock (301 days after the last dose)

## Select adverse events

The majority of select AEs were Grade 1-2, and most were considered drug-related by the investigator. The numerical difference noted between the two processes in several select AE categories including skin, endocrine, gastrointestinal, hepatic, and hypersensitivity/infusion reactions were primarily driven by low-grade AEs.

The most frequently reported all-causality select AE categories (any grade) [within 100 days of last dose] were as follows in each treatment group:

- Nivolumab Process C: skin (43.4%), endocrine (34.9%), gastrointestinal (25.6%), and hepatic (21.7%).
- Nivolumab Process D: skin (59.1%), endocrine (31.8%), gastrointestinal (31.1%), and hepatic (28.8%).

The most frequently reported all-causality select AE by PT (any grade) [within 100 days of last dose] were as follows in each treatment group:

- Nivolumab Process C: diarrhoea (24.8%), pruritus and hypothyroidism (20.2% each), hyperthyroidism (17.8%), and rash (17.1%).
- Nivolumab Process D: diarrhoea (28.8%), pruritus (26.5%), rash (23.5%), hypothyroidism (19.7%), and hyperthyroidism (16.7%).

The most frequently reported drug-related select AE categories (any grade) [within 100 days of last dose] were as follows in each treatment group:

- Nivolumab Process C: skin (40.3%), endocrine (33.3%), gastrointestinal (14.7%), and hepatic (14.0%).
- Nivolumab Process D: skin (57.6%), endocrine (28.8%), hepatic and gastrointestinal (19.7% each).

The most frequently reported drug-related select AE by PT (any grade) [within 100 days of last dose] were as follows in each treatment group:

- Nivolumab Process C: hypothyroidism (20.9%), hyperthyroidism (17.8%), rash (17.1%), and pruritus (16.3%).

<div style=\"page-break-after: always\"></div>

- Nivolumab Process D: pruritus (25.8%), rash (21.2%), hypothyroidism and diarrhea (18.9% each), and hyperthyroidism (15.9%).

All the reported drug-related serious select AEs by PT (any grade) [within 100 days of last dose] were as follows in each treatment group:

- Nivolumab Process C: pneumonitis (1.6%), and colitis, immune-mediated enterocolitis, pemphigus, rash, adrenal insufficiency, and diabetic ketoacidosis (0.8% each).
- Nivolumab Process D: colitis, diarrhoea, enteritis, hepatitis, pneumonitis, adrenal insufficiency, diabetic ketoacidosis, and hyperthyroidism (0.8% each).

Across the select AE categories, the majority of events were manageable using the established algorithms, with resolution occurring when IMMs (mainly systemic corticosteroids) were administered in the nivolumab Process C and Process D treatment groups. At the time of DBL, with the exception of the endocrine category, the majority of subjects' drug-related select AEs had resolved in the nivolumab Process C and Process D treatment groups.

Table 34: Select adverse events by worst CTC grade in ≥ 1% of all treated subjects in any treatment

| Select Adverse Event Category Sub Category_(%)   | Process C N = 129   | Process C N = 129   | Process C N = 129   | Process D N = 132   | Process D N = 132   | Process D N = 132   |
|--------------------------------------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| Preferred Tenm (%)                               | Any Gracle          | Grade 3-4           | Grade 5             | Any Grade           | Grade 3-4           | Grade 5             |
| GASIROINIESTINALADVERSEEVENT                     |                     |                     |                     |                     |                     |                     |
| TOIALSUBJECTSWIIHANEVENT                         | 33 (25.6)           | 3（ 2.3)             | 0                   | 41 ( 31.1)          | 6( 4.5)             | 0                   |
| Diarrhoea                                        | 32 (24.8)           | 0.8)                | 0                   | 38 (28.8)           | 3.0)                | 0                   |
| Colitis                                          | 2 1.6)              | 11 (8:0             | 0                   | 3 (2.3)             | 0                   | 0                   |
| HEPATICADVERSEEVENT                              |                     |                     |                     |                     |                     |                     |
| TOIALSUBJECISWIIHANEVENT                         | 28 ( 21.7)          | 2(1.6)              | 0                   | 38 (28.8)           | 5（ 3.8)             | 0                   |
| Alanine aminotransferase increased               | 18 ( 14.0)          | 1( 0.8)             | 0                   | 21 ( 15.9)          | 1 0.8)              | 0                   |
| Aspartate aminotransferase increased             | 17 (13.2)           | 1( 0.8)             | 0                   | 17 (12.9)           | 1 （ 0.8)            | 0                   |
| Blood bilirubin increased                        | 3.9)                | 0                   | 0                   | 3.0)                |                     | 0                   |
| Transaminases increased                          | 1.6)                | 0                   | 0                   | 3.8)                | 0.8)                | 0                   |
| Hepatitis                                        | 0.8)                | 0                   | 0                   | 3.8)                | 2.3)                | 0                   |
| Hepatic cytolysis                                | 1.6)                | 1 0.8)              | 0                   | ４５5２3 1.5)          | 0１３０0               | 0                   |
| Hyperbilinubinaemia                              | ５２１２０               |                     |                     | 2.3)                |                     |                     |
| FUIMONARYADVERSEEVENT                            |                     |                     |                     |                     |                     |                     |
| TOIALSUBJECTSWIIHANEVENT                         | 4 ? 3.1)            | 0                   | 0                   | 3.8)                | 11 0.8)             | 0                   |
| Pneumonitis                                      | 4 3.1)              |                     |                     | 3.0)                | 0.8)                | 0                   |
| Interstitial lumg cisease                        | 0                   | 0                   | 0                   | 542 1.5)            | 0                   | 0                   |
| RENALADVERSEEVENT                                |                     |                     |                     |                     |                     |                     |
| TOIALSUBJECTS WIIHANEVENT                        | 6 4.7)              | 0                   | 0                   | 6 6.8)              | 0                   | 0                   |
| Blood creatinine increased                       | 3.9)                | 0:0                 | 0:0                 | 3.8)                |                     |                     |
| Tubulointerstitial nephritis                     | 5１ 0.8)             |                     |                     | 52 1.5)             | 0:0                 | 0:0                 |
| SKINADVERSEEVENT                                 |                     |                     |                     |                     |                     |                     |
| TOTALSUBJECTSWITHANEVENT                         | 56 43.4)            | 2 （ 1.6)            | 0                   | 78 (59.1)           | 2 1.5)              | 0                   |
| Pruritus                                         | 26 20.2)            |                     | 0                   | 35 26.5)            |                     | 0                   |
| Rash                                             | 22 17.1)            | 01 0.8)             |                     | 31 23.5)            | 0.8)                | 0                   |
| Rash maculo-pepular                              | 3 2.3)              | 0                   |                     | 13 (8.6             | 0１000               | 0                   |
| vitiligo                                         | 6 4.7)              | 0                   | 0                   | 6.1)                |                     | 0                   |
| Denmatitis                                       | 2 1.6)              | 0                   | 0                   | 1.5)                |                     | 0                   |
| Erythema                                         | 4 3.1)              | 0                   | 0                   |                     | 0                   | 0                   |
| Rash macular                                     | 2 1.6)              | 0                   |                     | 820232 1.5)         | 0                   | 0                   |
| Rash papular                                     | 0.8)                | 0                   |                     |                     | 0:0                 | 0                   |
| Rash pruritic                                    | 12 1.6)             | 0                   | 00                  |                     |                     | 0                   |

<div style=\"page-break-after: always\"></div>

| Skin hypopigmentation                      | 0.8)         |          | 0000   |                | 0000    |       |
|--------------------------------------------|--------------|----------|--------|----------------|---------|-------|
| Dematitis acmeiform                        | 1121 0.8)    |          |        | 3212           |         |       |
| Eczema                                     | 1.6)         | 0000     |        |                |         |       |
| Psoriasis                                  | 0.8)         |          |        |                |         | 0000  |
| HYPERSENSITIVITY/INFUSIONREACTION          |              |          |        |                |         |       |
| TOIALSUBJECTSWIIHANEVENT                   | 2 C 1.6)     |          |        | 6.1)           | 0:0     |       |
| Hypersensitivity                           |              | 0        |        | 2.3)           |         |       |
| Infusion related hypersensitivity reaction | 2 1.6)       | 0        | 000    | 83１ 0.8)       | 0       | 0:0:0 |
| Infusion relatedl reaction                 | 0            | 0        | 0      | 3( 2.3)        | 0       | 0     |
| FNDOCRINEADVERSEEVENT                      |              |          |        |                |         |       |
| TOIALSUBJECTSWIIHANEVENT                   | 34.9)        | 3.1)     |        | 31.8)          | 4.5)    |       |
| THYROIDDISORDER                            | 33.3)        |          | 00     | 26.5)          | 0.8)    | 0:0   |
| Hypothyroidism                             | 20.9)        |          |        | 19.7)          |         |       |
| Hyperthyroicism                            | 532737 17.8) | 0000     |        | 42526:21 16.7) | 0.8)    | 0:0:0 |
| Blood thyroid stimlating hommone increased | 5.4)         |          |        | 0.8)           | ６１０１０   |       |
| Thyroicitis                                | 2 1.6)       |          | 0      | 1 0.8)         | 0       | 0     |
| DIABETES                                   |              | 33１      | 0      | 413 3.0)       |         | 0     |
| Diabetes mellitus                          | 33１          |          | 0      | 0.8)           | 3１3     | 0     |
| Diabetic ketoacidosis                      | 0.8)         | 0.8)     | 0      | 2.3)           | 2.3)    | 0     |
| ADRENALDISORDER                            | 22 C 1.6)    | 1 （ 0.8) | 0      | 4 3.0)         | 2  1.5) | 0     |
| Adlrenal insufficiency                     | 1.6)         | 1 （ 0.8) | 0      | 3.0)           | 1.5)    | 0     |
| PIIUTTARYDISORDER                          | 1( 0.8)      | 0        | 0      | 2 （ 1.5)       | 0       | 0     |
| Hypopituitarism                            | 0            | 0        | 0      | 2 1.5)         | 0       | 0     |

Source: Table S.6.5.1.3.9 (all-causality select AEs), Table S.6.5.1.3.13 (all-causality select endocrine AEs)

MedDRAVersion 24.1.CTC Version5.0.

Note: Includes events reported between first dose and 100 days after last dose of study therapy.

Table 35: Drug-related select adverse events by worst CTC grade in ≥ 1% of all treated subjects in any treatment

| Select Adverse Event Category Sub Category_(%)   |             | Process C N = 129   |         | Process D N = 132   | Process D N = 132   | Process D N = 132   |
|--------------------------------------------------|-------------|---------------------|---------|---------------------|---------------------|---------------------|
| Preferred Tenm (%)                               | Any Grade   | Grade 3-4           | Grade 5 | Any Grade           | Gradle 3-4          | Grade 5             |
| GASIROINIESTINALADVERSEEVENT                     |             |                     |         |                     |                     |                     |
| TOTALSUBJECTSWIIHANEVENT                         | 19 (14.7)   | 3 （ 2.3)            | 0       | 26 (19.7)           | 6 4.5)              | 0                   |
| Diarrhoea                                        | 18 14.0)    | 1 18.0              |         | 25 18.9)            | 4 3.0)              |                     |
| Colitis                                          | 2 1.6)      | 1 0.8)              | 0       | 2 1.5)              | 0                   | 0                   |
| HEPATICADVERSEEVENT                              |             |                     |         |                     |                     |                     |
| TOIALSUBJECTSWIIHANEVENT                         | 18 ( (14.0) | 1（ 0.8)             | 0       | 26 (19.7)           | 4 3.0)              | 0                   |
| Alanine aminotransferase increased               | 12 9.3)     | 0.8)                | 0       | 17 ( 12.9)          | 1 （ 0.8)            | 0                   |
| Aspartate aminotransferase                       | 10 7.8)     | 1 (0.8)             | 0       | 13 9.8)             | 1( 0.8)             | 0                   |
| increased Blood bilirbin increased               | 4 3.1)      |                     | 0       | 1.5)                | 0                   | 0                   |
| Hepatitis                                        | 0.8)        |                     | 0       | 1 3.0)              | 3 2.3)              | 0                   |
| Hyperbilirubinaemia                              | 101         | 0                   | 00      | ２43２                | 00                  |                     |
| Transaminases increased                          | 0.8)        |                     |         |                     |                     |                     |
| FUIMONARYADVERSEEVENT                            |             |                     |         |                     |                     |                     |
| TOTALSUBJECTSWITHANEVENT                         | 4( 3.1)     | 0                   | 0       | 4(3.0)              | 1 0.8)              | 0                   |
| Pneumonitis                                      | 4 3.1)      | 0                   | 0       | 4 (3.0)             | 1 0.8)              | 0                   |
| RENALADVERSEEVENT                                |             |                     |         |                     |                     |                     |
| TOTALSUBJECTSWIIHANEVENT                         | 3 2.3)      | 0                   | 0       | 4 3.0)              | 0                   | 0                   |
| Blood creatinine increased                       | 1.6)        | 0                   | 0       | 1 0.8)              | 0                   | 0                   |
| Tubulointerstitial nephritis                     | 21 0.8)     | 0                   |         | 2 1.5)              | 0                   | 0                   |
| SKINADVERSEEVENT                                 |             |                     |         |                     |                     |                     |
| TOIALSUBJECTSWIIHANEVENT                         | 52 (40.3)   | 2 1.6)              | 0       | 76 (57.6)           | 1 0.8)              | 0                   |
| Pruritus                                         | 21 16.3)    | 0                   | 0       | 25.8)               | 0                   | 0                   |
| Rash                                             | 22 17.1)    | 1 0.8)              | 0       | 21.2)               | 1 0.8)              | 0                   |
| Rash maculo-papular                              | 3 2.3)      | 0                   | 0       | 9.8)                | 0                   | 0                   |
| Vitiligo                                         | 5 3.9)      | 0                   | 0       | 6.1)                | 0                   | 0                   |
| Rash papular                                     | 1 0.8)      | 0                   | 0       | 2.3                 | 0                   | 0                   |
| Skin hypopigmentation                            | 1 0.8)      | 0                   | 0       | 2.3)                | 0                   | 0                   |
| Dermatitis acmeifom                              | 1 0.8)      | 0                   | 0       | 83320212 1 1.5)     | 0                   | 0                   |
| Erythema                                         | 2.3)        |                     |         |                     | 0                   | 0                   |
| Psoriasis                                        | 3 1 0.8)    | 0                   | 0       | 1.5)                | 0                   | 0                   |
| Rash pruritic                                    | 1.6)        | 0                   | 0       | 0.8)                | 0                   | 0                   |
| Rash macular                                     | 20          | 0                   |         | 1.5)                | 0                   | 0                   |

<div style=\"page-break-after: always\"></div>

| HYPERSENSITIVITY/INFUSIONREACTION          | 2 （ 1.6)   | 0       | 0   | 8 6.1)    | 0        | 0   |
|--------------------------------------------|------------|---------|-----|-----------|----------|-----|
| TOTALSUBJECTSWIIHANEVENT Hypersensitivity  | 0          | 0       |     | 3１ 2.3)   |          |     |
| Infusion related hypersensitivity reaction | 2 1.6)     | 0       | 00  | 0.8)      | 0        | 00  |
| Infusion related reaction                  | 0          | 0       | 0   | 3 2.3)    | 0        | 0   |
| FNDOCRINEADVERSEEVENT                      |            |         |     |           |          |     |
| TOIALSUBJECTSWIIHANEVENT                   | 43 ( 33.3) | 2 (1.6) | 0   | 38 (28.8) | 2.3)     | 0   |
| THYROIDDISORDER                            | 41 ( 31.8) | 0       | 0   | 34 (25.8) | 1 ( 0.8) | 0   |
| Hypothyroiclism                            | 20.9)      | 0       | 0   | 18.9)     |          | 0   |
| Hyperthyroiclism                           | 23 17.8)   |         | 0   | 252 15.9) | 0１0 0.8) | 0:0 |
| Blood thyroid stimulating hommoneincreased | 5 3.9)     | 0       | 0   | 1 0.8)    |          |     |
| Thyroiditis                                | 1.6)       | 0       | 0   | 1 0.8)    | 0        | 0   |
| ADRENALDISORDER                            | 2 （ 1.6)   | 0.8)    | 0   | 3 2.3)    | 1 0.8)   | 0   |
| Adrenal insufficiency                      | 2 （ 1.6)   | 1( 0.8) | 0   | 3 2.3)    | 1 0.8)   | 0   |
| PIIUITARYDISORDER                          | 1 （ 0.8)   | 0       | 0   | 2 1.5)    | 0        | 0   |
| Hypopituitarism                            | 0          | 0       | 0   | 2 1.5)    | 0        | 0   |

Source: Table S.6.5.1.3.10 (drug-related select AEs), Table S.6.5.1.3.14 (drug-related select endocrine AEs)

MedDRAVersion 24.1.CTCVersion5.0.

Note: Includes events reported between first dose and 100 days after last dose of study therapy.

Table 36: Drug-related serious select adverse events by worst CTC grade in all treated subjects

| Select Adverse Event Category Sub Category_(%)   | Process C N = 129   | Process C N = 129   | Process C N = 129   | Process D N = 132   | Process D N = 132   | Process D N = 132   |
|--------------------------------------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| Preferred Tenm (%)                               | Any Gradle          | Grade 3-4           | Grade 5             | Any Grade           | Grade 3-4           | Grade 5             |
| GASIROINIESTINALADVERSEEVENT                     |                     |                     |                     |                     |                     |                     |
| TOIALSUBJECTSWIIHANEVENT                         | 2 1.6)              | 2 （ 1.6)            | 0                   | 2 ( 1.5)            | 2 1.5)              | 0                   |
| Colitis                                          | 1 0.8)              | 100 0.8)            | 0                   | 1 0.8)              | 0                   | 0                   |
| Diarrhoea                                        |                     |                     | 0                   | 1 0.8)              | 1 0.8)              | 0                   |
| Enteritis                                        | 0                   |                     |                     | 1 0.8)              | 1 0.8)              |                     |
| Inmme-mecliated enterocolitis                    | 1 0.8)              | 1 0.8)              | 0                   | 0                   | 0                   | 0                   |
| HEPATICADVERSEEVENT                              |                     |                     |                     |                     |                     |                     |
| TOIALSUBJECTSWIIHANEVENT                         | 0                   | 0:0                 | 0                   | 1 (0.8)             | 1 (0.8)             | 0                   |
| Hepatitis                                        | 0                   |                     | 0                   | 1 (0.8)             | 1 (0.8)             | 0                   |
| PUIMONARYADVERSEEVENT                            |                     |                     |                     |                     |                     |                     |
| TOTALSUBJECTSWIIHANEVENT                         | 2 (1.6)             | 0                   | 0                   | 1 (0.8)             | 1 (0.8)             | 0                   |
| Pneumonitis                                      | 2  (1.6)            | 0                   | 0                   | 1 (0.8)             | 1 (0.8)             | 0                   |
| SKINADVERSEEVENT                                 |                     |                     |                     |                     |                     |                     |
| TOTALSUBJECTSWIIHANEVENT                         | 2 (1.6)             | 2 (1.6)             | 0                   | 0                   | 0                   | 0                   |
| Pemphigus                                        | 1 (0.8)             | 1 (0.8)             | 0                   | 0                   |                     | 0                   |
| Rash                                             | 1 (0.8)             | 1 (0.8)             | 0                   | 0                   |                     | 0                   |
| FNDOCRTINEADVERSEEVENT                           |                     |                     |                     |                     |                     |                     |
| TOTALSUBJECTSWIIHANEVENT                         | 2 (1.6)             | 2 (1.6)             | 0                   | 3 (2.3)             | 3 (2.3)             | 0                   |
| ADRENALDISORDER                                  | 1 (0.8)             | 1 (0.8)             | 0                   | 1 (0.8)             | 1 (0.8)             | 0                   |
| Adlrenal insufficiency                           | 1 (0.8)             | 1 (0.8)             | 0                   | 1 (0.8)             | 1 (0.8)             | 0                   |
| DIABETES                                         | 1 (0.8)             | 1 (0.8)             | 0                   | 1 (0.8)             | 1 (0.8)             | 0                   |
| Diabetic ketoacidosis                            | 1 (0.8)             | 1 (0.8)             | 0                   | 1 (0.8)             | 1 (0.8)             | 0                   |
| THYROIDDISORDER                                  | 0                   | 0                   | 0                   | 1 (0.8)             | 1 (0.8)             | 0                   |
| Hyperthyroidism                                  | 0                   | 0                   | 0                   | 1 (0.8)             | 1 (0.8)             | 0                   |

Source: Table S.6.5.1.3.12 (drug-related serious select AEs),Table S.6.5.1.3.16 (drug-related serious select endocrine AEs)

MedDRA Version 24.1. CTC Version 5.0.

Note: Includes events reported between first dose and 100 days after last dose of study therapy.

## Immune Mediated Adverse Events (IMAEs)

Overall, the majority of IMAEs were Grade 1-2. The most frequently reported IMAE categories (any grade) were as follows in each treatment group:

- Nivolumab Process C: hypothyroidism/thyroiditis (20.9%), hyperthyroidism (17.8%), and rash (10.1%).
- Nivolumab Process D: hypothyroidism/thyroiditis (19.7%), hyperthyroidism (15.9%), and rash (12.9%).

<div style=\"page-break-after: always\"></div>

The most frequently (&gt; 1%) reported Grade 3-4 IMAE categories were as follows in each treatment group:

- Nivolumab Process C: diabetes mellitus (1.6%).
- Nivolumab Process D: diarrhoea and hepatitis (2.3%), and diabetes ketoacidosis (1.5% each).

Across IMAE categories, the majority of events were manageable using the established management algorithms, with resolution occurring when IMMs (mostly systemic corticosteroids) were administered. Some endocrine IMAEs were not considered resolved due to the continuing need for hormone replacement therapy.

Table 37: Onset, management and resolution of all-causality IMAEs within 100 days of last dose - nivolumab Process C treated subjects (N= 129)

| IMAE Category               | N (%) Subj. with Any Grade/ Grade 3-4 IMAE:   | Median Time to IMIAE Onset (range), wks   | % Subj. with NIAEs Receiving IMIMI/High- dose Corticosteroids   | Median Duration IMIMI (range), wks   |   % Subj.with Resolution of IMAE | Median Time to Resolution (range), wlea, b   |
|-----------------------------|-----------------------------------------------|-------------------------------------------|-----------------------------------------------------------------|--------------------------------------|----------------------------------|----------------------------------------------|
| Pneumonitis                 | 3 (2.3)/ 0                                    | 12.86 (11.14 - 60.29)                     | 100.0/100.0                                                     | 6.71 (5.14- 18.71)                   |                            100   | 22.29 (6.00 - 31.57)                         |
| Diarrhea/Colitis            | 6 (4.7) /3 (2.3)                              | 29.79 (3.14 - 56.29)                      | 100.0/ 83.3                                                     | 12.86 (2.00 - 75.86)                 |                             83.3 | 6.86 (3.43 - 40.71+)                         |
| Hepatitis                   | 3 (2.3)/ 0                                    | 22.29 (7.14 - 24.14)                      | 100.0/ 100.0                                                    | 12.71 (3.14 - 34.00)                 |                             66.7 | 33.29 (2.14-33.29)                           |
| Nephritis/Renal Dysfunetion | 2 (1.6)/ 0                                    | 15.64(12.14- 19.14)                       | 100.0/50.0                                                      | 42.43 (35.43 - 49.43)                |                              0   | N.A. (49.71+ - 92.57+)                       |
| Rash                        | 13 (10.1)/ 2(1.6)                             | 5.14 (1.00 - 33.14)                       | 100.0/ 15.4                                                     | 62.57 (1.00 - 128.29)                |                             61.5 | 50.29 (1.14 - 106.86+)                       |
| Hypersensitivity            | 1 (0.8)/0                                     | 6.14 (6.14-6.14)                          | 100.0/0                                                         | 46.71 (46.71 - 46.71)                |                            100   | 0.14 (0.14-0.14)                             |
| Adrenal Insufficieney       | 2 (1.6)/ 1 (0.8)                              | 20.71 (16.29 - 25.14)                     | 100.0/ 50.0                                                     | 85.57 (85.00 - 86.14)                |                              0   | NA. (85.00+ - 86.14+)                        |
| Hypothyroidism Thyroiditis  | 28 (21.7)/ 0                                  | 14.21 (1.71 - 26.86)                      | 0/0                                                             | N.A.                                 |                             35.7 | N.A. (2.43 - 116.57+)                        |
| Diabetes Mfellitus          | 2(1.6)/2(1.6)                                 | 38.79 (31.43 - 46.14)                     | 0/0                                                             | N.A.                                 |                              0   | NA. (58.29+ - 65.14+)                        |
| Hyperthyroidism             | 23 (17.8)/ 0                                  | 6.14 (2.14 -45.71)                        | 13.0/0                                                          | 5.14 (2.29 - 12.00)                  |                             87   | 8.14 (2.71-88.29+)                           |
| Hypophysitis                | 1 (0.8)/0                                     | 30.71 (30.71 - 30.71)                     | 0/0                                                             | N.A.                                 |                              0   | N.A. (22.14+ - 22.14+)                       |

<div style=\"page-break-after: always\"></div>

Table 38: Onset, management and resolution of all-causality IMAEs within 100 days of last dose - nivolumab Process D treated subjects (N= 132)

| IMAE Category               | N(%) Subj. with Any Gradel Grade 3-4 IMIAE:   | Median Time to IMIAE Onset (range), wks   | % Subj. with MAEs Receiving INIMI / High- dose Corticosteroids   | Median Duration IMM (range), wks   |   % Subj. with Resolution of IMIAE | Median Time to Resolution (range), wksa, b   |
|-----------------------------|-----------------------------------------------|-------------------------------------------|------------------------------------------------------------------|------------------------------------|------------------------------------|----------------------------------------------|
| Pneumonitis                 | 3 (2.3)/1 (0.8)                               | 24.29 (15.86 - 48.14)                     | 100.0/ 66.7                                                      | 5.14 (2.00 - 48.00)                |                               66.7 | 5.57 (2.14- 52.57+)                          |
| Diarrhea/Colitis            | 7 (5.3)/5(3.8)                                | 24.57 (3.29 - 56.71)                      | 100.0/ 100.0                                                     | 7.57 (0.71 - 21.57)                |                              100   | 5.57 (3.14- 51.71)                           |
| Hepatitis                   | 8 (6.1)/4(3.0)                                | 36.14 (6.71 - 63.00)                      | 100.0/ 75.0                                                      | 6.00 (0.29 - 32.29)                |                              100   | 12.29 (1.00 - 38.14)                         |
| Nephritis/Renal Dysfunetion | 3 (2.3)/0                                     | 34.14 (29.14 - 35.14)                     | 100.0/100.0                                                      | 11.14 (0.57 - 85.29)               |                               33.3 | NA.(2.43 - 88.43+)                           |
| Rash                        | 17 (12.9)/2( 1.5)                             | 14.14 (0.43 - 51.14)                      | 100.0/17.6                                                       | 69.57 (1.71 - 124.29)              |                               82.4 | 25.71 (7.43 - 124.86+)                       |
| Hypersensitivity            | 2(1.5)/0                                      | 2.07 (2.0-2.14)                           | 100.0/0                                                          | 0.36 (0.14 - 0.57)                 |                              100   | 0.14 (0.14- 0.14)                            |
| Adrenal Insufficieney       | 3 (2.3)/1(0.8)                                | 56.57 (9.29 -63.14)                       | 66.7/0                                                           | 27.57 (6.00 - 49.14)               |                                0   | NA. (6.00+ - 87.29+)                         |
| Hypothyroidism Thyroiditis  | 27 (20.5)/0                                   | 14.14 (5.43 - 41.57)                      | 3.7/3.7                                                          | 2.29 (2.9 -2.9)                    |                               26.9 | NA. (0.71 - 114.14+)                         |
| Diabetes Mfellitus          | 3 (2.3)/2(1.5)                                | 6.43 (5.14-42.14)                         | 0/0                                                              | N.A.                               |                               66.7 | 1.00 (0.57 -65.43+)                          |
| Hyperthyroidism             | 21 (15.9)/ 1 (0.8)                            | 5.14 (1.86-42.0)                          | 9.5/4.8                                                          | 4.50 (1.86 - 7.14)                 |                               95.2 | 5.14 (2.14-66.43+)                           |
| Hypophysitis                | 2 (1.5)/0                                     | 32.86 (14.29 - 51.43)                     | 50.0/0                                                           | 68.00 (68.0 - 68.0)                |                                0   | N.A. (19.86+ - 68.14+)                       |

Note: Includes eventsreported after the fiurst dose and within l00 days oflast dose of shudy therapy. Denominator is based on the number of subjects who expenienced the event. Subjects who experienced IMAE without worsening from baseline grade were excluded fiom time to resolution analysis. Events without a stop date or with a stop date equal to the death as well as Grade 5 events are considered umresolved. For each subject, the longest duation of immune-mediated AEs is considered.

(A) From Kaplan-Meier estimation.

(B) Symbol + indicates a censored value.

Table S.6.1.4-1 (nephritis/renal dysfimction), Table 8.6.1.4-2 (nephritis/renal dysfimction), Table S.6.1.5-1 (rash), Table S.6.1.5-2 (rash), Table 8.6.1.6-1 (hypersensifivity), Table 8.6.1.6-2 (hypersensitivity), Table 8.6.2.1-1 (adrenal insufficieney), Table 8.6.2.2-1 (hypophysitis), Table 8.6.2.2-2 (hypophysitis), Table S.6.2.3-1 (hypothyroidism/thyroiditis).Table 8.6.2.3-2 (hypothyroidism/thyroiditis).Table S.6.2.4-1 (hyperthyroidism),Table 8.6.2.4-2 (hyperthyroidism), Table 8.6.2.5-1 (diabetes mellitus), and Table 8.6.2.5-2 (diabetes mellitus) in Addendum 01 to the CA2098FC Primay CSR 1

## Hepatitis

Any-grade hepatitis IMAEs (within 100 days of last dose) were reported in 3 (2.3%) subjects in the nivolumab Process C treatment group and 8 (6.1%) subjects in the nivolumab Process D treatment group. Grade 3-4 hepatitis IMAEs were reported in 4 (3.0%) subjects in the nivolumab Process D treatment group and no subjects in the nivolumab Process C treatment group.

Table 39: Immune-mediated adverse events adverse events by worst CTC grade in the hepatitis category - all treated subjects

|                                               | Process C N = 129   | Process C N = 129   | Process C N = 129   | Process D N = 132   | Process D N = 132   | Process D N = 132   |
|-----------------------------------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| Immne-Mediated AE Category Preferred Tenm (%) | Any Grade           | Grade 3-4           | Grade5              | Any Grade           | Grade 3-4           | Grade5              |
| HEPATITIS                                     |                     |                     |                     |                     |                     |                     |
| TOTALSUBJECTSWITHANEVENT                      | 3 (2.3)             | 0                   | 0                   | 8 (6.1)             | 4 (3.0)             | 0                   |
| Alanine aminotransferase increased            | 2 ( 1.6)            | 0                   | 0                   | 2 (1.5)             | 1 (0.8)             | 0                   |
| Hepatitis                                     | 0                   | 0                   | 0                   | 4 (3.0)             | 3 (2.3)             | 0                   |
| Aspartate aminotransferase increased          | 2 (1.6)             | 0                   | 0                   | 1 ( 0.8)            | 1 ( 0.8)            | 0                   |
| Hyperbilirubinaemia                           | 0                   | 0                   | 0                   | 2 (1.5)             | 0                   | 0                   |
| Transaminases increased                       | 1 (0.8)             | 0                   | 0                   | 0                   | 0                   | 0                   |

Source:TableS.6.2.02.2(non-endocrineimmune-mediatedAEs)

MedDRAVersion24.1.CTCVersion5.0.

Note: Includes events reported between first dose and 100 days after last dose of study therapy.

<div style=\"page-break-after: always\"></div>

## Other Events of Special Interest (OESIs)

Among all treated subjects, OESIs (regardless of causality or IMM treatment, with extended follow-up) were infrequent, and all events resolved by the time of DBL:

- Nivolumab Process C: OESIs were reported in 2 subjects (4 events), all of which resolved at the time of the DBL. Two of these events were resolved with IMMs.
- Nivolumab Process D: OESIs were reported in 5 subjects (17 events), of which all events resolved with IMMs at the time of the DBL.

Table 40: Treatment, onset, and resolution information for Other Events of Special Interest All treated subjects

| OESI Category Grade,Relationship to Study Therapy, PT   | Inmune-modulating Medication                               | Onset Date (Study Day)   | Duration of Event (Days)   | Resolution (Yes/No)   |
|---------------------------------------------------------|------------------------------------------------------------|--------------------------|----------------------------|-----------------------|
| NivolumabProcess C                                      |                                                            |                          |                            |                       |
| Uveitis                                                 |                                                            |                          |                            |                       |
| Grade 1 drug-related AE uveitis                         | none                                                       | 04-Sep-2020 (156)        | 1                          | Yes                   |
| Grade 2 drug-related AE uveitis                         | dexamethasone                                              | 05-Sep-2020 (157)        | 21                         | Yes                   |
| Grade 1 drug-related AE uveitis                         | none                                                       | 26-Sep-2020 (178)        | 42                         | Yes                   |
| Rhabdomyolysis                                          |                                                            |                          |                            |                       |
| Grade 2 drug-related AE rhabdomyolysis                  | prednisone                                                 | 07-Feb-2020 (31)         | 124                        | Yes                   |
| NivolumabProcess D                                      |                                                            |                          |                            |                       |
| Pancreatitis                                            |                                                            |                          |                            |                       |
| Grade 2 drug-related AE pancreatitis                    | pancrelipase, prednisone                                   | 13-0ct-2020 (86)         | 52                         | Yes                   |
| Grade3drug-relatedSAEpancreatitis                       | prednisone                                                 | 01-Feb-2021 (134)        | 26                         | Yes                   |
| Grade 2 drug-related AE pancreatitis                    | prednisone                                                 | 27-Feb-2021 (160)        | 11                         | Yes                   |
| Grade2drug-relatedAEpancreatitis                        | prednisone                                                 | 12-Mar-2021 (173)        | 83                         | Yes                   |
| Uveitis                                                 |                                                            |                          |                            |                       |
| Grade 1 drug-related AE uveitis                         | atropine, dexamethasone, oxytetracycline, sodium phosphate | 12-May-2020 (92)         | 59                         | Yes                   |
| Grade 2 drug-related AE uveitis                         | dexamethasone, sodium phosphate                            | 09-Jul-2020 (150)        | 14                         | Yes                   |
| Grade 1 drug-related AE uveitis                         | dexamethasone, sodium phosphate                            | 22-Jul-2020 (163)        | 7                          | Yes                   |
| Grade 1 drug-related AE uveitis                         | dexamethasone                                              | 04-Sep-2020 (156)        | 13                         | Yes                   |
| Grade 2 drug-related AE uveitis                         | dexamethasone                                              | 05-Sep-2020 (157)        | 4                          | Yes                   |
| Grade 1 drug-related AE uveitis                         | dexamethasone                                              | 26-Sep-2020 (178)        | 4                          | Yes                   |
| Myocarditis                                             |                                                            |                          |                            |                       |
| Grade 3 drug-related SAE myocarditis                    | methylprednisolone, prednisone                             | 11-Sep-2019 (38)         | 14                         | Yes                   |
| Grade 2 drug-related AE myocarditis                     | mycophenolate mofetil, prednisone                          | 25-Sep-2019 (52)         | 230                        | Yes                   |
| Grade3drug-relatedSAEmyocarditis                        | methylprednisolone, ramipril                               | 07-Nov-2019 (67)         | 5                          | Yes                   |
| Myositis                                                |                                                            |                          |                            |                       |
| Grade3drug-relatedSAEmyositis                           | methylprednisolone, mycophenolate mofetil, prednisone      | 11-Sep-2019 (38)         | 24                         | Yes                   |
| Grade 2 drug-related AE myositis                        | mycophenolate mofetil, prednisone                          | 05-0ct-2019 (62)         | 220                        | Yes                   |
| Grade 2 drug-related SAE myositis                       | Prednisone                                                 | 07-Feb-2020 (31)         | 13                         | Yes                   |
| Grade1drug-relatedAEmyositis                            | prednisone                                                 | 12-May-2020 (282)        | 84                         | Yes                   |

Source: Appendix 6.83.1 (for OESI and IMM), Appendix 6.1.1 (for seriousness and duration of event)

MedDRAVersion 24.1.CTCVersion5.0.

Note: Other Events of Special Interest included preferred terms describing specific events reported within 100 days of last dose.

## 2.6.8.4. Laboratory findings

## Haematology

Abnormalities in haematology tests performed during treatment or within 30 days of last dose of study drug were primarily Grade 1 or 2 in severity.

<div style=\"page-break-after: always\"></div>

The following Grade 3 hematologic abnormalities were reported in all treated subjects with ontreatment laboratory results:

- Nivolumab Process C: lymphocytes (absolute) decreased (2.7%) and absolute neutrophil count decreased (0.8%)
- Nivolumab Process D: haemoglobin decreased (2.3%), lymphocytes (absolute) decreased (0.9%), and absolute neutrophil count decreased (0.8%).

## Serum Chemistry

## Liver tests

During the treatment period, abnormalities (increases) in hepatic parameters (ALP, AST, ALT, and total bilirubin) were primarily Grade 1-2 in each treatment group.

One (0.8%) subject in the nivolumab Process C treatment group and no subjects in the nivolumab Process D treatment group had concurrent ALT or AST &gt; 3 × ULN with total bilirubin &gt; 1.5 × ULN within 30 days, based on laboratory results reported after the first dose and within 30 days of last dose of study therapy.

Table 41: Summary of laboratory abnormalities in specific liver tests (SI Units) - all treated subjects

| Abnormality (%)                                                                    | Process C N = 129   | Process D N = 132   | Total N = 261   |
|------------------------------------------------------------------------------------|---------------------|---------------------|-----------------|
|                                                                                    | N = 129             | N = 132             | N = 261         |
| ALT or AST> 3xULN(%)                                                               | 8 (6.2)             | 8 (6.1)             | 16 (6.1)        |
| ALT or AST > 5xULN (%)                                                             | 1 (0.8)             | 4 (3.0)             | 5 5 (1.9)       |
| AIT or AST > 10xUIN (%)                                                            |                     | 1 (0.8)             | 1 (0.4)         |
| ALT or AST > 20xULN (%)                                                            |                     | 0                   | 0               |
|                                                                                    | N = 129             | N = 132             | N = 261         |
| TOTALBILIRUBIN>2XULN                                                               | 1 (0.8)             | 4 (3.0)             | 5 (1.9)         |
|                                                                                    | N = 129             | N= 132              | N = 261         |
| ALP >1.5xUIN                                                                       | 5 (3.9)             | 5 (3.8)             | 10 (3.8)        |
|                                                                                    | N = 129             | N = 132             | N= 261          |
| CONCURRENTALTORASTELEVATION>3XULNWITH TOTAL BILIRUBIN > 1.5XUIN WITHIN ONE DAY (*) | 0                   | 0                   | 0               |
| CONCURRENTALTORASTELEVATION>3xULNWITH TOTAL BILIRUBIN>1.5XULN WITHIN 30DAYS ()     | 1 (0.8)             | 0                   | 1 (0.4)         |
| CONCURRENTAITORASTELEVATION>3XULNWITH TOTALBILIRUBIN>2XULN WITHINONE DAY()         | 0                   | 0                   | 0               |
| CONCURRENTAITORASTELEVATION>3XULNWITH TOTAL BILIRUBIN > 2XUIN WITHIN 30 DAYS ($)   | 0                   | 0                   | 0               |

Source:TableS.7.6.4

Note: Includes laboratory results reported after the first dose and within 30 days of last dose of study therapy. Denominator corresponds to subjects with at least one on-treatment measurement of the corresponding laboratory parameter.

## Kidney function tests

Most subjects with at least 1 on-treatment measurement had normal creatinine values during the treatment reporting period. The abnormalities in creatinine (increases from baseline) were reported as Grade 1 or 2. No subjects in the nivolumab Process C or Process D treatment groups had a Grade 3 or 4 increased creatinine level.

## Thyroid function tests

The majority of all treated subjects in each treatment group had normal TSH levels at baseline and throughout the treatment period.

<div style=\"page-break-after: always\"></div>

TSH (SI units) increases (&gt; ULN) from baseline ( ≤ ULN) were reported in 46 (35.7%) and 49 (37.1%) of subjects in the nivolumab Process C and Process D treatment groups, respectively. Decreases (&lt; LLN) from baseline ( ≥ LLN) were reported in 43 (33.3%) and 44 (33.3%) of subjects in the nivolumab Process C and Process D treatment groups, respectively.

Table 42: Summary of laboratory abnormalities in specific thyroid tests (SI Units) - all treated subjects with at least one on-treatment TSH measurement

| Abnommality (6)                               | Process C N = 129            | Process D N = 132           | Total N = 261                |
|-----------------------------------------------|------------------------------|-----------------------------|------------------------------|
| TSH >ULN                                      | N = 129 46 (35.7)            | N = 132 49 (37.1)           | N = 261 95 (36.4)            |
| WITHTSH<=ULNATBASELINE                        | N = 129 42 (32.6)            | N = 132 40(30.3)            | N = 261                      |
|                                               |                              |                             | 82 (31.4)                    |
|                                               | N =74                        | N = 76                      | N = 150                      |
| WITH ALL OIHER FT3/FT4 TEST VALUES >= LIN (A) | 24 (32.4) 20 (27.0) 2 ( 2.7) | 23(30.3) 16 (21.1) 10(13.2) | 47(31.3) 36 (24.0) 12 ( 8.0) |
| TSH <LIN                                      | N = 129 43(33.3)             | N = 132                     | N = 261                      |
| WITH TSH>= LIN AT BASELINE                    |                              | 44 (33.3)                   | 87 (33.3)                    |
|                                               | N = 129 41 (31.8)            | N = 132                     | N = 261                      |
|                                               |                              | 43 (32.6)                   | 84 (32.2)                    |
|                                               |                              |                             | N = 150                      |
|                                               | N = 74                       | N = 76                      | 61 (40.7)                    |
|                                               | 31 (41.9)                    | 30 (39.5)                   |                              |
| WITH ALL OIHER FT3/FT4 TEST VALUES <= ULN (A) | 11 (14.9)                    | 10 (13.2)                   | 21 (14.0)                    |
| WITH FT3/FT4 TEST MISSING (A)(B)              | 1 (1.4)                      | 4 ( 5.3)                    | 5 ( 3.3)                     |

Source: Table S.7.6.3

Note: Includes laboratory results reported after the first dose and within 30 days of last dose of study therapy.

(A) Within a 2-week window after the abnormal TSH test date.

- (B) Includes subjects with TSH abnormality and with no FT3/FT4 test values in the 2-week window or with non-abnormal value(s) from only one of the two tests and no value from the other test.

## Electrolytes

Most subjects had normal electrolyte levels during the treatment reporting period. Abnormalities in electrolytes during treatment were primarily Grade 1 to 2 in severity.

The following Grade 3 electrolyte abnormalities were reported in all treated subjects with on-treatment laboratory results:

- Nivolumab Process C: hyperkalaemia (1.6%), hypokalaemia (1.6%), hypoglycaemia (0.8%).
- Nivolumab Process D: hyponatremia (2.3%).

## 2.6.8.5. In vitro biomarker test for patient selection for safety

Not applicable.

## 2.6.8.6. Safety in special populations

Not applicable.

<div style=\"page-break-after: always\"></div>

## 2.6.8.7. Immunological events

## Effect of immunogenicity on safety

## Nivolumab Process C

In the nivolumab Process C treatment group, the incidence of nivolumab ADA was low, and an effect of ADA on the safety of nivolumab Process C treatment was not observed.

Among the nivolumab Process C treated subjects evaluable and positive for nivolumab ADA (N = 3), no subject had hypersensitivity/infusion-related reaction select AEs, compared with 2 of 115 subjects (1.7%) in the nivolumab ADA-negative subgroup. Thus, for the nivolumab Process C treatment, the presence of nivolumab ADA did not appear to be associated with the occurrence of these events.

## Nivolumab Process D

Overall, an effect of ADA on the safety of nivolumab Process D treatment was not observed.

Among the nivolumab Process D treated subjects evaluable and positive for nivolumab ADA, 1 of 8 subjects had hypersensitivity/infusion-related reaction select AEs, compared with 7 of 115 subjects in the nivolumab ADA-negative subgroup. The reported hypersensitivity/infusion reaction in the one ADApositive subject was a Grade 2 infusion-related reaction (infusion reaction back pain) that resolved within 1 day without treatment.

Table 43: Select AEs of hypersensitivity/infusion reaction by ADA status (positive, negative) for AEs - all treated subjects with ADA positive or ADA negative

|                                            | Process C                | Process C                    | ProcessD                 | ProcessD                     |
|--------------------------------------------|--------------------------|------------------------------|--------------------------|------------------------------|
| Preferred Tenm (%)                         | NivolumabADAPositive N=3 | NivolumabADANegative N = 115 | NivolumabADAPositive N=8 | NivolumabADANegative N = 115 |
| TOTALSUBJECTSWITHANEVENT                   | 0                        | 2 (1.7)                      | 1 (12.5)                 | 7 (6.1)                      |
| Hypersensitivity                           | 0                        | 0                            | 0                        | 4 (3.5)                      |
| Infusion related hypersensitivity reaction | 0                        | 2 (1.7)                      | 0                        | 1 (0.9)                      |
| Infusionrelatedreaction                    | 0                        | 0                            | 1 (12.5)                 | 1 (0.9)                      |
| Bronchospasm                               | 0                        | 0                            | 0                        | 1 (0.9)                      |

Source:TableS.7.13.3

MedDRAVersion24.0.CTCVersion5.0.

Note:Includes events between first dose and within the last dose of therapy+1o0 days.

For additional details on immunogenicity see section Outcomes and estimation - immunogenicity results.

## 2.6.8.8. Safety related to drug-drug interactions and other interactions

No formal pharmacokinetic drug interaction studies have been conducted with nivolumab. No new information has been generated in support of this submission.

<div style=\"page-break-after: always\"></div>

## 2.6.8.9. Discontinuation due to adverse events

Table 44: Adverse events leading to discontinuation in ≥ 1% of all treated subjects in any treatment

|                                                                                                  | Prooess C N = 129   | Prooess C N = 129   | Prooess C N = 129   | Process D N = 132   | Process D N = 132   | Process D N = 132   |
|--------------------------------------------------------------------------------------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| Syatem Orgsn Class (6) Prefemed Temm (t)                                                         | Any Grade           | Grade 3-4           | Grade 5             | Any Grade           | Grade 3-4           | Grade 5             |
| TUIALSUBJECISWILHANEVENT                                                                         | 22 (17.1)           | 9 ( 7.0)            | 0                   | 25 (18.9)           | 11 ( 8.3)           | 0                   |
| Gastrointestinal disorders Colitis Gastritis Diarrhoea                                           | 3.11 1.6 ( 1.6)     | ( 1.6) 10 ( 0.8)    | 0 0 00              | 88 9.81 1.3         | 10 ( 0.8)           | 9 0 9 0             |
| Respiratory, thoracic and mediastinal' disorders Pmeummitis                                      | 4 ( 3.1) 2 ( 1.6)   | 0 0                 | 0 0                 | 3 ( 2.3) 3 (2.3)    | 1 ( 0.8) 1 (0.8)    | 口 0                 |
| Neoplasms benigm, meligmant and uspecified (inel cysts and polyps) Metastatic maligmant melancma | 3 ( 2.3)            | 3 ( 2.3)            | 0                   | 0                   | 0                   | 0                   |
| Renal and urinary disorders Tubulointerstitial nephritis                                         | 2 ( 1.6)            | 2 ( 1.6)            | 0                   | 0                   | 0                   | 0                   |
|                                                                                                  | 116:8               | 06                  | 00                  | 211:8               | 00                  | 00                  |
| Cardiae disorders Myocardlitis                                                                   | 00                  | 00                  | 00                  | 311:3               | 211:3               | 00                  |
| Hepatobiliary disorders                                                                          |                     |                     |                     |                     | 211:8               |                     |
| Hepatitis                                                                                        |                     | 06                  | 00                  | 413:8               |                     | 00                  |

Sowce: Table S.6.4.2.5

MedDRA Version 24.1. CTC Version 5.0.

Kdereq Apysgo asop isel lage siep oot pue asop isag uaamyaq paprodar sjuana sapnpul alon

Table 45: Drug-related adverse events leading to discontinuation in ≥ 1% of all treated subjects in any treatment

|                                                 | Process C N = 129   | Process C N = 129   | Process C N = 129   | Prooess D N = 132   | Prooess D N = 132   | Prooess D N = 132   |
|-------------------------------------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| Syatem Orgsn Class (%) Prefermed Temm ($)       | Any Grade           | Grade 3-4           | Grade 5             | Any Grade           | Grade 3-4           | Grade 5             |
| TUIALSUBJECISWIIHANEVENT                        | 16 ( 12.4)          | 5( 3.9)             | 0                   | 23 ( 17.4)          | 10( 7.6)            | 0                   |
| Gastrointestinal disorders                      | 4 (3.1)             | 2( 1.6)             | 0                   | 81 6.1)             | 3.0)                | 0                   |
| Colitis                                         | 2( 1.6)             | 0                   | 0                   | 1( 0.8)             | 0                   | 0                   |
| Gastritis                                       | 2 1.6)              | 1 0.81              | 0                   | 1 0.8)              | 1 0.8)              | 0                   |
| Diarrhcea.                                      | 0                   | 0                   | 0                   | 2 1.5)              | 0                   | 0                   |
| Respiratory, thoracic and mediastinal cisorders | 3[ 2.3)             | 0                   | 0                   | 3( 2.3)             | 1 0.8)              | 0                   |
| Pneumnitis                                      | 2( 1.6)             | 0                   | 0                   | 3( 2.3)             | 1( 0.8)             | 0                   |
| Renal and urinary disorders                     | 2[ 1.6)             | 0                   | 0                   | 21 1.5)             | 口                   | 0                   |
| Tubulointerstitial nephritis                    | 1（ 0.8)             | 0                   | 0                   | 2( 1.5)             | 口                   | 0                   |
| Cardiac disorders                               | 0                   | 0                   | 0                   | 2( 1.5)             | 2( 1.5)             | 0                   |
| Myocarditis                                     | 0                   | 0                   | 0                   | 2( 1.5)             | 2( 1.5)             | 0                   |
| Hepatcbiliary disorders                         | 0                   | 0                   | 0                   | 4 (3.0)             | 2 1.5)              | 0                   |
| Hepatitis                                       | 0                   | 0                   | 0                   | 4 (3.0)             | 1.5)                | 0                   |

Source: Table S.6.4.2.6

MedDRA Version 24.1. CIC Version 5.0.

Note: Includes events reported between furst dose and l00 days after last dose of shudy therapy.

## 2.6.8.10. Post marketing experience

Not applicable. Nivolumab manufactured following Process D has not been commercialized yet.

<div style=\"page-break-after: always\"></div>

## Analyses performed across trials

Exposure-adjusted unique select adverse events in CA2098FC and across pooled nivolumab monotherapy studies

Numerically higher rates of select AEs in several categories including skin, hepatic, gastrointestinal, and hypersensitivity / infusion reactions were observed in the Process D arm compared to the Process C arm. In addition, 3 Grade 3 drug-related/treatment emergent cardiac disorder events (2 myocarditis events and 1 angina pectoris event) were reported in the Process D arm vs none in the Process C arm.

In order to better understand and provide context for these observed numerical differences between treatment arms in CA2098FC, an exposure-adjusted analysis was conducted. Exposure-adjusted safety data from study CA2098FC for nivolumab Process D and Process C were assessed side-by-side with a pooled nivolumab monotherapy group across all tumor types, as well as a pooled melanoma subset.

Table 46: Exposure-adjusted any grade unique select adverse event summary - All treated subjects

|                                     | CA2098FC Pr0cess C Arm N=129   | CA2098FC Pr0cess C Arm N=129   | CA2098FC Pr0cess C Arm N=129   | CA2098FC ProcessD Arm N=132   | CA2098FC ProcessD Arm N=132   | CA2098FC ProcessD Arm N=132   | Pooled Nivo Mono (multiple studies) N=7327   | Pooled Nivo Mono (multiple studies) N=7327   | Pooled Nivo Mono (multiple studies) N=7327   | Pooled Nivo Mono Melanoma Subset (multiple studies) N=1379   | Pooled Nivo Mono Melanoma Subset (multiple studies) N=1379   | Pooled Nivo Mono Melanoma Subset (multiple studies) N=1379   |
|-------------------------------------|--------------------------------|--------------------------------|--------------------------------|-------------------------------|-------------------------------|-------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
| AE Category/PT                      | n (%)                          | P-Y                            | IR/100 P-Y (95% CI)            | n (%)                         | P-Y                           | IR/100 P-Y (95% CI)           | (%) uI                                       | P-Y                                          | IR/100 P-Y (95% CI)                          | n (%)                                                        | P-Y                                                          | IR/100 P-Y (95% CI)                                          |
| Total subjects with anevent         | 94 (72.9)                      | 49.1                           | 191.4 (154.7, 234.3)           | 107 (81.1)                    | 47.5                          | 225.3 (184.6, 272.2)          | 5002 (68.3)                                  | 2350.4                                       | 212.8 (207.0, 218.8)                         | 1081 (78.4)                                                  | 425.6                                                        | 254.0 (239.1, 269.6)                                         |
| Hepatic                             | 28 (21.7)                      | 111.7                          | 25.1 (16.7, 36.2)              | 38 (28.8)                     | 118.4                         | 32.1 (22.7, 44.1)             | 1316 (18.0)                                  | 5469.4                                       | 24.1 (22.8, 25.4)                            | 210 (15.2)                                                   | 1333.9                                                       | 15.7 (13.7,18.0)                                             |
| Skin                                | 56 (43.4)                      | 86.4                           | 64.8 (49.0, 84.2)              | 78 (59.1)                     | 77.6                          | 100.5 (79.5, 125.4)           | 2683 (36.6)                                  | 3929.8                                       | 68.3 (65.7, 70.9)                            | 739 (53.6)                                                   | 709.6                                                        | 104.1 (96.8, 111.9)                                          |
| Hypersensitivity/ infusion reaction | 2 (1.6)                        | 131.6                          | 1.5 (0.2, 5.5)                 | 8 (6.1)                       | 136.2                         | 5.9 (2.5, 11.6)               | 337 (4.6)                                    | 5990.0                                       | 5.6 (5.0, 6.3)                               | 71 (5.1)                                                     | 1400.6                                                       | 5.1 (4.0, 6.4)                                               |
| Gastrointestinal                    | 33 (25.6)                      | 108.2                          | 30.5 (21.0, 42.8)              | 41 (31.1)                     | 112.8                         | 36.3 (26.1, 49.3)             | 1885 (25.7)                                  | 4828.5                                       | 39.0 (37.3, 40.8)                            | 501 (36.3)                                                   | 1007.3                                                       | 49.7 (45.5, 54.3)                                            |

P-Y = person-years of exposure based on time to first onset.

Incidence rate per 100 person-years of exposure (IR/100 P-Y) = event count * 100/person-years of exposure.

MedDRA Version: 24.1.

Studies included in the p0oled nivolumab monotherapy dataset - all indications globally: CA209003, CA209004, CA209010, CA209012,CA209017,CA209025, CA209032,CA209037,CA209039,CA209040,CA209057,CA209063,CA209066,CA209067,CA209078,CA209140,CA209141,CA209142,CA209143, CA209205,CA209227,CA209238,CA209274,CA209275,CA209331,CA209451,CA209459,CA209577,ONO-4538-12,ONO-4538-24

Studies included in the p00led nivolumab monotherapy dataset -melanoma, globally: CA209003, CA209004, CA209037, CA209066, CA209067, CA209238. Includes events reported between first dose and 100 days after last dose of study therapy, except for ONO-4538-12 and ONO-4538-24. ONO-4538-12 and ONO-

4538-24 include events reported between first dose and the earlier date between 28 days after the end of treatment period or thestart date ofthe posttreatment observation period.

95%Confidence interval for rate is based on the exact method forPoisson distribution.

Source: Table 2 and Table 4 in Appendix 1

<div style=\"page-break-after: always\"></div>

Table 47: Exposure-adjusted grade 3-4 unique select adverse event summary - all treated subjects

|                                    | CA2098FCPr0cessCArm N=129   | CA2098FCPr0cessCArm N=129   | CA2098FCPr0cessCArm N=129   | CA2098FCPr0cessDArm N=132   | CA2098FCPr0cessDArm N=132   | CA2098FCPr0cessDArm N=132   | Pooled Nivo Mono (multiple studies) N=7327   | Pooled Nivo Mono (multiple studies) N=7327   | Pooled Nivo Mono (multiple studies) N=7327   | Pooled Nivo Mono Melanoma Subset (multiple studies) N=1379   | Pooled Nivo Mono Melanoma Subset (multiple studies) N=1379   | Pooled Nivo Mono Melanoma Subset (multiple studies) N=1379   |
|------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
| AE Category/PT                     | n(%)                        | P-Y                         | IR/100 P-Y (95% CI)         | n(%)                        | P-Y                         | IR/100 P-Y (95% CI)         | n (%)                                        | P-Y                                          | IR/100 P-Y (95% CI)                          | n (%)                                                        | P-Y                                                          | IR/100 P-Y (95% CI)                                          |
| Total subjects with an event       | 12 (9.3)                    | 130                         | 9.2 (4.8, 16.1)             | 21 (15.9)                   | 138.3                       | 15.2 (9.4, 23.2)            | 1151 (15.7)                                  | 5800.3                                       | 19.8 (18.7, 21.0)                            | 207 (15.0)                                                   | 1370.9                                                       | 15.1 (13.1, 17.3)                                            |
| Hepatic                            | 2 (1.6)                     | 133.6                       | 1.5 (0.2, 5.4)              | 5 (3.8)                     | 143.5                       | 3.5 (1.1, 8.1)              | 476 (6.5)                                    | 6081.1                                       | 7.8 (7.1, 8.6)                               | 71 (5.1)                                                     | 1444.2                                                       | 4.9 (3.8, 6.2)                                               |
| Skin                               | 2 (1.6)                     | 133                         | 1.5 (0.2, 5.4)              | 2 (1.5)                     | 144                         | 1.4 (0.2, 5.0)              | 135 (1.8)                                    | 6218.1                                       | 2.2 (1.8, 2.6)                               | 29 (2.1)                                                     | 1458.9                                                       | 2.0 (1.3, 2.9)                                               |
| Hypersensitivity/ infusionreaction | 0                           | 134.1                       | 0.0 (0.0, 2.8)              | 0                           | 144.4                       | 0.0 (0.0, 2.6)              | 25 (0.3)                                     | 6268.7                                       | 0.4 (0.3, 0.6)                               | 3 (0.2)                                                      | 1470.0                                                       | 0.2 (0.0, 0.6)                                               |
| Gastrointestinal                   | 3 (2.3)                     | 133.6                       | 2.2 (0.5, 6.6)              | 6 (4.5)                     | 143.4                       | 4.2 (1.5, 9.1)              | 181 (2.5)                                    | 6219.4                                       | 2.9 (2.5, 3.4)                               | 57 (4.1)                                                     | 1451.3                                                       | 3.9 (3.0, 5.1)                                               |

Incidence rate per 100 person-years of exposure (IR/100P-Y)= event count * 100/person-years ofexposure.

MedDRA Version: 24.1.

Studies included in the p0oled nivolumab monotherapy dataset - all indications globally: CA209003,CA209004, CA209010, CA209012, CA209017, CA209025,

CA209032,CA209037,CA209039,CA209040,CA209057,CA209063,CA209066,CA209067,CA209078,CA209140,CA209141,CA209142,CA209143,

Studies included in the p00led nivolumab monotherapy dataset - melanoma, globally: CA209003, CA209004, CA209037, CA209066, CA209067, CA209238.

Includes events reported between first dose and 100 days after last dose of study therapy, except for ONO-4538-12 and ONO-4538-24. ONO-4538-12 and ONO4538-24 include events reported between first dose and the earlier date between 28 days after the end of treatment period or the start date of the posttreatment observation period.

95% Confidence interval for rate is based on the exact method for Poisson distribution.

Source: Table 2 and Table 4 in Appendix 1

Table 48: Exposure-adjusted grade 3-4 cardiac disorder adverse event summary - all treated subjects

|                    | CA2098FCProcessCArm N=129   | CA2098FCProcessCArm N=129   | CA2098FCProcessCArm N=129   | CA2098FCProcessDArm N=132   | CA2098FCProcessDArm N=132   | CA2098FCProcessDArm N=132   | Pooled Nivo Mono (multiple studies) N=7327   | Pooled Nivo Mono (multiple studies) N=7327   | Pooled Nivo Mono (multiple studies) N=7327   | Pooled NivoMonoMelanoma Subset (nultiple studies) N=1379   | Pooled NivoMonoMelanoma Subset (nultiple studies) N=1379   | Pooled NivoMonoMelanoma Subset (nultiple studies) N=1379   |
|--------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|
| AE Category/PT     | (%) I                       | P-Y                         | IR/100 P- Y (95% CI)        | n(%)                        | P-Y                         | IR/100 P-Y (95% CI)         | n (%)                                        | P-Y                                          | IR/100 P-Y (95% CI)                          | n (%)                                                      | P-Y                                                        | IR/100 P-Y (95% CI)                                        |
| Cardiac disordersa | 1 (0.8)                     | 134.1                       | 0.7 (0.0, 4.2)              | 5 (3.8)                     | 141.8                       | 3.5 (1.1, 8.2)              | 171 (2.3)                                    | 6210.3                                       | 2.8 (2.4,3.2)                                | 26 (1.9)                                                   | 1459.2                                                     | 1.8 (1.2, 2.6)                                             |
| Myocarditis        | 0                           | 134.1                       | 0.0 (0.0, 2.8)              | 2 (1.5)                     | 144                         | 1.4 (0.2, 5.0)              | 4 (<0.1)                                     | 6280.5                                       | 0.1 (0.0, 0.2)                               | 0                                                          | 1474.0                                                     | 0.0 (0.0, 0.3)                                             |
| Angina pectoris    | 0                           | 134.1                       | 0.0 (0.0, 2.8)              | 1 (0.8)                     | 144.1                       | 0.7 (0.0, 3.9)              | 3 (<0.1)                                     | 6280.5                                       | 0.0 (0.0, 0.1)                               | 0                                                          | 1474.0                                                     | 0.0 (0.0, 0.3)                                             |

Incidence rate per 100person-years of exposure (IR/100P-Y)=event count *100/person-years of exposure.

MedDRA Version: 24.1.

Studies included in the p0oled nivolumab monotherapy dataset - all indications globally: CA209003, CA209004, CA209010, CA209012, CA209017, CA209025, CA209032,CA209037,CA209039,CA209040,CA209057,CA209063,CA209066,CA209067,CA209078,CA209140,CA209141,CA209142,CA209143,

Studies included inthep0oled nivolumabmonotherapy dataset-melanoma,globally:CA209003,CA209004,CA209037,CA209066,CA209067,CA209238.

Includes events reported between first dose and 100 days after last dose of study therapy, except for ONO-4538-12 and ONO-4538-24. ONO-4538-12 and ONO-

4538-24include events reportedbetweenfirst dose and the earlier date between 28 days after the end of treatment periodor the start dateof theposttreatment observation period.

95%ConfidenceintervalforrateisbasedontheexactmethodforPoissondistribution.

?Cardiac Disorders is a SOC of interest instead of a select AE category per BMS definition.

Source:Table2andTable 4inAppendix1

<div style=\"page-break-after: always\"></div>

## Table 49: Exposure-adjusted pancreatitis event summary (any grade and G3-4), by category and PT - all treated subjects in CA2098FC

| Table 14                    | Exposure-AdjustedPancreatitisEventSummary(AnyGradeandGrade3-4),ByCategoryandPT-AllTreatedSubjectsin CA2098FC   | Exposure-AdjustedPancreatitisEventSummary(AnyGradeandGrade3-4),ByCategoryandPT-AllTreatedSubjectsin CA2098FC   | Exposure-AdjustedPancreatitisEventSummary(AnyGradeandGrade3-4),ByCategoryandPT-AllTreatedSubjectsin CA2098FC   | Exposure-AdjustedPancreatitisEventSummary(AnyGradeandGrade3-4),ByCategoryandPT-AllTreatedSubjectsin CA2098FC   | Exposure-AdjustedPancreatitisEventSummary(AnyGradeandGrade3-4),ByCategoryandPT-AllTreatedSubjectsin CA2098FC   | Exposure-AdjustedPancreatitisEventSummary(AnyGradeandGrade3-4),ByCategoryandPT-AllTreatedSubjectsin CA2098FC   | Exposure-AdjustedPancreatitisEventSummary(AnyGradeandGrade3-4),ByCategoryandPT-AllTreatedSubjectsin CA2098FC   | Exposure-AdjustedPancreatitisEventSummary(AnyGradeandGrade3-4),ByCategoryandPT-AllTreatedSubjectsin CA2098FC   | Exposure-AdjustedPancreatitisEventSummary(AnyGradeandGrade3-4),ByCategoryandPT-AllTreatedSubjectsin CA2098FC   | Exposure-AdjustedPancreatitisEventSummary(AnyGradeandGrade3-4),ByCategoryandPT-AllTreatedSubjectsin CA2098FC   | Exposure-AdjustedPancreatitisEventSummary(AnyGradeandGrade3-4),ByCategoryandPT-AllTreatedSubjectsin CA2098FC   | Exposure-AdjustedPancreatitisEventSummary(AnyGradeandGrade3-4),ByCategoryandPT-AllTreatedSubjectsin CA2098FC   |
|-----------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|
| Pancreatitis AE Category/PT | CA2098FCProcessCArm N=129                                                                                      | CA2098FCProcessCArm N=129                                                                                      | CA2098FCProcessCArm N=129                                                                                      | CA2098FCProcessDArm N=132                                                                                      | CA2098FCProcessDArm N=132                                                                                      | CA2098FCProcessDArm N=132                                                                                      | PooledNivoMono(multiple studies) N=7327                                                                        | PooledNivoMono(multiple studies) N=7327                                                                        | PooledNivoMono(multiple studies) N=7327                                                                        | PooledNivoMonoMelanoma Subset(multiplestudies) N=1379                                                          | PooledNivoMonoMelanoma Subset(multiplestudies) N=1379                                                          | PooledNivoMonoMelanoma Subset(multiplestudies) N=1379                                                          |
|                             | n (%)                                                                                                          | P-Y                                                                                                            | IR/100 P-Y (95% CI)                                                                                            | (%)u                                                                                                           | P-Y                                                                                                            | IR/100 P-Y (95% CI)                                                                                            | (%)u                                                                                                           | P-Y                                                                                                            | IR/100 P-Y (95% CI)                                                                                            | (%)u                                                                                                           | P-Y                                                                                                            | IR/100P-Y (95% CI)                                                                                             |
| Any Grade                   |                                                                                                                |                                                                                                                |                                                                                                                |                                                                                                                |                                                                                                                |                                                                                                                |                                                                                                                |                                                                                                                |                                                                                                                |                                                                                                                |                                                                                                                |                                                                                                                |
| Pancreatitis AE             | 0                                                                                                              | 134.5                                                                                                          | (0.0, 2.7) 0.0                                                                                                 | (1.5) 2                                                                                                        | 143.9                                                                                                          | (0.2,5.0) 1.4                                                                                                  | (0.5) 36                                                                                                       | 6265.8                                                                                                         | (0.4, 0.8) 0.6                                                                                                 | (1.0) 14                                                                                                       | 1467.8                                                                                                         | (0.5, 1.6) 1.0                                                                                                 |
| Pancreatitis                | 0                                                                                                              | 134.5                                                                                                          | (0.0, 2.7) 0.0                                                                                                 | (1.5) 2                                                                                                        | 143.9                                                                                                          | (0.2, 5.0) 1.4                                                                                                 | (0.4) 30                                                                                                       | 6267.1                                                                                                         | (0.3, 0.7) 0.5                                                                                                 | (0.9) 12                                                                                                       | 1468.2                                                                                                         | (0.4, 1.4) 0.8                                                                                                 |
| Autoimmune pancreatitis     | NR                                                                                                             | NR                                                                                                             | NR                                                                                                             | NR                                                                                                             | NR                                                                                                             | NR                                                                                                             | (<0.1) 3                                                                                                       | 6280.5                                                                                                         | (0.0, 0.1) 0.0                                                                                                 | (0.1) 2                                                                                                        | 1473.6                                                                                                         | (0.0, 0.5) 0.1                                                                                                 |
| Acute pancreatitis          | NR                                                                                                             | NR                                                                                                             | NR                                                                                                             | NR                                                                                                             | NR                                                                                                             | NR                                                                                                             | (<0.1) 2                                                                                                       | 6281.3                                                                                                         | (0.0, 0.1) 0.0                                                                                                 | 0                                                                                                              | 1474.0                                                                                                         | (0.0,0.3) 0.0                                                                                                  |
| Subacute pancreatitis       | NR                                                                                                             | NR                                                                                                             | NR                                                                                                             | NR                                                                                                             | NR                                                                                                             | NR                                                                                                             | (<0.1) 1                                                                                                       | 6281.4                                                                                                         | (0.0, 0.1) 0.0                                                                                                 | 0                                                                                                              | 1474.0                                                                                                         | (0.0, 0.3) 0.0                                                                                                 |
| Grade 3-4                   |                                                                                                                |                                                                                                                |                                                                                                                |                                                                                                                |                                                                                                                |                                                                                                                |                                                                                                                |                                                                                                                |                                                                                                                |                                                                                                                |                                                                                                                |                                                                                                                |
| Pancreatitis AE             | 0                                                                                                              | 134.5                                                                                                          | (0.0, 2.7) 0.0                                                                                                 | (0.8) 1                                                                                                        | 144.1                                                                                                          | (0.0, 3.9) 0.7                                                                                                 | (0.3) 20                                                                                                       | 6273.9                                                                                                         | (0.2, 0.5) 0.3                                                                                                 | (0.7) 10                                                                                                       | 1471.2                                                                                                         | (0.3, 1.2) 0.7                                                                                                 |
| Pancreatitis                | 0                                                                                                              | 134.5                                                                                                          | (0.0, 2.7) 0.0                                                                                                 | (0.8) 1                                                                                                        | 144.1                                                                                                          | (0.0, 3.9) 0.7                                                                                                 | (0.2) 16                                                                                                       | 6275.0                                                                                                         | (0.1, 0.4) 0.3                                                                                                 | (0.6) 8                                                                                                        | 1471.6                                                                                                         | (0.2, 1.1) 0.5                                                                                                 |
| Autoimmune pancreatitis     | NR                                                                                                             | NR                                                                                                             | NR                                                                                                             | NR                                                                                                             | NR                                                                                                             | NR                                                                                                             | (<0.1) 3                                                                                                       | 6280.5                                                                                                         | (0.0, 0.1) 0.0                                                                                                 | (0.1) 2                                                                                                        | 1473.6                                                                                                         | (0.0, 0.5) 0.1                                                                                                 |
| Acute pancreatitis          | NR                                                                                                             | NR                                                                                                             | NR                                                                                                             | NR                                                                                                             | NR                                                                                                             | NR                                                                                                             | (<0.1) 1                                                                                                       | 6281.4                                                                                                         | (0.0, 0.1) 0.0                                                                                                 | 0                                                                                                              | 1474.0                                                                                                         | (0.0, 0.3) 0.0                                                                                                 |

Studiesincluded in thepooled nivolumabmonotherapy dataset-melanoma,globally:CA209003,CA209004,CA209037,CA209066,CA209067,CA209238.

Includes events reported between first dose and 100 days after last dose of study therapy, except for ONO-4538-12 and ONO-4538-24. ONo-4538-12 and ONO-4538-24 includeeventsreportedbetweenfirstdoseand theearlierdatebetween28daysafter theendoftreatmentperiodorthestartdateof theposttreatmentobservation period.

95%Confidenceinterval forrate isbasedon theexact method forPoisson distribution.

Drug-related select adverse events and all causality cardiac disorder events in CA2098FC versus pooled nivolumab monotherapy and combination therapy studies

<div style=\"page-break-after: always\"></div>

Table 50: Drug-related select AEs (by category and PT) within 30 days of last dose reported in CA2098FC versus pooled nivolumab monotherapy and combination therapy studies

|                                                         |                               |                               |                               |                               |                               |                               |                   |                   |                   |                     |                     |                     |                              | (4.4)                        |                              |                  | (6.5)            |                  |
|---------------------------------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------|-------------------|-------------------|---------------------|---------------------|---------------------|------------------------------|------------------------------|------------------------------|------------------|------------------|------------------|
| Colitis                                                 | 2 (1.0)                       | 0                             | 0                             | 2 (1.5)                       | 0                             | 0                             | 50 (1.2)          | 23 (0.6)          | 0                 | 19 (1.5)            | 10 (0.8)            | 0                   | 108 (5.2)                    | 67 (3.2)                     | 0 (0.9)                      | (58.4) 3         | 0                | 0                |
| Autoimmunecolitis                                       | 0                             | 0                             | 0                             | (0.8) 1                       | (0.8) 1                       | 0                             | (<0.1) 2          | (0.1) 1           | 0                 | (0.2) 2             | (0.2) 2             | 0                   | (0.3) 7                      | (0.2) 4                      | 0                            | NR               | NR               | NR               |
| Enteritis                                               | 0                             | 0                             | 0                             | 1 (0.8)                       | 1 (0.8)                       | 0                             | 2 (<0.1)          | 1 (<0.1)          | 0                 | 2 (0.2)             | 1 (<0.1)            | 0                   | 3 ( 0.1)                     | 1 (<0.1)                     | 0 (0.3)                      | 1                | 1 (0.3)          | 0                |
| Frequent bowel movements                                | 1 (0.8)                       | 0                             | 0                             | 0                             | 0                             | 0                             | 9 (0.2)           | 0                 | 0                 | NR                  | NR                  | NR                  | 2 (<0.1)                     | 0                            | 0                            | 2 (0.6)          | 0                | 0                |
| Immune-mediated enterocolitis                           | (0.8) 1                       | (0.8) 1                       | 0                             | 0                             | 0                             | 0                             | (<0.1) 2          | (<0.1) 2          | 0                 | (0.2) 3             | (0.2) 2             | 0                   | (0.3) 6                      | (0.2) 5                      | 0                            | NR               | NR               | NR               |
| Hepatic                                                 | 18 (14.0)                     | 1 (0.8)                       | 0                             | 25                            | 3 (2.3)                       | 0                             | 311 (7.5)         | 73 (1.8)          | 0                 | 249 (19.6)          | 36 (2.8)            | 0                   | 402 (7:61)                   | 188 (9.0)                    | 0                            | 133 (41.6)       | 35 (10.9)        | 0                |
| ALT increased                                           | (9.3) 12                      | (0.8) 1                       | 0                             | (18.9) (11.4) 15              | 0                             | 0                             | (3.9) 161         | (0.8) 33          | 0                 | (9.1) 115           | (0.6) 8             | 0                   | (10.6) 223                   | (4.3) 89                     | 0                            | (26.9) 86        | (5.0) 16         | 0                |
| ASTincreased                                            | 10 (7.8)                      | 1 (0.8)                       | 0                             | 12 (9.1)                      | 0                             | 0                             | 164 (4.0)         | 27 (0.7)          | 0                 | 139 (11.0)          | 14 (1.1)            | 0                   | 215 (10.3)                   | 66 (3.2)                     | 0                            | 81 (25.3) 6      | 11 (3.4)         | 0                |
| Hepatitis                                               | (0.8) 1                       | 0                             | 0                             | (3.0) 4                       | (2.3) 3                       | 0                             | (0.1) 6           | (<0.1) 2          | 0                 | (0.2) 2             | (<0.1) 1            | 0                   | 22                           | 19                           | 0 0                          | (1.3) 4          | (1.3) 4          | 0                |
| Hyperbilirubinaemia                                     | 0                             | 0                             | 0                             | (2.3) 3                       | 0                             | 0                             | (0.2) 7           | 1                 | 0                 | (0.8) 10            | (0.2) 2             | 0                   | (1.1) 14                     | (0.9) 1                      | (1.9)                        | (5.0) 16         | (0.3) 1          | 0                |
| Bloodbilirubinincreased                                 | (3.1) 4                       | 0                             | 0                             | 2                             | 0                             | 0                             | (0.7) 30          | (<0.1) (<0.1) 3   | 0                 | 52                  | (0.3) 4             | (0.7) 31            |                              | (<0.1) 3                     | 0                            | 13 (4.1)         | (0.3) 1          | 0                |
|                                                         | 1                             | 0                             | 0                             | (1.5)                         |                               |                               | 24                | 6                 |                   | (4.1)               |                     | 0                   | (1.5) 42                     |                              | 0                            |                  | 2                | 0                |
| Transaminases increased                                 | (0.8)                         |                               |                               | 2 (1.5)                       | 0                             | 0                             | (0.0)             | (0.1)             | 0                 | 14 (1.1)            | 0                   | 0                   | (0.1) (2.0)                  | 22 (1.1)                     |                              |                  | (0.6)            | NR               |
| Hepatic cytolysis                                       | (0.8) 1                       | 0 0                           | 0                             | (0.8) 1                       | 0                             | 0                             | (0.2) 9 5         | (<0.1) 4          | 0                 | (<0.1) 1            | 0                   | 0                   | 15 9                         | (0.4) 8 7                    | 0                            | NR 3             | NR               |                  |
| Liver function test increased Blood alkalinephosphatase | 0 1 (0.8)                     |                               | 0                             | (0.8) 1                       | 0                             | 0                             | (0.1) 75          | (<0.1) 3          | 0                 | (0.3) 4             | (<0.1) 1            | (0.7) 0             |                              | (0.3)                        | 0 0                          |                  | 0                | 0 0              |
| increased                                               |                               | 0                             | 0                             | 0                             | 0                             | 0                             | (1.8)             | 7 (0.2)           | 0                 | 62 (4.9)            | 5 (0.4)             | 0                   | (0.4) 74 (0.6)               | 13                           | (0.9) 28                     |                  | 2 (0.6)          |                  |
| Pulmonary                                               | (3.1) 4                       | 0                             | 0                             | (2.3) 3                       | 0                             | 0                             | (3.0) 148         | (0.8) 33          | (0.1) 2           | (4.8) 61            | (1.3) 16            | 0                   | (3.5) (6.9) 145              | (1.5) 32                     | (8.8) 0                      | (5.6) 18         | (1.6) 5          | 0                |
| SelectAE Category Sub-Category/Preferred                | Nivo Process C CA2098FC N=129 | Nivo Process C CA2098FC N=129 | Nivo Process C CA2098FC N=129 | Nivo Process D CA2098FC N=132 | Nivo Process D CA2098FC N=132 | Nivo Process D CA2098FC N=132 | Nivo Monoa N=4122 | Nivo Monoa N=4122 | Nivo Monoa N=4122 | Nivo+Chemo b N=1268 | Nivo+Chemo b N=1268 | Nivo+Chemo b N=1268 | Nivo+Ipi (±Chemo) a,c N=2094 | Nivo+Ipi (±Chemo) a,c N=2094 | Nivo+Ipi (±Chemo) a,c N=2094 | Nivo+Caboa N=320 | Nivo+Caboa N=320 | Nivo+Caboa N=320 |
| Term                                                    | Any Grade                     | G3-4                          | G5                            | Any Grade                     | G3-4                          | G5                            | Any Grade         | G3-4              | G5                | Any Grade           | G3-4                | G5                  | Any                          | G3-4                         | G5 Any                       | Grade            | -                | G5               |
| Pneumonitis                                             | (3.1) 4                       | 0                             | 0                             | (2.3) 3                       | 0                             | 0                             | (3.0) 124         | (0.6) 26          | (<0.1) 2          | 4.1) 52             | (1.0) 13            | 0                   | Grade (6.0) 125 (71)         | 26 0                         |                              | (5.0) 16         | (1.6) 5          | 0                |
| Interstitiallungdisease                                 | 0                             | 0                             | 0                             | (0.8) 1                       | 0                             | 0                             | (0.5) 19          | (0.1) 5           | 0                 | (0.6) 8             | 3                   | 0                   | 16 (0.1) 3                   | 0                            |                              | (0.6) 2          | 0                | 0                |
| Renal                                                   | (2.3) 3                       | 0                             | 0                             | (2.3) 3                       | 0                             | 0                             | (2.7) 112         | (0.4) 18          | 0                 | (8.8) 112           | (0.2) 15            |                     | (0.8) (6.1) 128 (1.4)        | 30                           | 0                            | (10.0) 32        | (1.3) 4          | 0                |
| Tubulointerstitial nephritis                            | ( 0.8) 1                      | 0                             | 0                             | (1.5) 2                       | 0                             | 0                             | (<0.1) 4          | (<0.1) 3          | 0                 | (<0.1) 1            | (1.2) 1             | 0 0                 | 3 (<0.1) 2                   | 0                            |                              | NR               | NR               | NR               |
| Bloodcreatinineincreased                                | 2 (1.0)                       | 0                             | 0                             | 1 (0.8)                       | 0                             | 0                             | 85 (2.1)          | 4 (<0.1)          | 0                 | 69 (5.4)            | (<0.1) 2            | 0                   | (0.1) 91 4 (0.2)             | 0                            |                              | 21 (6.6)         | 2 (0.6)          | 0                |
| Renal failure                                           | 0                             | 0                             | 0                             | (0.8) 1                       | 0                             | 0                             | (0.2) 9           | (<0.1) 1          | 0                 | (0.8) 10            | (0.2) (0.3) 4       | (4.3) 0 (0.4) 9     | (<0.1) 2                     | 0                            |                              | (2.8) 9          | (0.3) 1          | 0                |
| Nephritis                                               | 1 (0.8)                       | 0                             | 0                             | 0                             | 0                             | 0                             | NR                | NR                | NR                | 1 (<0.1)            | 1 (<0.1)            | 0 4 (0.2)           | 1 (<0.1)                     | 0                            |                              | 2 (0.6)          | 1 (0.3)          | 0                |
| Skin                                                    | 52                            | 2                             | 0                             | 74                            | 1                             |                               | 1213              | 56                | 0                 | 306                 | 31                  | 0                   | 968 99                       |                              |                              | 201              | 34               | 0                |
|                                                         | (40.3) 21                     | (1.6) 0                       |                               | (56.1)                        | (0.8)                         | 0                             | (29.4)            | (1.4)             |                   | (24.1)              | (2.4)               | (46.2) 509          | (4.7)                        | 0                            |                              | (62.8)           | (10.0)           |                  |
| Pruritus                                                | (16.3)                        |                               | 0                             | (24.2) 32                     | 0                             | 0                             | (14.8) 609        | (0.1) 6           | 0                 | (6.5) 82            | (<0.1) 1            | 0                   | (1.0) 21                     | 0                            |                              | (17.2) 55        | (0.3) 1          | 0                |
| Rash                                                    | 22 (17.1)                     | 1 (0.8)                       | 0                             | 28 (21.2)                     | 1 (0.8)                       | 0                             | 520 (12.0)        | 24 (0.6)          | 0                 | 121 (9.5)           | 9 (0.7)             | (24.3) 462 0 (22.1) | 50 (2.4)                     | 0                            | 65                           | (20.3)           | 6 (1.9)          | 0                |
| Rash maculo-papular                                     | 3 (2.3)                       | 0                             | 0                             | 12 (9.1)                      | 0                             | 0                             | 154 (3.7)         | 11 (0.3)          | 0                 | 24 (61)             | 6 (0.5)             | 0                   | 160 (7.0)                    | 26 (71)                      | 0                            | 25 (7.8)         | 1 (0.3)          | 0                |
| Vitiligo                                                | (3.9) 5                       | 0                             | 0                             | (6.1) 8                       | 0                             | 0                             | (2.4) 98          | (<0.1) 1          | 0                 | (<0.1) 1            | 0                   | 0                   | 42 0                         |                              | 0                            | NR               | NR               | NR               |
|                                                         | 1                             | 0                             |                               | 3                             |                               |                               | 21                | 1                 |                   | 2                   |                     | (2.0) 22 (1.1)      | 2                            |                              | 5                            | 1                |                  |                  |
| Rash papular                                            | (0.8)                         |                               | 0                             | (2.3)                         | 0                             | 0                             | (0.5)             | (<0.1)            | 0                 | (0.2)               | 0                   | 0                   |                              | (<0.1)                       | 0                            | (1.6)            | (0.3)            | 0                |
| Skin hypopigmentation                                   | (0.8) 1                       | 0                             | 0                             | (2.3) 3                       | 0                             | 0                             | (0.3) 13          | 0                 | 0                 | (<0.1) 1            | 0                   | 0                   | (0.0) 13 10                  | 0                            | 0                            | (1.6) 5          | 0                | 0                |
| Psoriasis                                               | (0.8) 1                       | 0                             | 0                             | (S1) 2                        | 0                             | 0                             | (0.4) 15          | (<0.1) 2          | 0                 | (<0.1) 1            | 0                   | 0                   | (0.5) 2 (1.2) 25             | (<0.1) (<0.1) 2              | 0 0                          | (0.9) 3 (0.9) 3  | 0 0              | 0 0              |
| Rash macular Dermatitis acneifom                        | 0 1                           | 0 0                           | 0 0                           | (1.5) 2 2 (1.5)               | 0 0                           | 0 0                           | (0.7) 27 39       | (<0.1) 3 1 (<0.1) | 0 0               | (0.6) 7 7 (0.6)     | 0 0                 | 0 0                 | 36 2 (1.7) (<0.1)            |                              | 0 0                          | 13 (4.1) 8       | 0 1              | 0                |
| Dermatitis                                              | (0.8) 1 (0.8)                 | 0                             | 0                             | 1 (0.8)                       | 0                             | 0                             | (0.9) 27 (0.7)    | 1 (<0.1)          |                   | 7 (0.6)             | 0                   | 14 0 (0.7)          | 0                            |                              |                              | (2.5)            | (0.3)            | 0                |

<div style=\"page-break-after: always\"></div>

| SelectAE Category Sub-Category/Prefelred Term   | Nivo Process C CA2098FC N=129   | Nivo Process C CA2098FC N=129   | Nivo Process C CA2098FC N=129   | Nivo Process D CA2098FC N=132   | Nivo Process D CA2098FC N=132   | Nivo Process D CA2098FC N=132   | Nivo Monoa N=4122   | Nivo Monoa N=4122   | Nivo Monoa N=4122   | Nivo+Chemo b N=1268   | Nivo+Chemo b N=1268   | Nivo+Chemo b N=1268   | N=2094     | N=2094    | N=2094   | Nivo+Caboa N=320   | Nivo+Caboa N=320   | Nivo+Caboa N=320   |
|-------------------------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------|---------------------|---------------------|-----------------------|-----------------------|-----------------------|------------|-----------|----------|--------------------|--------------------|--------------------|
| SelectAE Category Sub-Category/Prefelred Term   | Any Grade                       | G3-4                            | G5                              | Any Grade                       | G3-4                            | G5                              | Any Grade           | G3-4                | G5                  | Any Grade             | G3-4                  | G5                    | Any Grade  | G3-4      | G5       | Any Grade          | G3-4               | G5                 |
| Pemphigoid                                      | 0                               | 0                               | 0                               | (0.8) 1                         | 0                               | 0                               | (<0.1) 4            | (<0.1) 4            | 0                   | NR                    | NR                    | NR                    | (<0.1) 2   | (<0.1) 1  | 0        | (0.6) 2            | (0.3) 1            | 0                  |
| Erythema                                        | (2.3) 3                         | 0                               | 0                               | 0                               | 0                               | 0                               | (6:1) 79            | 0                   | 0                   | (1.3) 16              | (0.2) 2               | 0                     | (2.1) 43   | (<0.1) 1  | 0        | (3.4) 11           | (0.3) 1            | 0                  |
| Rash pruritic                                   | (1.6) 2                         | 0                               | 0                               | 0                               | 0                               | 0                               | (0.9) 37            | (<0.1) 1            | 0                   | (0.6) 7               | (<0.1) 1              | 0                     | (1.0) 33   | (<0.1) 1  | 0        | (0.3) 1            | 0                  | 0                  |
| Eczema                                          | (0.8) 1                         | 0                               | 0                               | 0                               | 0                               | 0                               | (1.1) 44            | 0                   | 0                   | (0.2) 3               | 0                     | 0                     | (61) 18    | 0         | 0        | (0.3) 1            | 0                  | 0                  |
| Pemphigus                                       | (0.8) 1                         | (0.8) 1                         | 0                               | 0                               | 0                               | 0                               | NR                  | NR                  | NR                  | NR                    | NR                    | NR                    | NR         | NR        | NR       | NR                 | NR                 | NR                 |
| Photosensitivity reaction                       | (0.8) 1                         | 0                               | 0                               | 0                               | 0                               | 0                               | (0.2) 9             | 0                   | 0                   | (0.2) 3               | 0                     | 0                     | (0.3) 6    | 0         | 0        | NR                 | NR                 | NR                 |
| Hypersensitivity/Infusion Reactions             | (1.6) 2                         | 0                               | 0                               | (6.1) 8                         | 0                               | 0                               | (3.9) 160           | (0.3) 12            | 0                   | (10.0) 127            | (1.7) 21              | 0                     | (4.9) 103  | (0.3) 6   | 0        | (2.5) 8            | 0                  | 0                  |
| Infusionrelated reaction                        | 0                               | 0                               | 0                               | (2.3) 3                         | 0                               | 0                               | (2.7) 113           | (0.1) 6             | 0                   | (5.9) 75              | (0.9) 12              | 0                     | (3.2) 68   | (0.2) 5   | 0        | (0.9) 3            | 0                  | 0                  |
| Hypersensitivity                                | 0                               | 0                               | 0                               | (2.3) 3                         | 0                               | 0                               | (1.1) 44            | (<0.1) 2            | 0                   | (4.0) 51              | (0.3) 4               | 0                     | (1.0) 33   | (<0.1) 1  | 0        | (1.3) 4            | 0                  | 0                  |
| hypersensitivity reaction Infusion related      | (1.6) 2                         | 0                               | 0                               | (0.8) 1                         | 0                               | 0                               | (<0.1) 1            | 0                   | 0                   | (0.2) 3               | (<0.1) 1              | 0                     | (0.1) 3    | 0         | 0        | (0.3) 1            | 0                  | 0                  |
| Bronchospasm                                    | 0                               | 0                               | 0                               | (0.8) 1                         | 0                               | 0                               | (<0.1) 3            | (<0.1) 1            | 0                   | NR                    | NR                    | NR                    | NR         | NR        | NR       | NR                 | NR                 | NR                 |
| Endocrine                                       | 43 (33.3)                       | 2 (1.6)                         | 0                               | 37 (28.0)                       | 3 (2.3)                         | 0                               | 556 (13.5)          | 28 (0.7)            | 0                   | 155 (12.2)            | 10 (0.8)              | 0                     | 582 (27.8) | 104 (5.0) | 0        | 142 (44.4)         | 8 (2.5)            | 0                  |
| THYROIDDISORDER                                 | 40 (31.0)                       | 0                               | 0                               | 34 (25.8)                       | 1 (0.8)                         |                                 | 516 (12.5)          | 7 (0.2)             | 0                   | 137 (10.8)            | 0                     | 0                     | 479 (2.9)  | 21 (1.0)  | 0        | 138 (43.1)         | 3 (0.9)            | 0                  |
| Hypothyroidism                                  | 26 (20.2)                       | 0                               | 0                               | 24 (18.2)                       | 0                               | 0                               | 313 (7.0)           | 2 (<0.1)            | 0                   | 92 (7.3)              | 0                     | 0                     | 303 (14.5) | 5 (0.2)   | 00       | 112 (35.0)         | 1 (0.3)            | 0                  |
| Hyperthyroidism                                 | 23 (17.8)                       | 0                               | 0                               | 21 (15.9)                       | 1 (0.8)                         | 0                               | 166 (4.0)           | 2 (<0.1)            | 0                   | 37 (2.9)              | 0                     | 0                     | 171 (8.2)  | 7 (0.3) 0 |          | 29 (9.1)           | 2 (0.6)            |                    |
| hormone increased Blood thyroid stimulating     | (3.9) 5                         | 0                               | 0                               | (0.8) 1                         | 0                               | 0                               | (1.4) 58            | (<0.1) 1            | 0                   | (2.0) 25              | 0                     | 0                     | (S:1) 32   | 0         | 0        | (7.5) 2            | 0                  | 0                  |
| Thyroiditis                                     | 2 (1.0)                         | 0                               | 0                               | 1 (0.8)                         | 0                               | 0                               | 32 (0.8)            | 1 (<0.1)            | 0                   | 2 (0.2)               | 0                     | 0                     | 44 (2.1    | 4 (0.2)   | 0        | 2 (0.6)            | 0                  | 0                  |
| Blood thyroid stimulating homone decreased      | (0.8) 1                         | 0                               | 0                               | 0                               | 0                               | 0                               | (0.0) 25            | 0                   | 0                   | (0.6) 7               | 0                     |                       | (1.1) 23   | 0         | 0        | (0.3) 1            | 0                  | 0                  |

CA2098FC

N=129

Nivo Process C

Any

Grade

G5

1

(0.8)

1

(0.8)

0

1

(0.8)

2

(1.6)

2

(1.0)

1

(0.8)

1

(0.8)

1

(0.8)

1

(0.8)

N=4122

Nivo Monoa

Any

Grade

G3-4

1

(&lt;0.1)

24

(0.0)

6

(0.1)

16

(0.4)

25

(0.0)

22

(0.5)

11

(0.3)

3

(&lt;0.1)

2

(&lt;0.1)

6

(0.1)

0

9

(0.2)

1

(&lt;0.1)

8

(0.2)

8

(0.2)

6

(0.1)

7

(0.2)

3

(&lt;0.1)

1

(&lt;0.1)

2

(&lt;0.1)

G5

0

0

0

0

0

0

0

0

0

0

N=1268

Nivo+Chemo

Amy

Grade

G3-4

NR

8

(0.6)

&gt;

(0.6)

1

(&lt;0.1)

11

(0.9)

11

(0.9)

5

(0.4)

1

(&lt;0.1)

2

(0.2)

3

(0.2)

NR

4

(0.3)

3

(0.2)

1

(&lt;0.1)

3

(0.2)

3

(0.2)

3

(0.2)

1

(&lt;0.1)

1

(&lt;0.1)

1

(&lt;0.1)

b

G5

NR

0

0

0

0

0

0

0

0

0

Nivo+Ipi (±Chemo)a,c

N=2094

Any

G5

G3-4

Grade

2

(&lt;0.1)

115

(5.5)

30

(1.4)

84

(4.0)

94

(4.5)

82

(3.9)

18

(0.9)

2

(&lt;0.1)

6

(0.3)

10

(0.5)

0

45

(2.1)

11

(0.5)

33

37

(1.0)

(.8)

32

(1.5)

11

(0.5)

2

(&lt;0.1)

2

(&lt;0.1)

4

(0.2)

0

0

0

0

0

0

0

0

0

0

Nivo+Caboa

N=320

Any

Grade

NR

2

(0.6)

NR

2

(0.6)

15

(4.7)

1

(4.4)

NR

NR

NR

NR

G3-4

NR

0

NR

0

6

(61)

6

(61)

NR

NR

NR

NR

G5

NR

0

NR

0

0

0

NR

NR

NR

NR

SelectAE Category

Term

Sub-Category/Preferred

Immune-mediated thyroiditis

PITUITARYDISORDER

Hypopituitarism

Hypophysitis

ADRENALDISORDER

Adrenal insufficiency

Diabetes

Diabetic ketoacidosis

Type 1 diabetes mellitus

Diabetes mellitus

G3-4

0

0

0

0

1

(0.8)

1

(0.8)

1

(0.8)

1

(0.8)

0

1

(0.8)

0

0

0

0

0

0

0

0

0

0

CA2098FC

N=132

Nivo Process D

Any

G5

Grade

0

2

(S1)

2

(1.5)

0

2

(S1)

2

(1.5)

2

(1.5)

1

(0.8)

1

(0.8)

0

G3-4

0

0

0

0

1

(0.8)

1

(0.8)

1

(0.8)

1

(0.8)

0

0

0

0

0

0

0

0

0

0

0

0

Abbreviations: ALT: alanine aminotransferase; AST: aspartate aminotransferase; cabo: cabozantinib; chemo: chemotherapy; ipi: ipilimumab; mono: monotherapy, nivo: nivolumab; NR:(PT)notreportedinthesourceoutputs.

MedDRAVersion 24.1,CTCVersion5.0forCA2098FC.MedDRAVersion 24.0;CTC Version:3.0forCA209004;CTCVersion 4.0forother studies

Includes events between first dose and 30 days (or min 28 days, subsequent therapy) for ONO-4538-24) after last dose of study therapy.

Nivolumab monotherapy studies: a

- CA209063,CA209017,CA209057: NSCLC
- CA209037,CA209066,CA209067, CA209238:Melanoma
- CA209025:RCC
- CA209039:cHL
- CA2009141:SCCHN
- CA209275,CA209032,CA209274:UC
- ONO-4538-24(CA209473):ESCC
- CA209577:Adjuvant EC or GEJC

b

Nivo + Chemo studies:

- ●CA209648:ESCC
- CA209649: Gastric, GEJ or esophageal adenocarcinoma
- CA209816:NSCLC

Nivo + Ipi (± Chemo) studies: a

Nivo + Cabo study:

- ·CA209004(cohort8), CA209067,·CA2099ER:RCC CA209069:Melanoma
- ●CA209142:dMMRorMSI-HCRC
- ·CA209214:RCC
- . CA209648: ESCC
- ●CA209743:Mesothelioma
- ·CA2099LA: NSCLCC

<div style=\"page-break-after: always\"></div>

For nivolumab monotherapy, nivo+ipi (± chemo), and nivo+cabo, the pooled safety data include data from approved regimens, as presented within the currently approved ProductInformation.

bFor nivo+chemo, the pooled dataset included all nivo+chemoregimens approved(StudiesCA209648and CA209649) aswellas safety datafrom Study CA209816whichis currentlyongoingreview(procedureEMEA/H/C/003985/Il/117,submittedinMar-2022)

CStudyCA2099LA haschemo included in theregimen.

Source:CA2098FC:RefertoTableS.6.5.1.3.2andTableS.6.5.1.3.6of theAddendum01 to theCA2098FCPrimaryCSR;Pooled nivomonoand combodata:Table 4.1(pooled nivomonoandcombo;drug-relatedselect AEs)andTable5.1(pooled nivomonoandcombo;endocrine drug-relatedselectAEs);Table9.2andTable10.2(poolednivomono; drug-related selectAEs byAny grade,Grade 3-4,Grade5);Table 9.9 andTable10.9 (pooled nivo+ipitchemo; drug-related select AEs byAny grade,Grade 3-4,Grade5);Table9.16 andTable10.16(poolednivo+chemo;drug-related selectAEsbyAnygrade,Grade3-4,Grade5)inAppendix 2.

## 2.6.9. Discussion on clinical safety

The primary safety data of this submission are the results of the biocomparability study CA2098FC; based on 129 subjects treated with nivolumab Process C and 132 subjects treated with nivolumab Process D.

Treatment exposure was similar in both arms, with a majority of patients receiving 90% to &lt; 110% of the planned dose intensity for both the 3 mg/kg IV Q2W and the 480 mg IV Q4 posology; although the percentage of patients who achieved this dose intensity was higher for the flat dose (95.2% in the Process C arm vs. 95.7% in the Process D arm for the 480 mg flat dose; compared with 88.4% in the Process C arm vs. 85.6% in the Process D arm for the 3 mg/kg dose). Median number of doses was 9 in both arms. Median duration of therapy was also similar in both arms: 11.53 months in the Process C arm vs. 11.55 months in the Process D arm. However, it seems that a slightly higher percentage of patients remained on treatment in the Process D arm compared with the Process C arm: 68.2% of patients in Process C and 75.0% of patients in Process D remained on treatment for longer than 9 months; and 11.6% of patients in Process C vs. 15.2% of patients in Process D remained on treatment for longer than 12 months. Overall, it does not seem that there were relevant differences in terms of treatment exposure. Median follow-up was 25.9 months (range: 15.7, 31.8), with a minimum followup of 15.7 months. At DBL (18 February 2022) there were no patients still on treatment.

Dose delays were reported with a slightly higher frequency in Process D arm: 38.8% of patients in the Process C arm had at least one dose delay vs. 43.9% of patients in the Process D arm. In both arms the most frequent reason for a dose delay was the occurrence of an adverse event (62.7% of dose delays in the Process C arm vs. 55% of dose delays in the Process D arm). AEs leading to dose delay were reported in a similar percentage of patients in both arms (28.7% of patients in the Process C arm vs. 29.5% of patients in the Process D arm), although some slight imbalances were noted. Particularly, this imbalance was observed in the gastrointestinal disorders: in the Process C arm 3 (2.3%) patients had a dose delay due to AEs belonging to the gastrointestinal SOC, vs. 9 (6.8%) patients in the Process D arm. In the Process C arm 2 (1.6%) of those patients had AEs which were considered drug-related, vs. 8 (6.1%) in the Process D arm.

Regarding infusion interruptions , there were 2 patients (1.6%) in Process C who had at least one infusion interruption, vs. 8 patients (6.1) in Process D. In Process C the total number of interrupted infusions was 2, whereas in Process D the total number of interrupted infusions was 15. The 2 infusion interruptions in the Process C arm were due to 'other reasons'; whereas in the Process D arm there were 3 interruptions due to hypersensitivity reactions, 1 due to 'infusion admin issues' and 11 due to 'other reasons'. Upon request, the MAH provided the 'other reasons' for infusion interruptions in Process D, being 5 out of the 11 infusion interruptions due to 'infusion -related hypersensitivity reaction' and having been recorded as 'other reasons' instead of 'hypersensitivity reaction' by mistake. Therefore, there were 8 hypersensitivity reactions in Process D (instead of 3, as initially stated) vs. none in Process C. The reasons for the observed difference, which suggest tolerability differences between arms, remain unclear.

<div style=\"page-break-after: always\"></div>

The frequency of all-causality any-grade AEs was similar between arms (96.9% of patients in Process C vs. 95.5% of patients in Process D), although the frequency of all-causality G3-4 AEs was relevantly higher in Process D than in Process C: there were 32 patients (24.8%) with an event in Process C, vs. 44 patients (33.3%) in Process D. Although it is agreed with the MAH that it does not seem that this difference is driven by any specific PT or SOC, this difference between arms should not be disregarded, since it suggests that Process D might be associated with a worse tolerability profile than Process C. Regarding any-grade AEs, some relevant differences in terms of the frequency of AEs belonging to a particular SOC have been noted. Namely, AEs belonging to the SOC 'skin and subcutaneous tissue disorders' were reported in 69 patients (53.5%) in Process C vs. in 96 patients (65.2%) in Process D. This difference seems to be driven by an increase in the frequency of the PT 'pruritus' (20.2% vs. 26.5%), 'rash' (17.1% vs. 23.5%) and 'rash maculo -papular' (2.3% vs. 9.8%). Reassuringly, in this SOC the frequency of G3-4 events was similar between both arms. Another SOC in which a difference is observed is the SOC 'gastrointestinal disorders': 63 patients (48.8%) in Process C reported an AE, vs. 75 patients (56.8%) in Process D. This difference seems to be driven by PTs such as 'diarrhoea' (24.8% vs. 28.8%; 0.8% vs. 3% G3 -4 events) and 'nausea' (10.9% vs. 15.9%). AEs belonging to the SOC 'infections and infestations' were also reported with a relevantly higher frequency in the Process D arm than in the Process C arm: 55 patients (41.7%) in the Process D arm vs. 39 patients (30.2%) in the Process C arm. Importantly, a difference in the frequency of G34 events was also observed: 9 patients (6.8%) in the Process D arm reported a G3-4 event, vs. no patients in the Process C arm; although this difference was not driven by any particular PT: those 9 patients had a different PT and all events were G3 events, except for one ev ent of 'sepsis'. The most frequently reported PTs in the Process C arm were 'COVID -19' (6 events 4.7%), 'urinary tract infection' (4 events 4.7%) and 'upper respiratory tract infection' (5 events 3.9%); and in the Process D arm were 'COVID -19' (8 eve nts -6.1%), 'nasopharyngitis' (6 events 4.5%) and 'rhinitis' (6 events -4.5%). Similarly, events belonging to the 'respiratory, thoracic and mediastinal disorders' SOC were reported with a higher frequency in the Process D arm than in the Process C arm: 33.3% subjects in the Process D vs. 20.2% in the Process C arm; although in this SOC the difference between arms in terms of G34 events was not as marked as in the 'infections and infestations' SOC: in Process D there were 3 subjects (2.3%) who had a G3-4 event vs. no patients in Process C. A difference between arms was also evident in the 'blood and lymphatic system disorders' SOC: in the Process C arm there were 7.8% of patients who had an any-grade AE vs. 14.4% in the Process D arm; being this differe nce mainly driven by the PT 'anaemia' (3 patients (2.3%) in the Process C arm vs. 12 patients (9.1%) in the Process D arm). Most subjects in both arms had drug-related AEs : 114 patients (88.4%) in the Process C arm vs. 112 patients (84.8%) in the Process D arm. In the Process C arm 16 patients (12.4%) had a drug-related G3-4 AE , vs. 22 patients (16.7%) in the Process D arm. The SOC in which there was a more marked difference between arms was the 'skin and subcutaneous tissue disorders' SOC: 61 patients (47. 3%) in the Process C arm reported an any-grade event vs. 81 patients (61.4%) in the Process D arm. The PTs that contributed the most to this difference between arms were: 'pruritus' (25.8% in Process D vs. 16.3% in Process C), 'rash' (21.2% in Process D vs . 17.1% in Process C) and 'rash maculo -papular' (9.8% in Process D vs. 2.3% in Process C). AEs belonging to the 'gastrointestinal disorders' SOC were also slightly higher in the Process D arm than in the Process C arm: 34.8% in the Process D arm (9 of them [6.8%] had a G3-4 event) vs. 30.2% in the Process C arm (5 of them [3.9%] had a G3-4 event). This difference seems to be driven by the 'diarrhoea' PT: 14% patients in the Process C arm (including 1 G3 -4 event) vs. 18.9% patients in the Process D arm (including 4 G3-4 events).

Deaths were reported with a similar frequency in both arms: 15 subjects (11.6%) died in the Process C arm vs. 14 subjects (10.6%) in the Process D arm. Primary reason for death was disease progression in both arms, accounting for 13 subjects (10.1%) in the Process C arm vs. 10 subjects (7.6%) in the Process D arm. Notably, in the Process D arm there was 1 death due to study drug

<div style=\"page-break-after: always\"></div>

toxicity, vs. no deaths in the Process C. This death occurred 130 days after the last dose of nivolumab, and was due to a multiple organ dysfunction considered to be related to treatment by the investigator, this not being agreed by the MAH. However, the MAH did not provide any discussion on why the investigator's opinion is not agreed by them. Before suffering a 'multiple organ dysfunction' and dying on day 320, this patient had previously suffered from several IMAEs ('uveitis', which started on day 92; an d 'tubulointerstitial nephritis', which started on day 204).

Additionally, there were 4 patients (2 in each arm) who died due to 'other' reasons. Those reasons were 'sudden cardiac death' and 'cardiogenic shock' for the Process C arm, and 'sepsis secondary to COVID' and 'cardiogenic shock' for the Process D arm. Of note, in the Process D arm there was an additional death due to 'unknown reasons'. The MAH did not provide any additional information on that death, although it is remarkable that this patient had a cardiovascular history of first-degree artery block, and that during the clinical trial he had a G4 serious cardiac tamponade, a G2 serious pericardial effusion, and a G3 serious pleural effusion.

SAEs were reported with an overall similar frequency between both arms: in Process C any-grade SAEs were reported in 24 (18.6%) patients, 16 (12.4%) of whom were G3-4 SAEs; vs. 28 (21.2%) any-grade SAEs and 22 (16.7%) G3-4 SAEs in Process D. By PT no relevant differences were noted, except for the 2 myocarditis cases reported in the Process D arm. Of note, no myocarditis cases were reported in the Process C arm.

Regarding all-causality select adverse events, it should be noted that some differences were observed between arms, although these differences were mainly driven by low-grade select AEs (G12). In terms of select adverse events, the categories in which a more marked difference between arms was observed were the 'skin AE' category, 'hepatic AE' category, 'gastrointestinal AE' category, and 'hypersensitivity / infusion reaction' category, with a higher incidence in the Process D arm. In terms of drug-related select AEs , the differences between arms remained similar to the differences between arms in all-causality select AEs, suggesting that there are no relevant differences in the percentages of all-causality and drug-related AEs.

Immune-mediated adverse events (IMAEs) were reported with a similar frequency in both arms, although it is noted that the category 'hepatitis' was reported with a higher frequency in the Process D arm than in the Process C arm: in the Process C arm 3 (2.3%) subjects had an any-grade IMAE, none of them considered a G3-4 event; whereas in the Process D arm there were 8 (6.1%) subjects with an any-grade IMAE and 4 (3%) of them were G34 IMAEs. It should be noted that the category 'hepatitis' included the follo wing PTs: 'alanine aminotransferase increased', 'hepatitis', 'aspartate aminotransferase increased', 'hyperbilirubinemia' and 'transaminases increased'. It is worth mentioning the higher frequency of hepatic IMAEs in Process D compared with Process C not only in terms of any-grade IMAEs, but also in terms of G3-4 IMAEs. Reassuringly, all the hepatic IMAEs in the Process D arm resolved. No relevant differences were observed in the endocrine IMAEs rates between both arms.

Other events of special interest (OESIs) were infrequent in both arms, although it should be noted that a clear higher frequency was observed in Process D compared with Process C. In Process C there were 4 events (2 patients), while in Process D there were 17 events (5 subjects). Reassuringly, all events in both arms resolved at the time of DBL. In Process D all events resolved with IMMs. In terms of the nature of those events, in Process C there were 3 uveitis and 1 rhabdomyolysis; all of them of grade 1-2; while in Process D there were 4 pancreatitis (two of them were grade 2 and one was grade 3), 6 uveitis (all were grade 1-2), 3 myocarditis (two of them were grade 3) and 4 myositis (one of them was grade 3 and the other three were grade 1-2). Special importance should be given to the events of myocarditis and pancreatitis, which were clearly imbalanced between arms and could be lifethreatening. The MAH has provided an exposure-adjusted analysis for the events of myocarditis

<div style=\"page-break-after: always\"></div>

(together with an event of angina pectoris); therefore, these events are discussed in the section focused on this analysis (see below). Regarding the events of pancreatitis, it is noted that the 4 events occurred in 2 subjects and that all were reported as recovered without sequalae. One patient had a G3 pancreatitis on day 134, which was considered as related and led to the discontinuation of nivolumab on day 135. The other patient had G2 pancreatitis on day 86, followed by G2 pancreatic failure on day 144, which also was considered as related and led to the discontinuation of nivolumab. Upon request, an exposure-adjusted analysis for this PT was provided, in which an increase in terms of any-grade events was observed in comparison with the mononotherapy pool (N=7327) and with the monotherapy pool in melanoma (N=1379). In terms of G3-4 events the difference between Process D and the pools is subtler. Considering that there were only 4 events and that all events were reported as recovered without sequalae, no further regulatory action is deemed necessary.

Laboratory findings were overall similar in both arms, with no major differences observed. However, it should be noted that some imbalances were observed in the liver tests: ALT or AST &gt; 5xULN was reported in 4 (3%) patients in the Process D arm vs. in 1 (0.8%) patient in the Process C arm; and total bilirubin &gt; 2xULN was also reported in 4 (3%) patients in the Process D arm vs. in 1 (0.8%) in the Process C arm. Reassuringly, no patient met Hy's law in the Process D arm. These findings were in line with the slightly higher frequency of hepatic AEs (i.e. hepatitis) in the Process D arm compared with the Process C arm.

As mentioned in the clinical efficacy discussion, immunogenicity incidence was higher in the Process D arm than in the Process C arm: in Process C there were 3 (2.5%) ADA-positive subjects, vs. 8 (6.5%) ADA-positive subjects in Process D. Median duration of ADAs was notably longer in Process D than in Process C, although the small number of patients who developed ADAs is acknowledged. Of note, this increased immunogenicity in Process D compared with Process C was already highlighted in the FU SA provided in 2022 (EMA/SA/0000074196). Although the fact that in Process D the immunogenicity incidence was more than twice the incidence in Process C is not reassuring, it should be noted that the immunogenicity incidence of nivolumab in monotherapy included in the SmPC is 9%; that is, the reported incidence in the Process D arm, although higher than in the Process C arm, is lower than the reported incidence for the pool of studies of nivolumab in monotherapy. Additionally, it does not seem that safety is impacted by ADAs, since in Process D only 1 patient having developed ADAs had an AE ('infusion related reaction'), although the number of patients is too low.

AEs leading to discontinuation were reported with a similar frequency in both arms: in the Process C arm any-grade AEs were reported in 22 subjects (17.1%) and G3-4 AEs in 9 subjects (7.0%); vs. 25 subjects (18.9%) with any grade AEs and 11 subjects (8.3%) with G3-4 AEs in the Process D arm. However, although the overall frequencies are similar, some imbalances in some SOCs/PTs have been noted. Namely, in the gastrointestinal SOC 4 (3.1%) patients in the Process C arm had any-grade AEs leading to discontinuation; 2 (1.6%) of whom were G3-4; vs. 8 (6.1%) any-grade AEs and 4 (3.0%) G3-4 in the Process D arm. There were 2 (1.5%) patients with myocarditis in Process D (both of them were G3-4 events) vs. no patients in Process C. Importantly, in Process D there were 4 (3%) anygrade hepatitis, 2 (1.5%) of whom were G3-4 events; vs. no patients in Process C. The frequencies of the above-mentioned PTs and SOCs were unchanged after establishing the causality: all the mentioned events (gastrointestinal disorders' SOC, myocarditis PT and hepatitis PT) were considered drug-related.

The MAH has presented exposure-adjusted analyses for all-causality unique select AEs to contextualize numerically higher incidences of some select AE categories noted in nivolumab Process D compared to nivolumab Process C. The analysis presented compares side-by-side the number and percentage of patients with a select any-grade and G3-4 A E category ('hepatic', 'skin', 'hypersensitivity/infusion reaction', 'gastrointestinal' and 'cardiac disorders' [including myocarditis and angina pectoris]), the person-years of exposure based on time to first onset and the incidence rate per 100 person-years of exposure of the Process C arm, the Process D arm, a pool of studies of

<div style=\"page-break-after: always\"></div>

nivolumab in monotherapy for all indications (hereinafter referred as 'all -indications pool'), and a pool of studies of nivolumab in monotherapy for the melanoma indications (hereinafter referred as 'melanoma pool'). Regarding the analysis on any -grade AEs it is noted that for both the 'hypersensitivity/infusion reaction' category and the 'gastrointestinal' category the IR/100 P -Y in the Process D arm is similar to the IR/100 P-Y in the all-indications pool and in the melanoma pool. Therefore, although a difference in the incidences of those events is observed between Process C and Process D, it does not seem that the incidence in Process D is considerably higher than in the allindications pool and in the melanoma pool. In the case of the 'skin' category, it is noted that the IR/100 P-Y appears markedly higher in the Process D arm than in the all-indications pool (100.5 [95% CI:79.5, 125.4] in the Process D arm vs. 68.3 [95%CI: 65.7, 70.9] in the all-indications pool). However, when the IR/100 P-Y in Process D is compared with the IR/100 P-Y in the melanoma pool the difference is considerably subtler (100.5 [95% CI: 79.5, 125.4] in the Process D arm vs. 104.1 [95% CI: 96.8, 111.9] in the melanoma pool), which is reassuring since it suggests that the incidence observed in the Process D arm is similar to the incidence previously reported for other studies of nivolumab in the melanoma setting. However, this tre nd is not observed in the case of the 'hepatic' category: for the hepatic category the IR/100 P-Y seems higher in the Process D arm (32.1 [95% CI: 22.7, 44.1]) than in either the all-indications pool (24.1 [95% CI: 22.8, 25.4)) or the melanoma pool (15.7 [95%CI: 13.7, 18.0]). This observation is not reassuring, since it suggests that the administration of nivolumab manufactured following Process D could somehow translate into a higher incidence of any-grade hepatic AEs. Nevertheless, in the exposure-adjusted G3-4 analysis it is noted that the IR/100 P-Y of G3-4 hepatic events in the Process D arm appears lower than in the allindications pool and in the melanoma pool. This trend is also observed for the skin and the hypersensitivity / infusion reaction categories, although in the gastrointestinal category the IR/100 P-Y seems to be slightly higher in the Process D arm (4.2 [95% CI: 1.5, 9.1]) compared with the allindications pool (2.9 [95% CI:2.5, 3.4]) and the melanoma pool (3.9 [95% CI: 3.0, 5.1]). As previously mentioned, the MAH has also analysed the G34 AEs belonging to the 'cardiac disorders' SOC. It should be noted that the total percentage of events seemed higher in the Process D arm than in either of the pools: 5 events (3.8%) in the Process D arm vs. 171 events (2.3%) in the allindications pool and 26 events (1.9%) in the melanoma pool. Among the reported PTs there were 2 myocarditis events (1.5%) in the Process D arm, vs. 4 events (&lt;0.1%) in the all-indications pool and 0 events in the melanoma pool. The IR/100 P-Y was also higher in the Process D arm than in the pools: 1.4 (95% CI: 0.2, 5.0) in the Process D arm vs. 0.1 (95% CI: 0.0, 0.2) in the all-indications pool and 0.0 (95% CI: 0.0, 0.3) in the melanoma pool. Although the number of G3-4 myocarditis events is very low and therefore it is difficult to draw conclusions, it is noted that there were 2 events reported in the Process D arm, in which there were 132 patients included; vs. 4 events in the all-indications pool, in which there were 7327 patients included. This suggests that with Process D there is a higher incidence of these events compared with the safety pool of studies of nivolumab in the approved indications. There was 1 event (0.8%) of 'angina pectoris' in the Process D arm vs. 3 even ts (&lt;0.1%) in the allindications pool and 0 events in the melanoma pool. The IR/100 P-Y in the Process D arm is 0.7 (95% CI: 0.0, 3.9), vs. 0.0 (95% CI: 0.0, 0.1) in the all-indications pool and 0.0 (95% CI: 0.0, 0.3) in the melanoma pool. Considering that there was only 1 event in the Process D arm and that therefore this could have been a random finding, no conclusions can be drawn on the existence of potential differences between the Process D arm and the pools.

Additionally, the MAH has performed a non-exposure adjusted descriptive analysis of drugrelated select AEs within 30 days of last dose, to further address the differences observed in certain select AEs and cardiac disorders events with nivolumab Process D compared with nivolumab Process C. In this analysis the MAH presents side-by-side the total number and percentages of any-grade, G3-4 and G5 events in the Process C arm, in the Process D arm, in the monotherapy all-indications pool (hereinafter referred a s 'monotherapy pool'), in the pool of studies of nivolumab in combination with

<div style=\"page-break-after: always\"></div>

chemotherapy, in the pool of studies of nivolumab in combination with ipilimumab ± chemotherapy, and in a study of nivolumab in combination with cabozantinib. Since nivolumab was administered as monotherapy in the study CA2098FC, the comparison which has been considered more relevant is the one referring to the pool of monotherapy studies, which included 4122 patients. It should be noted that, as previously mentioned, the frequency of events in some categories seems to be increased in the Process D arm in comparison with the monotherapy pool. This increase was observed in the 'hepatic' category, with 25 (18.9%) any -grade events in Process D vs. 311 (7.5%) in the monotherapy pool. Overall, all PTs in this category were reported with a higher frequency in the Process D arm than in the monotherapy pool. Similarly, events in the 'skin' category were reported with a higher frequency in the Process D arm than in the monotherapy pool: 74 (56.1%) any-grade events vs. 1213 (29.4%) in the monotherapy pool. In this category all PTs were also overall increased in the Process D arm with respect to the monotherapy pool, although the differences were more marked in some PTs (pruritus: 24.2% vs. 14.8%; rash: 21.2% vs. 12.6% and rash maculo-papular: 9.1% vs. 3.7%). Additionall y, the 'endocrine' category was also increased in the Process D arm compared with the monotherapy pool: 28% vs. 13.5%. However, in this case the difference between Process C and Process D is subtler (28% in Process D vs. 33.3% in Process C) and, therefore, the differences observed between Process D and the monotherapy pool are not considered as worrisome. Reassuringly, all the mentioned differences in any-grade events are overall not observed (or are subtler) for G34 events, except for the 'hepatitis' PT, in which 3 (2.3%) events were reported in the Process D arm vs. 2 (&lt;0.1%) in the monotherapy pool.

Considering the results of the pivotal study (CA2098FC), together with both the exposure-adjusted and the non-exposure adjusted analyses, the frequency of some PTs seems to be slightly higher with nivolumab manufactured following Process D than with nivolumab manufactured following Process C. Although it is acknowledged that these differences were mainly due to G1-2 events, it is unclear why such differences (which in some cases are appreciably higher) were observed; considering that no differences between arms were supposed to be observed. The MAH was requested to further elaborate on the potential reasons why there seems to exist some differences in the safety profile of nivolumab between both processes, and a thorough justification on the differences between both manufacturing processes was provided. After reviewing the provided data, it does not seem that any of the implemented changes could have led to the observed differences in the safety profile of Process D nivolumab vs. Process C nivolumab. Therefore, there is no apparent explanation for the observed differences. A close monitoring on those events is needed in the following PSURs.

## 2.6.10. Conclusions on the clinical safety

The administration of nivolumab manufactured following Process C and following Process D was associated with the same AEs in nature, not being identified any new signal with Process D. However, it has been noted that the frequency of some AEs was unexpectedly higher in the Process D arm than in the Process C arm. Notably, this increase has been noted in AEs belonging to the following categories: hypersensitivity/infusion reactions, skin, hepatic, cardiac and gastrointestinal; as well as the PT of pancreatitis. The MAH has presented two additional analyses comparing the results obtained in the Process D arm with different safety pools of nivolumab administered in other settings. The results of those analyses provide reassurance for some AEs, but uncertainties remain for others (i.e. hepatic events). The MAH also provided a thorough review on the differences between both manufacturing processes, with the aim of identifying the potential reasons for the observed differences in terms of safety. However, it does not seem that any of the implemented changes could have led to the observed differences in the safety profile of Process D vs. Process C. Considering there is no apparent explanation for these observed differences and taking into account the small data size, no

<div style=\"page-break-after: always\"></div>

changes in the SmPC or RMP are warranted, although those events should be closely monitored in the following PSURs.

## 2.7. Risk Management Plan

No changes in the safety concerns, PhV plan and RMM were included in this procedure.

## 2.7.1. Safety concerns

Table 51 : Summary of safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                       |
|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Immune-related adverse reactions (including immune-related pneumonitis, colitis, hepatitis, nephritis and renal dysfunction, endocrinopathies, skin ARs, and other irARs) Severe infusion reactions                              |
| Important potential risks    | Embryofetal toxicity Immunogenicity Risk of GVHD with nivolumab after allogeneic HSCT                                                                                                                                            |
| Missing information          | Patients with severe hepatic and/or renal impairment Patients with autoimmune disease Patients already receiving systemic immunosuppressants before starting nivolumab Long-term safety in adolescent patients ≥ 12 years of age |

## 2.7.2. Pharmacovigilance plan

Table 52: Ongoing and Planned Additional Pharmacovigilance Activities

| Study / Status                                                                                                                                                                                                                  | Summary of objectives                                                                                                                                                                                                           | Safety concerns addressed                                                                                                                                                                                                                                                                                                                                                                                                                     | Milestone(s)                                                                                                                                                                                                                    | Due Date(s)                                                                                                                                                                                                                     |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization None                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization None                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization None                                                                                                                                                                                                                                                                                                               | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization None                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization None                                                                                                 |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances None | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances None | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances None                                                                                                                                                                                                               | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances None | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances None |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                   | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                   | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                                                                                                                                                                                                 | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                   | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                   |
| CA209234: Pattern of use and safety/effectiveness of nivolumab in routine oncology practice Ongoing                                                                                                                             | To assess use pattern, effectiveness, and safety of nivolumab, and management of important identified risks of nivolumab in patients with lung cancer or melanoma in routine oncology practice                                  | Postmarketing use safety profile, management and outcome of immune-related ARs (including pneumonitis, colitis, hepatitis, nephritis and renal dysfunction, endocrinopathies, rash, other irARs [uveitis, pancreatitis, demyelination, Guillain-Barre syndrome, myasthenic syndrome, encephalitis, myositis, myocarditis, rhabdomyolysis, solid organ transplant rejection, and Vogt-Koyanagi-Harada disease]), and severe infusion reactions | 1. Interim report 2. Final CSR submission                                                                                                                                                                                       | Interim results provided annually 4Q2024                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| Study / Status                                                                                                                                                         | Summary of objectives                                                 | Safety concerns addressed                                 | Milestone(s)                                                                         | Due Date(s)             |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------|--------------------------------------------------------------------------------------|-------------------------|
| Long-term follow-up of ipilimumab, nivolumab and nivolumab in combination with ipilimumab treated paediatric patients enrolled in the DMTR (CA184557) a Voluntary PASS | To assess safety and long- term outcomes in children and adolescents. | Long-term safety in adolescent patients > 12 years of age | 1. Submission of protocol a 2. Interim Study Report 3. Final report of study results | 4Q 2023 4Q 2026 4Q 2033 |

a The protocol, CA184557, which includes patients treated with ipilimumab monotherapy, will be amended to include patients who received nivolumab monotherapy or nivolumab in combination with ipilimumab (including those receiving therapy prior to the start of data collection). The study milestones presented are specific to the protocol extension for nivolumab or nivolumab in combination with ipilimumab treated patients.

## 2.7.3. Risk minimisation measures

Table 53: Summary of Risk Minimisation Measures

| Safety Concern                                                                                                                                                             | Risk Minimisation Measures                                                                                                   | Pharmacovigilance Activities                                                                                                                                                                    |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Immune-related adverse reactions (including immune- related pneumonitis, colitis, hepatitis, nephritis and renal dysfunction, endocrinopathies, skin ARs, and other irARs) | Routine risk minimisation measures: SmPC Sections 4.2, 4.4 and 4.8 Additional risk minimisation measures: Patient Alert Card | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: Postmarketing pharmacoepidemiology study (CA209234) |
| Severe Infusion Reactions                                                                                                                                                  | Routine risk minimisation measures: SmPC Sections 4.4 and 4.8 Additional risk minimisation measures: None                    | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: Postmarketing pharmacoepidemiology study (CA209234) |
| Embryofetal toxicity                                                                                                                                                       | Routine risk minimisation measures: SmPC Sections 4.6 and 5.3 Additional risk minimisation                                   | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance                                                                 |
| Immunogenicity                                                                                                                                                             | Routine risk minimisation measures: SmPC Section 4.8 Additional risk minimisation measures: None                             | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None                                                |
| Risk of GVHD with nivolumab after allogeneic HSCT                                                                                                                          | Routine risk minimisation measures: SmPC Section 4.4 and 4.8                                                                 | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None                                                                                              |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                                   | Risk Minimisation Measures                                    | Pharmacovigilance Activities                                                                                                                                                                                            |
|----------------------------------------------------------------------------------|---------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                  | Additional risk minimisation measures: None                   | Additional pharmacovigilance activities: None                                                                                                                                                                           |
| Patients with severe hepatic and/or renal impairment                             | Routine risk minimisation measures: SmPC Sections 4.2 and 5.2 | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None                                                                                                                      |
| Patients with severe hepatic and/or renal impairment                             | Additional risk minimisation measures: None                   | Additional pharmacovigilance activities: None                                                                                                                                                                           |
| Patients with autoimmune disease                                                 | Routine risk minimisation measures: SmPC Section 4.4          | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None                                                                                                                      |
| Patients with autoimmune disease                                                 | Additional risk minimisation measures: None                   | Additional pharmacovigilance activities: None                                                                                                                                                                           |
| Patients already receiving systemic immunosuppressants before starting nivolumab | Routine risk minimisation measures: SmPC Sections 4.4 and 4.5 | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None                                                                                                                      |
| Patients already receiving systemic immunosuppressants before starting nivolumab | Additional risk minimisation measures: None                   | Additional pharmacovigilance activities: None                                                                                                                                                                           |
| Long-term safety in adolescent patients ≥ 12 years of age                        | Routine risk minimization measures: None                      | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None                                                                                                                      |
| Long-term safety in adolescent patients ≥ 12 years of age                        | Additional risk minimization measures: None                   | Additional pharmacovigilance activities: MAH to sponsor the extension of the DMTR to include paediatric subjects treated with nivolumab monotherapy and nivolumab + ipilimumab to collect their safety data (CA184557). |

## 2.7.4. Conclusion

The CHMP considered that the risk management plan version 34.1 is acceptable.

## 2.8. Pharmacovigilance

## 2.8.1. Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the MAH fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## 2.8.2. Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

<div style=\"page-break-after: always\"></div>

## 2.9. Product information

## 2.9.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable based on the fact that no changes were made to the package leaflet.

## 3. Benefit-Risk Balance

The object of this submission is to support the nivolumab drug substance manufacturing process change from the current approved Process C to newly optimized Process D, developed using a new nivolumab cell line. No changes in the already approved indications or, in general, to the SmPC were introduced.

## 3.1.1. Main clinical studies

The basis of this submission is Study CA2098FC, a randomized, double-blind, parallel, Phase 1 study aimed to demonstrate biocomparability of Process C IV nivolumab to Process D IV nivolumab in 261 patients with Stage IIIa/b/c/d or Stage IV melanoma after complete resection. The primary endpoints of the study were PK endpoints, AUC(TAU) (0-336 h) at Week 1 Day 1 (after first dose) and AUC(TAU) (0-336 h) at Week 17 Day 1 (after multiple doses). Secondary endpoints included safety and tolerability, together with immunogenicity. Efficacy, measured as recurrence-free-survival (RFS) was an exploratory endpoint.

## 3.2. Favourable effects

In terms of PK, which was the main objective of the study, nivolumab Process C and Process D were found to be biocomparable as the AUC(0-336 h) geometric mean ratios (90% CI) were 1.012 (0.984, 1.041) and 0.998 (0.951, 1.047) at Week 1 and Week 17, respectively.

In terms of efficacy, which was an exploratory endpoint, the HR for RFS in all randomized subjects was 0.81 (95% CI: 0.53-1.23), with 47 events (36.4%) reported in Process C vs. 43 events (32.6%) in Process D. Median RFS was not reached in either arm. In subjects with no relevant protocol deviations the HR was 0.75 (95% CI: 0.46-1.21), with 38 events (37.3%) reported in Process C vs. 31 events (30.4%) in Process D.

## 3.3. Uncertainties and limitations about favourable effects

None.

## 3.4. Unfavourable effects

Dose delays were reported with a similar frequency in both arms: 38.8% of patients in the Process C arm had at least one dose delay vs. 43.9% of patients in the Process D arm. In both arms the most frequent reason for a dose delay was the occurrence of an adverse event (62.7% of dose delays in the Process C arm vs. 55% of dose delays in the Process D arm).

<div style=\"page-break-after: always\"></div>

Regarding infusion interruptions , there were 2 patients (1.6%) in Process C who had at least one infusion interruption, vs. 8 patients (6.1%) in Process D. In Process C the total number of interrupted infusions was 2, whereas in Process D the total number of interrupted infusions was 15.

The frequency of all-causality any-grade AEs was similar between arms (96.9% of patients in Process C vs. 95.5% of patients in Process D), although the frequency of all-causality G3-4 AEs was higher in Process D than in Process C: there were 32 patients (24.8%) with an event in Process C, vs. 44 patients (33.3%) in Process D. AEs belonging to some SOCs were reported with a higher frequency in the Process D than in the Process C: 'skin and subcutaneous tissue disorders' (53.5% vs. 65.2%), 'gastrointestinal disorders' (48.8% vs. 56.8%), 'infections and infestations' (30.2% vs. 41.7%), 'respiratory, thoracic and mediastinal disorders' (20.2% vs. 33.3%) and 'blood and lymphatic system disorders' (7.8% vs. 14.4%).

Most subjects in both arms had drug-related AEs : 114 patients (88.4%) in the Process C arm vs. 112 patients (84.8%) in the Process D arm. In the Process C arm 16 patients (12.4%) had a drug-related G3-4 AE, vs. 22 patients (16.7%) in the Process D arm.

Regarding deaths, 15 subjects (11.6%) died in the Process C arm vs. 14 subjects (10.6%) in the Process D arm. Primary reason for death was disease progression in both arms, accounting for 13 subjects (10.1%) in the Process C arm vs. 10 subjects (7.6%) in the Process D arm.

In Process C any-grade SAEs were reported in 24 (18.6%) patients compared with 28 (21.2%) patients in Process D.

Regarding all-causality select adverse events , some differences were observed between arms, although these differences were mainly driven by low-grade select AEs (G1-2). The categories in which a more marked difference between arms was observed were the 'skin AE' category, 'hepatic AE' category, 'gastrointestinal AE' category, and 'hypersensitivity / infusion reaction' category.

Immune-mediated adverse events (IMAEs) were reported with a similar frequency in both arms, although the category 'hepatitis' was reported with a higher frequency in the Process D arm than in the Process C arm: in the Process C arm 3 (2.3%) subjects had an any-grade IMAE, none of them considered a G3-4 event; whereas in the Process D arm there were 8 (6.1%) subjects with an anygrade IMAE and 4 (3%) of them were G3-4 IMAEs. All hepatic IMAEs in the Process D resolved.

Other events of special interest (OESIs) were infrequent in both arms, although a higher frequency was observed in Process D compared with Process C: in Process C there were 4 events (2 patients), while in Process D there were 17 events (5 subjects). All events in both arms resolved at the time of DBL. In Process D there were 4 pancreatitis (two of them were grade 2 and one was grade 3), and 3 myocarditis (two of them were grade 3), whereas in Process C there were no events of pancreatitis or myocarditis.

Immunogenicity incidence was higher in the Process D arm than in the Process C arm: in Process C there were 3 (2.5%) ADA-positive subjects, vs. 8 (6.5%) ADA-positive subjects in Process D. The median duration of nivolumab ADAs was longer in Process D than in Process C: 14.29 (95% CI: 13.86, 34.14) weeks in Process D vs. 8.07 (95% CI: 2.14, NA) weeks in Process C. No patients in either arm developed neutralizing ADAs.

AEs leading to discontinuation were reported with a similar frequency in both arms: in the Process C arm any-grade AEs were reported in 22 subjects (17.1%) vs. 25 subjects (18.9%) in the Process D arm.

<div style=\"page-break-after: always\"></div>

## 3.5. Uncertainties and limitations about unfavourable effects

The frequency of some AEs was unexpectedly higher in the Process D arm than in the Process C arm; notably in AEs belonging to the following categories: hypersensitivity / infusion reactions, skin, hepatic, cardiac and gastrointestinal; together with the PT of pancreatitis. The MAH presented two additional analyses comparing the results obtained in the Process D arm with different safety pools of nivolumab administered in other settings. The results of those analyses provided reassurance for some AEs, but uncertainties remain for others (i.e., hepatic events). Although thorough explanations were provided on the differences between both manufacturing processes with the aim of identifying the potential reasons for the observed safety differences, the reasons for these differences remain unknown. Considering there is no apparent explanation for these observed differences and taking into account the small data size, no changes in the SmPC or RMP are warranted.

## 3.6. Effects Table

Not applicable.

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

Nivolumab Process C and Process D were found to be biocomparable as the AUC(0-336 h) geometric mean ratios (90% CI) were 1.012 (0.984, 1.041) and 0.998 (0.951, 1.047) at Week 1 and Week 17, respectively.

No relevant differences were observed in terms of RFS; although it should be noted that efficacy was included as an exploratory endpoint, and, therefore, these results are only descriptive.

While the overall safety profile of nivolumab Process D was comparable and consistent with nivolumab Process C in Study CA2098FC and reflective of the historical experience with nivolumab, the frequency of some AEs was unexpectedly higher in Process D than in Process C. Although the reasons for this observed imbalanced between arms are unclear, it should be noted that these differences were mainly driven by G1-2 AEs, and that those events resolved. Additionally, no differences in the number of deaths or treatment discontinuations were observed between arms, suggesting that the differences observed did not translate into major safety problems. The additional analyses performed by the MAH provided reassurance for some AEs categories such as the skin category, but are not enough to provide reassurance for some other categories, such as the hepatic category or the cardiac disorders category. Although it seems that somehow nivolumab Process D translate into a slightly worse tolerability profile than Process C, the limitations of study CA2098FC, which included only 261 patients, are acknowledged.

Immunogenicity of Process D appears to be higher than Process C although it seems lower than the reported incidence in the pool of studies of nivolumab as monotherapy.

From a quality point of view, comparability of both Process C and Process D is demonstrated. The quality dossier provides comprehensive information regarding the new development of manufacturing Process D and only one minor issue is still pending.

<div style=\"page-break-after: always\"></div>

## 3.7.2. Balance of benefits and risks

Comparability of Process D with Process C can be considered demonstrated from a quality point of view. From a clinical point of view, the basis of this submission is the comparability of PK results between Process C and Process D in Study CA2098FC. In this regard, the primary endpoints of the study were met and therefore biocomparability is considered demonstrated. In terms of safety, no new signals have been identified with Process D compared to Process C, although the frequency of some AEs was unexpectedly higher in Process D than in Process C. Considering there is no apparent explanation for these observed differences and taking into account the small data size, no changes in the SmPC or RMP are warranted.

## 3.7.3. Additional considerations on the benefit-risk balance

Not applicable.

## 3.8. Conclusions

The overall benefit/risk balance of OPDIVO is positive, subject to the conditions stated in section 'Recommendations'.

## 4. Recommendations

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that Opdivo is not similar to Adcetris within the meaning of Article 3 of Commission Regulation (EC) No. 847/2000.

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus decision that the benefit-risk balance of, OPDIVO is favourable in the following indications:

## Melanoma

OPDIVO as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults.

Relative to nivolumab monotherapy, an increase in progression-free survival (PFS) and overall survival (OS) for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression.

## Adjuvant treatment of melanoma

OPDIVO as monotherapy is indicated for the adjuvant treatment of adults with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.

## Non-small cell lung cancer (NSCLC)

OPDIVO in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.

OPDIVO as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer after prior chemotherapy in adults.

<div style=\"page-break-after: always\"></div>

## Malignant pleural mesothelioma (MPM)

OPDIVO in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.

## Renal cell carcinoma (RCC)

OPDIVO as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults.

OPDIVO in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma.

OPDIVO in combination with cabozantinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma.

## Classical Hodgkin lymphoma (cHL)

OPDIVO as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.

## Squamous cell cancer of the head and neck (SCCHN)

OPDIVO as monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum-based therapy.

## Urothelial carcinoma

OPDIVO as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy.

## Adjuvant treatment of urothelial carcinoma

OPDIVO as monotherapy is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (MIUC) with tumour cell PD-L1 expression ≥ 1%, who are at high risk of recurrence after undergoing radical resection of MIUC.

## Mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC)

OPDIVO in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.

## Oesophageal squamous cell carcinoma (OSCC)

OPDIVO in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1%.

OPDIVO in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1%.

OPDIVO as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy.

<div style=\"page-break-after: always\"></div>

## Adjuvant treatment of oesophageal or gastro-oesophageal junction cancer (OC or GEJC)

OPDIVO as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy.

## Gastric, gastro-oesophageal junction (GEJ) or oesophageal adenocarcinoma

OPDIVO in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) ≥ 5.

The CHMP therefore recommends the extension(s) of the marketing authorisation for OPDIVO subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

## Conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## · Risk Management Plan (RMP)

The Marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
- Additional risk minimisation measures

The MAH shall ensure that in each Member State where OPDIVO is marketed, all healthcare professionals and patients/carers who are expected to prescribe and use OPDIVO have access to/are provided with the patient alert card.

- The patient alert card shall contain the following key messages:
- That OPDIVO treatment may increase the risk of:
- o Immune related pneumonitis
- o Immune related colitis

<div style=\"page-break-after: always\"></div>

- o Immune related hepatitis
- o Immune related nephritis and renal dysfunction
- o Immune related endocrinopathies
- o Immune related skin adverse reactions
- o Other immune related ARs
- Signs or symptoms of the safety concern and when to seek attention from a HCP
- Contact details of the OPDIVO prescriber

Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States.

Not applicable.